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‘Infectious disease is one of the few genuine adventures left in the world. The dragons are all dead 
and the lance grows rusty in the chimney corner... About the only sporting proposition that remains 
unimpaired by the relentless domestication of a once free-living human species is the war against 
those ferocious little fellow creatures, which lurk in dark corners and stalk us in the bodies of rats, 
mice and all kinds of domestic animals; which fly and crawl with the insects, and waylay us in our 
food and drink and even in our love’ 
Hans Zinsser – ‘Rats, Lice and History’ (1935)
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Abstract:  
An appraisal of health datasets to enhance the surveillance of Lyme disease in the United 
Kingdom – J.S.P. Tulloch 
Lyme disease is a tick-borne disease of increasing global public health interest. Clinical 
presentation is varied, posing challenges for case definition. Currently national incidence 
figures for the United Kingdom (UK) are derived from two-tier confirmatory laboratory 
diagnostic results. These figures have the potential to underestimate incidence as clinical 
cases managed without diagnostic investigation are unrecorded.  
This thesis aimed to identify and evaluate a variety of datasets for their ability to describe 
the incidence and sociodemographics of Lyme disease cases in the UK, and to assess whether 
they could be utilised in future national surveillance programmes. The datasets analysed 
were: Public Health England (PHE)’s Lyme disease diagnostic laboratory, PHE’s laboratory 
surveillance system, hospital episode statistics data for England and Wales, an electronic 
health records database of primary care in the UK, Twitter, and the Small Animals Veterinary 
Surveillance Network (SAVSNET).  
A generalised Lyme disease population could be described from these data. This population 
had a bimodal age distribution, was predominately white, was from rural areas, and 
increasingly from areas with lower societal deprivation. Geographic distribution of cases 
could be described for England and Wales and showed the highest incidence of disease in 
southern central to south western England. These data showed an increasing incidence of 
Lyme disease. The relative incidence of Lyme disease cases varied between datasets, with 
the primary care data having the largest incidence of 4.42 per 100,000 person-years (95% CI 
4.23-4.67). Multiplication factors were described between the three datasets of routinely 
collected health care data. The most important being a multiplication factor of 2.35 (95% CI 
1.81-2.88) between laboratory-confirmed incidence and primary care incidence in England 
and Wales.  
The results from this thesis start to describe the epidemiological picture of Lyme disease in 
the UK; specifically identified as a research gap by the NICE guidelines. They will provide a 
platform for the many unanswered questions about the changing landscape of Lyme disease 
in the UK. It was concluded that a combination of health datasets could be used for future 
Lyme disease surveillance systems in the UK. Ideally this would include laboratory and 
primary care data. Until this is in place, the multiplication factor can be used to estimate the 
national incidence of Lyme disease and the potential burden it places on the National Health 
Service and the patients it afflicts.  
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Chapter 1 An Introduction 
 
 ‘it is believed that Lyme arthritis extends beyond the three communities 
studied here; but how far beyond is not known’ Allen Steere [1] 
In 1977 a group of American clinicians described ‘a previously unrecognized clinical entity’ 
and named it “Lyme arthritis” [1]. Lyme disease had entered the medical lexicon and the 
general public’s consciousness. Soon after this case description, Willy Burgdorfer isolated a 
spirochaete as the causal pathogen [2]. In his honour, this spirochaetal genospecies complex 
was named Borrelia burgdorferi sensu lato. Since Lyme disease’s ‘discovery’, interest grew in 
this ‘new’ disease and soon cases were being identified in the United Kingdom, the first cases 
being reported in the early 1980’s, with concerns being raised that we were on the brink of 
a new epidemic [3–8]. 
After the emergence of this pathogen onto the world stage, cases have steadily risen in 
number across the Northern Hemisphere [9,10]. The dawn of the social media age has led to 
a jump in the public’s awareness, with media stories, health scares, and subsequent cases 
spreading in a meme-like manner around the globe [11–15]. Despite the relatively recent 
recognition of this disease, cases had been seen in Europe prior to it being identified in Lyme, 
Connecticut. In fact, the first clinical description of the pathognomonic erythema migrans 
(EM) rash, was by a Swedish dermatologist, Arvid Afzelius, at a Swedish Dermatology 
conference in 1909 [16]. In the 1950’s, Hollström described a spirochaete being isolated from 
the EM lesion, and patients being successfully treated with penicillin [17], something which 
some clinicians still recommend for specific presentations of the disease today [18]. 
Recent research indicates that B. burgdorferi has infected humans since at least the Copper 
age (between the 5th and 3rd millennia BCE) [19], and has existed in the global environment 
for around 60,000 years [20]. The authors of the latter paper conclude that;  
‘the recent emergence of human Lyme disease probably reflects ecological change 
– climate change and land use changes over the past century – rather than 
evolutionary change of the bacterium.’ 
Despite the history and high profile nature of this disease within the general public and 
media’s minds, little epidemiological knowledge exists about Lyme disease within the United 
Kingdom (UK). The aim of this thesis is to utilise health data to fill in some of the gaps about 
Lyme disease in the UK, specifically in terms of incidence and patient demographics.  
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1.1 What is Lyme disease? 
1.1.1 Pathogen, vectors and hosts  
The causal pathogen of Lyme disease is B.burgdorferi sensu lato, which includes at least 
twenty different genospecies [21–23]. The three main genospecies responsible for disease 
in humans are B.burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinnii [22]. They rely 
on a variety of tick species to act as vectors to transmit the pathogen to humans and other 
species. These ticks all belong to the Ixodes genus, Ixodes ricinus is the predominant tick 
species in the UK (Fig. 1.1) [22,24].  
 
Figure 1.1 A female I.ricinus questing. ©ECDC/Guy Hendrickx. 
The enzootic cycle of B.burgdorferi is complex and varies depending upon geography, climate 
and local ecology [25,26]. Ixodes ricinus has been found on a wide range of host species, from 
deer, to small mammals and birds [24,27,28]. Within the tick life cycle, there is no vertical 
transmission of the spirochaetes, and the perpetuation of Lyme disease is reliant on 
horizontal transmission [21]. Therefore, at a local level, infected nymphs must feed and 
infect a host animal in spring, with subsequent uninfected larvae becoming infected by 
feeding on these reservoir hosts, which then moult to become infected nymphs the 
subsequent year. Some animals, such as deer and humans, will only act as dead end hosts in 
this cycle (Fig. 1.2).  
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Figure 1.2 The life cycle of Ixodes ticks and their relationship with reservoir and dead-end hosts. 
This life cycle can take up to three years to complete [21,29]. Only the nymph and adult life 
cycle stages can feed on humans [21,29]. They identify potential blood meals by detecting 
hosts through a process called questing, during which they wait on the edge of leaves or 
grass with their third and fourth pairs of legs waiting to grasp on to a host, whom they detect 
through odours, heat, moisture and vibrations [30]. Lyme borrelia reside within a tick’s 
midgut and undergo phenotypic change on exposure to a blood meal. This enables the 
spirochaetes to increase in number and populate the tick’s salivary gland [21]. To transmit 
Borrelia spp they must feed on the host’s blood. They appear to have to feed for at least 24 
hours to transmit the pathogen, with 10% transmission at 48 hours and 70% by 72 hours of 
attachment [31]. In the Netherlands it has been estimated that 2.6% of tick bites (with 
unknown Lyme status) result in the development of Lyme borreliosis [32]. This risk increased 
if the tick was engorged at time of removal and with the length of time attached increasing 
[32]. Once B.burgdorferi has been transmitted into the host’s dermis, it will multiply locally 
and be disseminated via the blood and lymphatic vessels [21]. 
1.1.2 Pathogenesis, clinical presentations and epidemiology 
Upon the inoculation of B.burgdorferi into a human host an innate and adaptive immune 
response is elicited. The majority of the resultant tissue damage to the host is due to this 
inflammatory process. The intensity of this varies depending upon the mix of genospecies 
present in the tick’s saliva.  
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Early dissemination is typified by erythema migrans (EM), Lyme neuroborreliosis or Lyme 
carditis. The type of erythema migrans lesion varies depending upon the genospecies 
involved. B.burgdorferi sensu stricto (predominantly found in North America) usually 
presents with multiple rapidly expanding rashes and is accompanied by flu-like symptoms. 
B.afzelii and B.garinii (most prevalent in Europe) tend to expand slower. B.afzelii is also 
associated with the rare manifestation of Borrelial lymphocytoma. B.garinii can present with 
a solitary lesion and can be associated with a burning sensation [18,21,23].  
Between days to weeks B.burgdorferi sensu stricto disseminates to multiple skin sites, 
causing multiple EM lesions, or to other organs. It appears to have a predilection to the 
peripheral and central nervous system (PNS and CNS), the heart and joints. B.afzelii tends 
not to disseminate and can persist at the same skin site for a long time. B.garinii is very 
neurotropic and will cause PNS and CNS abnormalities [18,21,23].  
The type of Lyme neuroborreliosis presentation appears to vary by genospecies. 
B.burgdorferi sensu stricto typically leads to lymphocytic meningitis with headaches and 
neck stiffness, neuropathies of the cranial nerves, and sensory or motor radiculopathies. 
B.garinii presents as Bannwarth syndrome, a lymphocytic meningoradiculitis. B.afzelii causes 
less specific neurological symptoms such as headaches, dizziness, and memory or 
concentrations disturbances [18,21,23].  
Late dissemination of Lyme borrelia infection is characterised by arthritis, acrodermatitis 
chronica atrophicans (ACA), and rarer neurological conditions. The main genospecies 
associated with arthritis is B.burgdorferi sensu stricto. Symptoms appear on average 6 
months post infection and are typified by swelling of the large joints and a persistent 
synovitis that can persist up to 4-5 years. ACA is associated predominately with B.afzelii and 
is seen more frequently in older women, though the reasons for this are unknown [18,21,23].  
In the United States between 2001 and 2016, 70% of 253,690 cases showed erythema 
migrans, 30% showed arthritis, 9% Bell’s Palsy, 4% radiculoneuropathy, 4% meningitis or 
encephalitis, and 1% showed cardiac symptoms [33]. There are no nationwide prevalence 
studies of clinical manifestations of Lyme disease in the UK. A few UK studies have identified 
the prevalence of B.burgdorferi genospecies found in I.ricinus ticks, however most were  
limited to localised tick collections (from one habitat or one region) or from ticks found on a 
specific city. The prevalence of B.burgdorferi s.l. carrying ticks ranged from 1.8-18.1%. Of the 
borrelia positive ticks between 10.5% and 60% were carrying B.garinii, 1.6-48% were carrying 
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B.afzelii, and 0-25.5% were carrying B.burgdorferi sensu stricto [34–37]. The largest study, 
based in Scotland, surveyed over 2200 ticks and found 5.6% positive for B.burgdorferi s.l.. Of 
these 48% were B.afzelii, 36% were B.garinii, 7% were B.burgdorferi sensu stricto, and 14% 
had a mix of genospecies [38]. One could hypothesis that, due to the genospecies mix, there 
would be less presentations of arthritis and more neurological presentations in the UK 
compared to the USA. Research is needed to establish the prevalence of different clinical 
presentations of Lyme disease in the UK.  
The very varied and subtle clinical presentation of Lyme disease presents a challenge for 
clinicians and researchers when creating a case definition. In this thesis, the case definition 
will be based on the recently published National Institute for Health and Care Excellence 
(NICE) guidelines [23]. This was chosen as the research committee who wrote the guidelines 
thoroughly reviewed all the scientific and medical literature, have many years of clinical and 
personal experience, and have applied this knowledge to make UK specific conclusions. 
Outlined below is a brief summary of the clinical presentations of Lyme disease outlined by 
NICE [23]. 
• Erythema migrans - A pathognomonic rash that usually arises a few days to four 
weeks post-exposure and lasts for several weeks. It is a red rash, which increases in 
size and can present with a central clearing, thus presenting with a textbook ‘bull’s 
eye’ rash (Fig. 1.3). Although it usually appears near the tick bite site and is not hot, 
itchy or painful, there can be multiple expanding rashes, away from the tick bite site. 
This latter feature is unlike a tick bite reaction, which it could be easily confused with. 
 
Figure 1.3 An erythema migrans rash. Image provided by the CDC. 
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• Non-focal symptoms – These include: flu-like symptoms (pyrexia, sweats, 
lymphadenopathy, fatigue), neck pain and stiffness, joint or muscle pain, cognitive 
impairment, headache, and paraesthesia. These symptoms matched with a history 
of possible tick exposure, increases the likelihood that a patient is infected with Lyme 
disease. 
• Cranial nerves and peripheral nervous system symptoms – These include: facial and 
cranial nerve palsies (including Bell’s palsy), mononeuritis multiplex, and 
unexplained radiculopathies. 
• Central nervous system symptoms – These include: meningitis, encephalitis, 
neuropsychiatric presentations, and unexplained white matter changes on brain 
imaging. 
• Other symptoms – These include: inflammatory arthritis often affecting multiple 
joints, cardiac problems (heart block and pericarditis), ocular symptoms (uveitis, 
keratitis), and other dermatological presentations (acrodermatitis chronica 
atrophicans (ACA), lymphocytoma). 
The age distribution of cases is bimodal, with peaks in pre-adolescence and late middle age 
[21,23,29,39]. The sex ratio is varied between nations and datasets analysed.   
In areas known to have Ixodes ticks, the risk of human infection is associated with: the 
abundance of ticks, the prevalence of B.burgdorferi infected ticks, the presence of a human 
in a tick habitat, and human behaviours that could increase the chance of being bitten 
[22,23]. This would include occupational and recreational habits.  
1.1.3 Diagnosis  
The NICE guidelines and other international guidelines all commonly state that clinicians 
should ‘Diagnose and treat Lyme disease without laboratory testing in people with erythema 
migrans’ [23,39–44]. This is due to the high specificity (88-99%) of this presentation [23]. If 
any of the other clinical presentations arise with a history suggestive of tick exposure, but in 
the absence of an EM, then a two-tier testing system is recommended by NICE [23]. The 
initial screening test is an enzyme-linked immunosorbent assay (ELISA) for IgM and IgG 
antibodies, based on C6 peptide or an equivalent VlsE antigen. If this test is positive or 
equivocal a confirmatory immunoblot should be performed. Timing of these tests is critical 
for interpretation, as a humoral immune response may not be strong enough to be diagnostic 
if the test is performed at symptom onset. It is recommended that diagnostic tests are 
performed at least 4 weeks after symptom onset and then potentially repeated 4 to 6 weeks 
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later. If signs persist for 12 weeks after a negative ELISA, an immunoblot should be 
performed. However, there is a consensus that patients with non-specific subjective 
symptoms are not recommended to undergo diagnostic testing because of a low positive 
predictive value [44]. 
Despite what appears to be a straight-forward diagnostic pathway there are some 
limitations. Firstly, the decision that an EM rash is pathognomonic only remains valid if the 
clinician recognises that the rash is an EM rash. An American study showed that 72% of 
clinicians are unable to correctly identify an EM over other common rash lesions in an 
ambulatory population [45,46]. Similar work has not been conducted in the UK. These results 
suggest that there is the potential for a high number of false negatives and a lot of missed 
early cases. The degree of missed diagnoses is likely to be highly variable due to the 
knowledge and experience of the clinician involved and the frequency and volume of Lyme 
disease cases seen in their clinic.  
The diagnostic recommendations currently all revolve around identifying a humoural 
response in a patient rather than identifying the presence of a pathogen. Methodologies 
proving the presence of the spirochaete involve culture and PCR. Due to the low bacterial 
load in blood it is very challenging to find the spirochaete in high enough numbers for 
diagnosis. They can be found in higher concentrations at the skin lesion, in synovial fluid and 
in cerebrospinal fluid. However, borrelia DNA persist after spirochaetal killing and so 
identification of the pathogen may not demonstrate an active infection. Results from these 
tests are highly variable with suboptimal sensitivities and are only utilised in research settings 
[18,21,23,44].  
Basing diagnosis on an immune response has its own set of limitations. It assumes that a 
patient produces an immune response and that this response is related to a current, rather 
than a past, infection. It also assumes that a diagnostic test is performed at the correct time 
to identify the immune response. Fifty percent of patients presenting with an EM rash are 
initially seronegative, but by 6-8 weeks after the presentation of clinical signs 99% will 
become seropositive [44]. Therefore, cases could be missed if the diagnostic tests are 
performed too early.  
When the tests, outlined above, are utilised at the correct time the average sensitivity across 
Europe has been reported at 80%, with an average specificity of around 95% [41,44]. To 
interpret the results of a test appropriately the background seroprevalence is needed. In the 
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UK this is unknown, but the Scottish population has an estimated seroprevalence of 4.2%, 
with regional seroprevalences ranging from 0% to 8.6% [47]. It is known that higher risk 
populations, such as hunters and forest workers, can have a seroprevalence of greater than 
20% [41,44]. When the background seroprevalence is low it makes interpreting a positive 
diagnostic test result harder as the positive predictive value will also be low. Using the above 
figures (prevalence = 4.2%, sensitivity = 80%, specificity = 95%) a positive predictive value of 
41.2% and a negative predictive value of 99.1% can be calculated. This means that, regardless 
of clinical presentation, only 41.2% of positive results are likely to represent infected 
individuals, where as 99.1% of test negative results correctly represent uninfected 
individuals. This example is only hypothetical and should be treated with a certain degree of 
caution, but it highlights why current recommendations suggest that serological testing is 
only requested when the clinical symptoms and case history are supportive of Lyme disease 
[23,41,44]. By adopting these guidelines, the likelihood of false positive results is reduced in 
patients with no Lyme specific symptoms and a low pre-test probability of Lyme disease.  
The diagnostic pathway for Lyme disease has some challenges. It is vital that clinicians at all 
stages of the diagnostic process, from primary care clinics to diagnostic laboratories, have as 
thorough clinical history as possible. This enables contextualisation of the diagnostic results 
and would lead to an appropriate interpretation and subsequent management of the 
patient.  
1.1.4 Management and Treatment  
For the majority of cases, which present with erythema migrans as the primary clinical 
complaint, patients can be managed in primary care. Those presenting with symptoms 
suggestive of a central nervous symptom infection or complete heart block are 
recommended to be referred under standard clinical emergency referral practices. For 
children, all presentations barring erythema migrans should be discussed with a specialist 
[23].  
Antibiotic therapy is the recommended course of treatment for all cases. Depending on the 
clinical presentation and age of the patient, the active ingredients used are: doxycycline, 
amoxicillin, azithromycin, or intravenous ceftriaxone. Use of non-antibiotic therapy is 
encouraged for certain symptoms, such as depression, chronic pain and fatigue [23]. 
1.1.5 Prognosis and controversies  
Persistent symptoms can occur after a course of antibiotics either due to re-infection, an 
interruption of the antibiotic course, or organ damage caused by Lyme disease. Some 
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patients can have prolonged arthritis as the inflammatory process during infection which can 
lead to the development of degenerative arthritis [22,23]. Patients with neuroborreliosis can 
have residual motor or sensory deficits. This is due to permanent nerve damage or the 
lengthened healing process of nervous tissue. ACA can also have prolonged symptoms after 
treatment, similar to other sequelae of long term skin infections. These include, skin atrophy 
and subluxation of small joints. However, the classical presentations of disease normally 
resolve after the completion of an antibiotic course [18]. Any non-specific subjective 
symptoms such as fatigue, cognitive impairment and musculoskeletal pain should also 
resolve.  
Some patients report symptoms for more than six months after treatment completion [48–
57]. These can last in excess of ten years and have been described as either ‘post-treatment 
Lyme disease syndrome’ (PTLDS) or ‘chronic Lyme disease’. There is much debate about 
whether these symptoms are more common with Lyme disease compared to healthy 
controls or other infections and how they should be managed [48–57]. This cohort of 
patients often present with similar symptoms to other infectious diseases with post-
infectious/latent sequelae. Notable examples include chronic Q fever [58–61] and infectious 
mononucleosis [62]. 
The pathogenesis and management of this presentation of disease for this subset of patients 
remains unclear, which can lead to great anger, frustration and tension between patients 
and clinicians. It is outside the scope of this thesis to discuss such a large and controversially 
debated topic. Nevertheless, regardless of disease pathogenesis this cohort of patients are 
ill and should not be dismissed. They deserve the most appropriate management and 
treatment based on the current scientific evidence base. 
1.2 What is the situation globally? 
As part of the Department of Health’s commissioned review into Lyme disease (section 1.3), 
a systematic review was performed into Lyme disease surveillance programmes that occur 
globally [9]. Before considering their findings, it must be noted that current evidence 
suggests that endemic Lyme disease cases can only occur where the Ixodes tick vectors live. 
This is restricted to the Northern hemisphere. Countries where Ixodes spp have been found 
in wild habitats are displayed in Fig. 1.4 [18,63]. 
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Figure 1.4 The known distribution of the tick vectors of Lyme disease, adapted from figures in [18,55] (The 
southern hemisphere hasn’t been included, as no competent tick vectors have been found there). 
Note that only a handful of countries in the Northern hemisphere do not have Ixodes ticks. 
This is may be a result of inhospitable habitats for the ticks (i.e. the ticks are truly absent), or 
a lack of tick surveillance in these countries (i.e. the ticks have not been reported). A 
Department of Health review of surveillance systems in Europe and North America [9] 
reported that, of the 34 countries assessed, 28 had national Lyme disease surveillance 
systems, 25 of which publicly reported surveillance figures (Fig. 1.5 and 1.6). 
 
Figure 1.5 The 2015 annual incidence (cases per 100, 000 population) of countries with national surveillance 
systems for Lyme disease in place (countries in grey have no national surveillance systems). Figures adapted 
from tabular results in [9]. 
As one can see, there is a large range in incidence figures, with Slovenia having the highest 
reported national incidence (181 cases per 100,000 per year) and many countries having an 
incidence of less than one case per 100,000 per year [9]. Not all countries have national 
surveillance systems in place (for example, Germany and Austria), but have regional 
surveillance systems. These countries were therefore not included in this systematic review.  
Surveillance data from the United States of America (USA) describes Lyme disease incidence 
rising from 6.7 cases per 100,000 population in 2004 to 8.1 in 2016 [29,64,65]. Surveillance 
methods in the USA vary between states and so it is likely that there is a large underestimate 
of cases [64,65]. There is also a huge range between states, with Louisiana having an 
incidence of zero and Maine having the highest at 86.4 [65]. This variability is likely due to 
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the differences in surveillance methods, the differing tick species and their relative 
abundance in each state, and the prevalence of Borrelia-carrying ticks. Nelson et al 
attempted to get a more representative incidence figure by looking at medical insurance 
claims; they calculated an incidence of 106.6 cases per 100,000 per year [64]. In 1990, less 
than 5,000 cases were reported from Europe to the World Health Organisation (WHO) 
Centralized Information System for Infectious Diseases; this has risen to over 35,000 cases in 
2010 [10]. A population-weighted incidence rate in Western Europe has been estimated at 
22.05 cases per 100,000 person-years [66]. Like the USA, there is a huge range in annual 
incidence captured by national surveillance systems in Europe (Fig. 1.5 and 1.6). This is likely 
due to the same reasons mentioned above. Overall there appears to be an increase in 
incidence both in Europe and North America over the last twenty years. Reasons for this are 
likely to include a mixture of: the different national surveillance systems, the changing case 
definitions between countries and globally, the increased awareness of the disease by the 
general public and clinicians, and a real increase in disease. 
 
Figure 1.6 The 2015 annual incidence (cases per 100,000 population) of national surveillance systems for Lyme 
disease, stratified by surveillance system type. Figures adapted from tabular results in [9]. 
Throughout North America and Europe, there are a variety of surveillance systems in place 
(Fig. 1.6). Only three surveillance systems, including the UK, rely solely on laboratory-
confirmed cases. The remainder either base their figures solely on clinician reported cases 
or a combination of confirmed cases and clinician reported cases. Seventy-five percent 
(n=21) of these systems require mandatory notifications; however the case definitions vary 
widely between the systems [9]. It was noted that the level of clinical detail needed to define 
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a case varied considerably, which was reflected in the precision of the incidence estimate. 
As a result, direct comparison of incidence between countries remains challenging. Some 
countries have no national surveillance (Sweden, Austria, Germany), which is surprising as 
they have reported high levels of Lyme disease. For example, some German states have an 
incidence as high as 74.8 cases per 100,000 [67], but surveillance is led by each state rather 
than at a national level.  
Lorenc et al’s systematic review found sixteen papers that attempted to compare different 
surveillance data to determine the completeness of surveillance systems [9]. Comparisons 
were only included in the analysis if they used consistent case definitions. A median estimate 
of the percentage of unreported cases was calculated at 30%, with a range of 10-120%. The 
studies were all performed in countries with mandatory clinician reporting; only five studies 
were based in Europe (Belgium, Denmark, Germany, Norway, and Slovakia). Data comparing 
laboratory data and clinician data were very limited. With a huge range of unreported cases, 
one could consider that the surveillance systems are performing badly. However, patient 
demographics, geographic location, and incidence trends remained constant over time in 
each of the studies. This suggests that each system is collecting a representative sample of 
the overall Lyme disease affected population, but not in the same consistent proportions. 
This led the authors to conclude that the introduction of mandatory clinician notification 
would increase the number of cases captured by surveillance, but it would not necessarily 
be a more reliable methodology than laboratory-confirmed cases alone. The systematic 
review succinctly concluded that, 
‘a combination of methods gives more complete coverage in terms of the 
identification of cases than any single method alone, but also that no combination 
can guarantee full coverage of all cases. Whether such a combination of systems 
gives a better representation of overall trends cannot be determined from the 
available data ’ [9] 
1.3 What is the situation in the United Kingdom? 
In November 2015, National Health Service (NHS) England commissioned NICE to develop 
clinical guidelines for Lyme disease. In May 2016, the Department of Health commissioned 
three reviews into the diagnosis, treatment and management of Lyme disease in the UK [68]. 
These were commissioned due to the growing call for UK-specific guidance and the increase 
in public and parliamentary lobbying of the UK government, as evident by recent 
parliamentary records. Between May 2014 and the end of 2017 there were 58 written 
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parliamentary questions to the Department of Health (Fig. 1.7), these peaked in 2016 when 
both the NICE guidelines and systematic reviews had been commissioned [68]. During this 
period there were two Commons Chambers debates, a House of Lords Grand Committee and 
four minor Commons debates, with at least four general public petitions to the government 
relating to Lyme disease with over 12,000 signatures [69].  
 
Figure 1.7 The number of written parliamentary questions by theme between May 2014 and December 2017. 
Based upon parliamentary records [60]. 
The main themes identified in these questions were around diagnosis (36%, n=21), incidence 
(24%, n=14), general public and medical practitioner awareness (14%, n=8), and NHS care 
provision (12%, n=7). 
To place this level of concern in to context, we can compare Lyme disease to Campylobacter. 
Campylobacter is a zoonotic infection, which has a much higher reported incidence (90.8 
cases per 100,000 in 2016), and has the potential for great political concern because of its 
impact on food safety. However, during the same time period there were only 15 written 
questions, and 15 verbal mentions in parliament, there were no parliamentary debates or 
petitions by the general public [68–70].  
Further evidence for the general public’s interest in Lyme disease can be observed in the 
increase in relative internet searches using the Google search engine in the UK (Fig. 1.8) [71]. 
These show a gradual increase until the summer and autumn of 2015, when there is a large 
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spike in searches. This is just before the announcement of the commissioning of NICE 
guidelines.  
 
Figure 1.8 The frequency score and annual sum of Google searches in the United Kingdom for ‘Lyme disease’. 
Based upon data provided by Google Trends [63]. 
This overwhelming increase in awareness of the general public and frequent debates and 
questions in parliament understandably led to the NICE guidelines and the Evidence for 
Policy and Practice Information (EPPI) systematic reviews being commissioned by the 
Department of Health. EPPI published their findings in November 2017 through five projects 
with the following scopes: 
1) The nature and extent of research evidence on Lyme disease in humans [22] 
2) The incidence of Lyme disease in the UK and the type of surveillance systems in 
different countries [9]. 
3) Patient, clinician and researcher experiences of Lyme disease diagnosis [72]  
4) Patient, clinician and researcher experiences of Lyme disease treatment [73] 
5) The effectiveness of different approaches for preventing Lyme disease [74] 
The second of these projects detailed the current epidemiological situation in the UK, and is 
most pertinent to the current thesis [9], finding eleven studies that detailed the incidence of 
Lyme disease in the UK. They were all based on official surveillance reports from the devolved 
nations of the UK, which are based on laboratory-confirmed cases only. They described a 
peak incidence in later middle age (40-64 years), with similar rates in men and women, and 
a large variation in incidence between nations (Fig. 1.9). 
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Figure 1.9 Government published Lyme disease incidence figures based on laboratory-confirmed cases (2007-
2016). NB. Reporting standards in Scotland changed in 2012. Figure derived from Public Health England’s 
Zoonosis Report [62]. 
UK incidence figures have risen from 1.67 cases per 100,000 in 2007 to 2.00 in 2016. This rise 
has been reflected in England and Wales (1.47 to 1.95), and Northern Ireland (0 to 0.21) [70]. 
In Scotland cases have remained relatively stable between 3 and 4 cases per 100,000, or the 
incidence may in fact be decreasing; in 2016 the incidence was 3.15 per 100,000. However, 
there is evidence that disease hot spots exist and national figures mask potentially significant 
geographical variation. In Scotland hot spots have been explicitly defined in the Highlands 
[75,76]. In England, hotspots are predominantly anecdotal, and no geographical surveillance 
data is published. With this lack of evidence the authors of the review conclude that,  
‘Given the absence of geographically comparable routine data, we cannot 
determine how much of the discrepancy is due to geographical variation and how 
much to under-reporting or under-diagnosis of Lyme disease. It seems likely that 
there is some combination of both these factors.’[9] 
Since these surveillance reports only use laboratory-confirmed cases; cases which do not 
require laboratory confirmation (predominantly erythema migrans) will not be captured and 
these surveillance figures will represent an underestimate. The report stated,  
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‘We do not know how many cases are diagnosed and treated in the UK on the basis 
of clinical symptoms alone, without a diagnostic test being ordered. Hence, it is 
challenging to establish the true extent of under-reporting.’ [9] 
The report’s authors also discussed how little is known about the reasons behind the rise in 
cases and whether it is reflective of the true incidence or a result of changes in reporting 
practice, awareness of clinicians and the general public, clinical practice, and healthcare-
seeking behaviours in patients.  
 The following conclusions were made: 
• The incidence figures in the UK are likely an underestimate. 
• Current UK data is currently unable to identify disease hotspots, especially important 
as publications suggest there is a large variation in localised incidence. 
• No contextual information is provided on location, demographics and clinical 
presentation of cases. 
The authors of the report suggested several surveillance policy options from their findings: 
a) Maintain the existing system with no change  
b) Introduce mandatory clinician reporting for all Lyme disease cases 
c) Introduce mandatory clinician reporting for late or disseminated Lyme disease cases 
d) Include Lyme disease in clinician sentinel networks 
e) Introduce enhanced surveillance using clinician questionnaires.  
NICE is an executive non-departmental public body of the UK’s Department of Health. It 
publishes guidelines on clinical practice, specifically guidance on the appropriate treatment 
and care of persons with a specific disease or condition. The NICE guidelines for Lyme disease 
were published in April 2018 [23]. Alongside recommendations of awareness, diagnosis, 
management and information to be provided to people affected by Lyme disease, they also 
published recommendations for research, including research into the clinical epidemiology 
of Lyme disease in the UK. They ask and state; 
‘What are the incidence, presenting features, management and outcome of Lyme 
disease…in the UK?’ 
‘There is a lack of robust epidemiological data on Lyme disease in the UK, 
particularly in people who are immunocompromised or pregnant. A large clinico-
epidemiological study to collect data on incidence, presenting clinical features, 
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management and outcome of Lyme disease in community and hospital settings in 
the UK would generate population-based statistics. These statistics would enable 
interventions such as antibiotic treatment and service improvements to be assessed 
properly, and for services to be tailored so they best serve people with Lyme disease; 
this was felt to be of high priority. There is no current requirement to notify cases 
of Lyme disease, therefore, current data are likely to under-estimate the number of 
people who are seen and treated in the community without serological testing. The 
morbidity of those who are not rapidly diagnosed and those who seek and receive 
non-standardised care outside the NHS would justify the costs of this large study.’ 
1.4 Summary and aims 
Little is known about the epidemiological situation of Lyme disease in the United Kingdom, 
specifically around the incidence, sociodemographics, clinical presentation, and 
management of Lyme disease cases. The government, non-departmental public bodies, and 
patient groups have all called for this situation to be redressed. If this enhanced data were 
to be analysed it would potentially impact on surveillance policy and enable the assessment 
of any future health interventions. The aims of this thesis, conceived before the NICE 
guidelines were published, were to appraise health datasets for their ability to describe the 
epidemiology of Lyme disease in the United Kingdom, and to evaluate their potential for 
Lyme disease surveillance.  
This will be achieved through the following research questions: 
• For each health dataset appraised (Chapters 3-8); 
o What is the incidence of Lyme disease? 
o What are the sociodemographics of the patient population? 
o Can any geographical hotspots be identified? 
o Can any data about patient presentation and management be extracted? 
o Is there any additional information about the epidemiology and 
management of cases which is unique to this dataset? 
• Using the current laboratory-confirmed based surveillance system (RIPL) as a 
reference point, how does each of the other dataset compare? How complete is each 
dataset, and is there a stable multiplication factor that can be applied to RIPL, that 
can provide an improved overall annual incidence estimate? (Chapter 9) 
• Based on the datasets analysed, what policy described by EPPI should the public 
health authorities of the United Kingdom adopt? (Chapter 10) 
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1.5 Thesis Outline 
This thesis is a research paper style thesis, that has two papers published (Chapter3 and 8), 
three in peer-review (Chapters 4, 5, 7), two additional non-published results chapters 
(Chapters 6, and 9), and a dataset selection chapter (Chapter 2). To maintain consistency in 
style, chapters 6 and 9 have been written in the style of research papers. In accordance with 
University of Liverpool guidelines, each chapter containing a published/in peer-review paper 
will have an introductory and discussion section explaining how it links to preceding and 
following chapters.  
The structure of this thesis follows the design of the hypothesised surveillance pyramid, 
displayed in Fig. 2.1, by initially exploring datasets at the top of the surveillance pyramid, and 
with each chapter descending to a lower level in the pyramid. 
Chapter 2 explains the decisions behind selecting the datasets that were chosen for analysis. 
Chapter 3 describes the incidence and sociodemographics of laboratory-confirmed Lyme 
disease patients in England and Wales’ national Lyme reference laboratory (RIPL), and PHE’s 
laboratory surveillance system (SGSS).  
Chapter 4 describes the incidence and sociodemographics of Lyme disease patients 
identified through ICD-10 codes in English (HES) and Welsh (PEDW) hospitals.  
Chapter 5 describes the incidence and sociodemographics of Lyme disease patients 
identified through Read codes in a primary care electronic health record dataset (THIN).  
Chapter 6 describes a novel blinded questionnaire study of primary care clinicians to identify 
coding behaving in relation to Lyme disease, as a methodology to validate the Read codes 
utilised to produce the results in Chapter 5.  
Chapter 7 describes the spatial and temporal incidence of Twitter users who tweet about 
Lyme disease in the UK and the Republic of Ireland.  
Chapter 8 describes the spatial and temporal incidence of ticks identified in companion 
animal electronic health records (SAVSNET).  
Chapter 9 compares each dataset, their degree of agreement and completeness. 
The thesis concludes with a discussion in Chapter 10, drawing personal conclusions and 
recommendations about what surveillance strategy and policy the British government could 
adopt in the future.  
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Chapter 2 Dataset selection for analysis 
 
When assessing which health dataset may capture information on Lyme disease patients, 
and prove beneficial for this research, it was useful to construct a surveillance pyramid (Fig. 
2.1). 
 
Figure 2.1 A proposed surveillance pyramid for Lyme disease in the United Kingdom 
This pyramid displays where patients may interact with the NHS in relation to Lyme disease, 
with each level being relatively proportional in size to the suspected number of patients at 
each level. At each of these points health records may be generated that if assessed could 
help answer the aims of this thesis. Below is a description of the datasets available, and the 
reasoning behind why certain datasets were used in analysis. It must be first noted that this 
research took place within the National Institute for Health Research Health Protection 
Research Unit in Emerging and Zoonotic Infections, which is a partnership between the 
University of Liverpool, the Liverpool School of Tropical Medicine (LSTM), and Public Health 
England (PHE). This means that certain datasets are directly accessible through PHE, and as 
such were prioritised to minimise project costs. Due to the project being funded through 
PHE, it was important that the predominant focus was exploring datasets that described the 
situation in England and Wales, however, if information was collected about Scotland and 
Northern Ireland this was also considered beneficial. It was also beneficial to access data that 
could easily be made available to PHE, as any adaptations to PHE’s surveillance systems as a 
result of this thesis would require on-going access to the same data. 
Laboratories
Hospitals
Primary Care/General 
Practice
Unreported cases in the general 
population
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2.1 Laboratory datasets 
In the 2010 Health Protection (Notification) Regulations [77], Borrelia spp are classified as a 
‘Schedule 2 – Causative Agent’. Thus, if any of the species of the Borrelia genus capable of 
causing Lyme disease are identified by a diagnostic laboratory, they should be notified to 
PHE [78]. The system that captures this reported data is The Second Generation Surveillance 
System (SGSS). This represents the official pathway for any laboratories (NHS or private) 
across England, Wales and Northern Ireland to notify PHE of any positive identification of 
Borrelia burgdorferi. SGSS performs surveillance for many other pathogens that can be 
identified through routine laboratory diagnostics. A recent example of its surveillance 
activities include a study exploring the relationship between laboratory-confirmed cases of 
Campylobacter and Cryptosporidium and daily weather parameters [79].  
However, the national Lyme disease surveillance figures in the ‘Zoonoses Report’ are not 
based on SGSS reports but instead come from two reference laboratories [70]. These are the 
Rare and Imported Pathogens Laboratory (RIPL) based at Porton Down, England [80], and 
the National Lyme Borreliosis Testing Service based in Inverness, Scotland [81,82]. RIPL 
performs critical laboratory work for the British government; examples of which include 
performing infectious disease seroprevalence studies of British military personnel in 
Afghanistan [83], and investigating outbreaks of hantavirus, a potentially emerging public 
health threat in the UK [84]. 
Both of the reference laboratories use the two-tier diagnostic protocol described in Chapter 
1 and recommended by the NICE guidelines [23]. RIPL provides services for England and 
Wales, whilst Inverness provides services for Scotland. It is unclear where Northern Ireland’s 
official figures originate from as no laboratory is specifically mentioned in reference to 
diagnostic sample submission [85]. As this project is supported by PHE, only the RIPL 
database was used for further analysis. It must be noted that some private laboratories will 
perform Lyme disease diagnostics; some following NICE guidelines and others not. Results 
from these will only appear in the SGSS dataset if these laboratories are following the Health 
Protection Regulations. Any patients that have diagnostic tests performed abroad won’t be 
captured by the two datasets included in this analysis. RIPL and SGSS datasets will be 
discussed in Chapter 3. 
2.2 Hospital datasets  
Information about patient care during hospital emergency department visits, inpatients 
admittance and procedures, and outpatient clinics varies between the four nations of the 
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UK. All have the potential to describe Lyme disease patients and their care by utilising 
International Classification of Diseases, 10th Revision (ICD-10) codes [86]. In England, Hospital 
Episode Statistics (HES) captures data from NHS England emergency departments, 
admissions, and outpatients [87]. HES were developed to primarily calculate payments, 
monitor trends in NHS hospital activity patterns, assess effective delivery of care and support 
policy and accountability. As such, HES was never envisioned to be used as an 
epidemiological research dataset; nevertheless, this is now one of its main secondary uses 
[87–91]. In Wales, Patient Episode Database for Wales (PEDW) has collected data on NHS 
Wales hospital admissions since 1997 [92,93]. No information is collected on emergency 
departments and outpatient departments. Scotland collects NHS Scotland hospital data on 
inpatient admissions, inpatient day cases and outpatient, and is published as ‘Acute Hospital 
Activity and NHS Beds Information’ [94]. No data is collected from emergency departments. 
Northern Ireland collects data on outpatients, admissions and day cases as hospital activity 
statistics [95]. It also collects data on emergency care activity [96]. Both HES and PEDW have 
been used previously as research datasets. A recent systematic review reviewed 148 
research articles that used HES as their data source [88]. Many of these were exploring 
specific treatment and outcome trends, and 11.5% were exploring the epidemiology of a 
specific disease or condition. Examples include, a study exploring the admission trends of 
adverse drug reactions for a ten year period [97], and a study exploring the prevalence and 
associated mortality of lower limb amputation [98]. Likewise, PEDW has been used as a data 
source for many epidemiological studies including a study exploring the demographic and 
socioeconomic inequalities of emergency admission for violence [99], and another describing 
the rising trend of obstetric anal sphincter injuries [100]. Due to the ease of data access 
through PHE, the HES and PEDW datasets were taken forward for further analysis. Similarly 
to the laboratory datasets there are no publicly available datasets that explore information 
about patient care in private hospitals. These datasets will be discussed in Chapter 4. 
2.3 Primary care datasets 
Since the 1980s, patient primary care clinical records have been increasingly collected and 
stored on computer databases rather than traditional paper records [101]. To support this 
digitalisation, Read codes were developed. Read codes are a hierarchical standard clinical 
terminology system that encode multiple patient details including; clinical signs, symptoms, 
laboratory tests and results, diagnoses, therapeutics, surgical procedures, demographics, 
and a variety of administrative items [101]. These codes are now used by virtually all general 
practitioners (GPs) in the UK and have enabled the development of the Quality and 
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Outcomes Framework (QOF), GP commissioning, and GP fundholding; all of which are 
integral parts of modern UK primary care. Practice management systems (PMS) are 
computer software used for the day-to-day administration of a GP practice but also the 
recording of clinical records. In 2011, seven PMSs held 99% of the market share in England 
[102,103]; equivalent figures are not available for the rest of the UK. The PMSs are; EMIS 
systems (54.7% share of practices), Vision V.3 (18.1%), SystmOne (17.8%), and the remaining 
9.4% is made up of Synergy, Practice Manager, Premiere and EMIS Web [102,103]. For all the 
databases, information on geographic coverage is restricted to England. The use of PMSs has 
enabled the creation of large databases of primary care electronic health records (EHRs), 
which by utilising patient’s Read codes can be used for medical research. The owners of the 
PMSs have enabled the use of these EHR databases for the research community, the four 
with the greatest number of patient records being the Clinical Practice Research Datalink 
(CPRD), The Health Improvement Network (THIN), QResearch and ResearchOne. All of these 
had the potential to be used in this project, below is a brief summary of each system.  
CPRD [104] – This database has existed since 1987 (previously the General Practice Research 
Database), and in 2017 covered around 8% of the UK population, with over 700 contributing 
practices and heath records from over 17 million patients in its database. It primarily utilises 
data from Vision and is in the process of adding EMIS and SystmOne practices. The strength 
of CPRD lies in the fact that it is the best established as a research tool with over 1,800 
publications. However, along with THIN, it has one of the most restricted geographical 
distributions with a lack of significant coverage in the North and East of England [102], with 
most practices in London, the south and West Midlands. Many studies have explored CPRD 
data, notable examples include: survival analysis of patients with liver cirrhosis [105], 
validation of Read codes to identify patients with chronic obstructive pulmonary disease 
[106], and validation of cases of suicide and self-harm [107]. At the time of planning and 
design of the work presented in this thesis, the University of Liverpool or PHE did not have a 
license to access the data, and a data extract just for this project was beyond the realms of 
the project budget. 
THIN [108] – This was established in 2003 and collects records from Vision with around a 
60% overlap with CPRD. In 2015 it covered around 6% of the UK population, with over 500 
practices and over 11 million patient heath records. It is the second most commonly used 
database in terms of research with over 500 publications. Two studies using THIN include; a 
2013 study exploring gender differences in consultations in UK primary care [109] and a large 
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study exploring the incidence, prevalence and treatments of patients diagnosed with type 2 
diabetes mellitus [110]. The same issues with geographical distribution as CPRD remain. The 
biggest advantage of this database was that PHE holds an institute THIN license, and so 
access to the database would have no cost for this project.  
QResearch [111] – This is the largest UK database as it collects data from the EMIS system. 
In 2017 it contained around 1,500 practices and over 30 million patient health records. 
QResearch has the best geographic coverage with only small isolated regions with no 
coverage. It is partnered with the University of Nottingham, who is the sole data controller 
and point of access. Over 200 papers have been published, but the majority have been 
authored by three University of Nottingham researchers [112]. Examples include: a study 
exploring the adverse outcomes of antidepressant use in an adult non-geriatric population 
[113], and a study describing the risk of pneumonia in patients who have been prescribed 
statins [114]. Dataset extracts are limited to 100,000 patients to non-University of 
Nottingham users, and a cost would be involved to receive this extract.  
ResearchOne [115] – This collects data from the SystmOne PMS and is held in partnership 
with the University of Leeds . It holds over 15 million active records from primary care from 
over 2000 GP practices. It has the second greatest geographical coverage; however, there is 
no presence in parts of the North West, West Midlands, London and the South East. It is a 
relative new comer as an EHR database, with less than 50 publications and so there is less 
familiarity with how to utilise its data. Examples of its usage include a paper showing the 
increased use of opiates and a resultant premature mortality among patients with 
inflammatory bowel disease [116], and a paper estimating primary care attendance after 
vaccination [117]. The newness of this dataset has resulted in it being the cheapest cost for 
data extraction out of the databases identified.  
It must be noted that all of these databases have been deemed demographically 
representative of the UK general population [117–120]. At the time of choosing the 
appropriate database to analyse for this thesis, the research on geographic coverage had not 
been published and so the decision was based on ease of access, cost and population 
coverage. THIN came top in the first two out of these three categories as it sits on the PHE 
servers, and would be cost neutral to the project. We therefore took THIN forward for 
analysis. This dataset will be discussed in Chapters 5 and 6.  
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2.4 Datasets describing unreported cases in the general population 
The estimation of the incidence of community-level infections that do not present to a health 
care professional will always be a challenge. To date, large studies have been performed in 
disease areas that have much higher morbidity and mortality, and higher general public 
knowledge and awareness than Lyme disease. This includes infectious intestinal disease, 
acute respiratory infections, and influenza type illnesses. For infectious intestinal disease a 
UK population cohort study was performed following 6,836 participants for a year to 
understand rates of disease in the community [121]. This was then compared GP 
presentation rates and national surveillance figures. They found 274 (253-295) cases per 
1000 person-years in the community compared to 17.7 (14.4-21.8) in general practice and 
1.9 reported to national surveillance. This resulted in a community to national surveillance 
incidence ratio of 147 (136-158) and 9.5 (7.7 to 11.7) between GP and national surveillance. 
The MoSAIC study was a similar design but following 789 New Yorkers for acute respiratory 
infections and influenza like illnesses [122]. Only 23.5% of participants who had a disease 
episode had an associated medical visit, 16.6% to primary care and 4.4% to a hospital 
emergency department. Both of these studies demonstrate that there is the potential that 
for any given condition there is a large portion of the population that won’t seek professional 
health care help and advice. Therefore, relying on an incidence figure based solely on a 
primary care, hospital or laboratory diagnosis is almost always going to underestimate the 
true incidence of disease. 
Estimation of the size of this population in regards to Lyme disease poses a challenge. Lyme 
disease has a much lower incidence than either gastrointestinal or respiratory disease 
described above, and a cohort study would therefore need a very large study population and 
long follow-up period to obtain enough cases. This was deemed beyond the realms of 
possibility for this thesis both in terms of time and cost. Instead, it was decided to see 
whether there were datasets that could be used as a proxy to estimating incidence and 
seasonal trends. 
In recent years the increasing global access and utilisation of the internet has led to a huge 
increase in using internet data as potential sources for disease surveillance and outbreak 
prediction. The most infamous of these has been Google flu trends [71,123]. However, after 
its initial well-trumpeted success, errors soon appeared in its outbreak detection. Suggested 
reasons for this included its vulnerability to overfitting seasonal terms unrelated to flu, and 
that it did not account for changes in search behaviours over time. Other criticisms were a 
lack of transparency and replicability with a lot of the research, such that, rather than being 
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a substitute for more traditional surveillance, it should be seen as a complement [124]. To 
do research on Google data with a degree of geographical resolution is expensive. Due to the 
expense and the lack of clear methodology and transparency, it was decided not to explore 
this dataset in this thesis. However, more accessible internet data sources are social media 
[125–129].  
Social media are websites and applications that allow users to share and create content, and 
to participate in social networking. Millions of users in the UK use these platforms to network 
over a wide variety of topics, just one of which may be Lyme disease. In 2017, the most 
popular UK platforms in terms of users were Facebook (32 million users, 48% of the UK 
population), YouTube (19.1 million, 29%), and Twitter (20 million, 30%) [130]. These 
platforms all offer the opportunity to utilise their users’ data for research and marketing 
purposes, and they have all had their potential utility for disease surveillance explored [125–
129]. Unless fees are paid, Facebook currently only allows users to explore data related to 
their own social network. It was therefore ruled out as a platform to explore. YouTube is a 
mixed media platform primarily based on user-uploaded videos and related comments. This 
poses a large challenge for research, as hours of video content would need to be watched to 
draw any conclusions; this was considered too time consuming and beyond the scope of this 
project [131,132]. Twitter allows users to post and interact with messages of 280 characters 
(Tweets) that are created by the users. Twitter has enabled users to create databases on all 
tweets defined by a search term and geographical area. A number of projects have 
successfully used this platform for disease surveillance and measuring the concern of the 
general public  [129,133–136]. These have included a study exploring the spatiotemporal 
nature of tweets in relation to the 2012-2013 influenza season in New York [134], and 
another using Twitter to explore the general publics’ concerns and ability to monitor disease 
activity in a national H1N1 influenza outbreak in the USA [135]. With well-recognised 
methodology and free access, it provides an excellent resource to use as a database, and will 
be discussed in Chapter 6. 
It has been proposed by numerous authors that companion animals, and dogs in particular, 
can be used for sentinels for both tick distribution and Lyme disease incidence [34,137–142]. 
In 2008 the University of Liverpool launched the Small Animal Veterinary Surveillance 
Network (SAVSNET) [143]. At the time of writing, this surveillance scheme collects EHRs from 
over 500 veterinary primary care clinics across the UK and laboratory data from most of the 
largest veterinary diagnostic laboratories in the UK. SAVSNET has previously been used to 
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describe diseases with a zoonotic potential, in particular salmonellosis [144] and Babesia spp 
[145]. SAVSNET provides the perfect platform to examine whether companion animals 
infested with ticks can act as a proxy for Lyme disease risk. The SAVSNET data is my final 
dataset to be analysed and will be discussed in Chapter 8.   
2.5 Ethical requirements of data access 
During the selection of the above datasets consideration had to be taken about data access 
and the ethical requirements needed to enable this. Within the NHS, scientific studies and 
data analysis can be defined as research, service evaluation, clinical audit or surveillance 
[146,147]. Each of these have varying levels of ethical approval, it is therefore critical to 
understand how the studies outlined in this thesis are defined. The key determinants to 
understanding whether a study is defined as research are intent, intervention, allocation, 
and randomisation [146]. The primary intent of research is to derive generalisable new 
knowledge, for audit and service evaluation it is to measure standard of care, and for 
surveillance it is to investigate health issues in a population to improve population health or 
to investigate outbreak or incidence to help in disease control and prevention. Only research 
involves an intervention, an allocation of treatment or service by protocol, and 
randomisation. Using these criteria and in discussion with PHE’s Research Ethics and 
Governance Group, including the local Caldicott Guardian, the analysis for each dataset was 
categorised accordingly. 
RIPL and SGSS collect anonymised patient data for public surveillance under The Health 
Protection Legislation (England) Guidance 2010 [148]. The analysis of these data was for 
disease surveillance purposes and there was no intervention, allocation or randomisation. It 
was therefore defined as surveillance and no ethical approval was needed. These data were 
provided to the author securely and anonymised in summary tables over the PHE network 
and were analysed and stored on PHE’s secure servers. 
HES and PEDW collect anonymised patient data. The analysis was for disease surveillance 
purposes and there was no intervention, allocation or randomisation. The analysis of these 
data was therefore defined as surveillance and no ethical approval was needed. HES pseudo-
anonymised data can be accessed internally within PHE through the application of a data 
access form. This ensures that, in this instance, data can only be used for health surveillance 
and mapping patient pathways. Data can only be accessed through a PHE network. The 
applicant must have completed NHS data security training and must understand how to 
maintain patient confidentiality. The application includes a summary of the project and if 
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probity issues are raised data access would not be granted. Data access was provided for this 
project. To access PEDW a data access request was sent to NHS Wales Informatics Service 
[92] clearly stating the data was being analysed for surveillance purposes, the intent to 
publish the data, and that the data would be stored securely on PHE servers. Access was duly 
provided, and NHS Wales was acknowledged on the resultant publication.  
PHE have a data access agreement in place with IMS Health, the data owners of THIN, to 
allow pseudo-anonymised non-linked data to sit on their servers. To access the THIN dataset 
a data access request and study protocol must be submitted to IMS Health’s independent 
Scientific Review Committee. This committee treat all requests as research and as such they 
go through a rigorous scientific and ethical review process. They are given this remit by the 
NHS Multi-centre Research Ethical Committee (MERC) and is certified by the Information 
Commissioner’s Office [108]. Access, analysis and publication of the results of the data was 
granted under the reference number 16THIN103.  
In chapter 6 a mixed methods questionnaire was utilised to validate the Lyme disease 
associated Read codes used in the analysis of THIN data. The questionnaires were targeted 
at primary care clinicians. Any scientific study involving clinicians is deemed as research and 
ethical approval was therefore sought. The project was granted REC (NHS Research Ethics 
Committee) and HRA (Health Research Authority) approval under the IRAS (Integrated 
Research Application System) project ID: 208815. 
All the data provided through Twitter’s API (Application Programming Interface) is publicly 
available. The University of Liverpool’s Research Support Office [149] clearly stated that any 
research that ‘involves information freely available in the public domain’ does not require 
research ethics approval. Therefore, research ethics approval was not sought for the 
methodology described in chapter 7.  
The overall ethical approval for the SAVSNET research project was provided by the University 
of Liverpool research committee (RETH00964). To apply for data access for specific projects 
a request and project protocol must be sent to the SAVSNET Data Access and Publication 
Panel. They review the methodology and any resultant publication to ensure robust analysis 
and to maintain anonymity of any potentially identifiable person. Permission to analyse the 
data as described in this thesis and the publication were approved by the Data Access and 
Publication Panel (201601AR002). 
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2.6 Conclusion 
It was decided to take seven datasets forward for analysis. RIPL and SGSS were chosen as 
laboratory datasets (Chapter 3). HES and PEDW were chosen as hospital datasets (Chapter 
4). THIN was chosen as the primary care dataset (Chapter 5). Finally, Twitter (Chapter 7) and 
SAVSNET (Chapter 8) were chosen as datasets representing unreported cases in the general 
population. 
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Chapter 3 Surveillance of Lyme disease in laboratory datasets 
 
Parts of this chapter, relating to the Rare and Imported Pathogens Laboratory data, are 
currently in press as: Tulloch, J., Semper, A., Brooks, T., Russell, K., Halsby, K., Christley, R., 
Radford, A., Vivancos, R., Warner, J. (2019). The demographics and geographic distribution 
of laboratory-confirmed Lyme disease cases in England and Wales (2013-2016): an ecological 
study (BMJ Open). 
3.1 Introduction 
In the United Kingdom (UK) Lyme disease is currently not a notifiable disease, but laboratory-
confirmed Borrelia spp. are notifiable causative organisms [77]. In the 2010 Health 
Protection (Notification) Regulations [77], Borrelia spp are classified as a ‘Schedule 2 – 
Causative Agent’. By obeying Provisions 4.1 of this legislature, ‘the operator of a diagnostic 
laboratory must notify the Health Protection Agency ([sic] Public Health England (PHE), from 
2013) in accordance with this regulation where the diagnostic laboratory identifies a 
causative agent in a human sample’, and ‘notification must be provided in writing within 7 
days’. Thus, if any species of the Borrelia genus capable of causing Lyme disease were 
identified by a diagnostic laboratory, it should be notified to PHE [78]. 
The Second Generation Surveillance System (SGSS) is a tool developed by PHE, for the 
electronic reporting, storage and management of information regarding laboratory 
notifications [150]. It is the recommended method for capturing infectious disease 
laboratory surveillance data across England, Wales and Northern Ireland. Information 
captured via SGSS are summarised in Table 3.1. 
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Table 3.1 Information captured via SGSS, mandatory fields (according to The Health Protection (Notification) 
Regulations 2010) (69) are marked with an *. 
Field More details 
Source lab  
Reference lab  
Reporting lab and address * Usually source lab, sometimes reference 
lab 
Patient identification * • Patient’s surname and initial * 
• Patient’s hospital number 
• Patient’s NHS number * 
Date of Birth (DOB)* If DOB is unknown, then patient’s age 
Sex *  
Organism * Full organism name 
Date of onset Date of onset of illness caused by organism 
reported 
Specimen type(s) *  
Specimen date(s) *  
Identification method Method used to identify the organism 
Patient’s home 
address/residence including 
postcode * 
 
Ethnicity *  
 
SGSS, therefore, represents the official pathway for laboratories across England and Wales 
to notify PHE of any positive identification of Borrelia burgdorferi; some cases from Northern 
Ireland are also recorded. 
Public Health England’s current Lyme borreliosis reference diagnostic service has been based 
at the Rare and Imported Pathogens Laboratory (RIPL) since 2012 [23,151]. It provides 
specialist advice and diagnostics for Lyme disease to the National Health Service (NHS) in 
England and Wales. For Lyme disease it offers the current best practice diagnostic protocol 
for disease confirmation [23,41,42,44,152]. This uses a two-tier methodology: an initial C6 
antigen-based ELISA screening test, followed by a confirmatory Western blot. RIPL offers 
advice from consultants with years of experience with Lyme disease, and is the reference 
laboratory for England and Wales. As RIPL forms part of PHE, disease notification is an 
31 
 
automated process. The RIPL laboratory-confirmed cases are used to construct PHE’s 
England and Wales Lyme disease surveillance figures [153]. 
Upon receiving a patient’s tissue sample, NHS and private diagnostic laboratories have a 
choice to make. They can send all their suspect Lyme disease samples directly to RIPL, 
perform screening tests and send onwards only confirmatory samples, or do both screening 
and confirmatory tests themselves. In theory these referring laboratories should only report, 
through SGSS, positives from their own confirmatory tests. However, it is unknown how they 
report, which of the tests they report, and which tests they perform. Without understanding 
what the incidence and demographics of RIPL confirmed Lyme disease cases, and SGSS 
notifications are, and how they compare, it would be challenging to get an understanding of 
the laboratory-confirmed incidence of Lyme disease in England and Wales. 
Historical information regarding the demographics, geographic distribution, and 
socioeconomic status of Lyme disease cases in England and Wales is limited. Laboratory 
surveillance data published in 2000 describe an equal sex ratio at all ages; however, numbers 
were not provided and statistical comparison was not performed [154]. The authors of this 
paper described a bimodal age distribution with peaks in childhood and at 45-64 years old. 
They also described a tendency for cases in southern England, especially around the New 
Forest. However, this data may not reflect the current distribution of Lyme disease cases in 
England and Wales. More current data is urgently needed to enable targeted public health 
messaging and intervention strategies.  
Work to explore the association between socioeconomic status and Lyme disease incidence 
is limited. In the United States of America (USA), persons were found to be at greatest risk 
of Lyme disease if they lived in the highest or lowest socially vulnerable areas [155]. Two 
studies found a relationship between Lyme disease incidence and median annual household 
income, with incidence peaking at around 80,000 USD [156,157]. However, a consistent 
relationship between the socioeconomic state of an individual and their Lyme disease 
acquisition risk has yet to emerge. No in-depth research has been published in Europe 
investigating the socioeconomics of the Lyme disease patient cohort. 
The aim of this chapter is firstly to describe the incidence, socio-demographics and 
geographic distribution of laboratory-confirmed Lyme disease cases captured through 
routine Lyme disease surveillance in both the RIPL and SGSS datasets. Secondly the two 
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datasets will be compared, and formal recommendations made about how PHE’s laboratory 
surveillance could be improved. 
3.2 Methodology 
3.2.1 RIPL Data Analysis 
A retrospective analysis was performed using data extracted from the PHE Rare and 
Imported Pathogens Laboratory’s (RIPL) laboratory information management system (LIMS), 
between 1st January 2013 and 31st December 2016, for laboratory-confirmed Lyme disease 
cases, the same data as used for PHE’s Zoonoses Report [153]. The RIPL LIMS contains 
information provided on the Lyme disease referral form submitted at the time of sample 
submission and any additional information provided by clinicians during case follow up and 
management [158]. The form captures information on the age, gender, location, clinical 
symptoms and travel history of the patient. Data were cleaned, and duplicates were 
removed where necessary. 
Annual Lyme disease incidence estimates were calculated using the Office for National 
Statistics (ONS) mid-year population estimates as the denominator population [159]. A Chi-
squared test for trend and a Chi-squared test for departure from the trend were used to 
analyse trends in incidence. Cases were stratified by age and gender. Using binomial tests, 
the null hypothesis that there was no difference in case numbers between males and females 
was tested within differing age bands, and overall. 
Geographical information was collated based on (1) the regional origin of a diagnostic sample 
(usually a hospital microbiology department) consisting of eight PHE regions, and Wales as a 
whole [160], and (2) the postcode area of the patient. These were used to calculate average 
annual incidence for the study period. In an attempt to account for the unknown distance 
between a patient’s home address and where they were bitten, the disease incidence map 
for postcode area was smoothed using a k-nearest neighbours (k-NN) approach [161–163]. 
k is defined as the number of neighbours used for smoothing and is equal to the square root 
of the total number of discrete geographical areas rounded to the nearest whole odd number 
(i.e. 105 postcode areas, its square root being 10.2, therefore k=11). Exploratory spatial data 
analysis (ESDA) [164,165] was used to explore the spatial autocorrelation of the postcode 
area incidence map. Global and local Moran’s I values were calculated, and a LISA (Local 
Indicators of Spatial Association) significance map constructed to highlight any significant 
clusters. In both the k-NN smoothing and Moran’s I calculations, a queen adjacency matrix 
was used. A queen contiguity was chosen as, unlike a rook contiguity, it defines neighbours 
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as being on both the edges and vertices of a polygon, and therefore better captures all true 
neighbours of a postcode area [166].  
Patient postcode was linked to ONS socioeconomic data [159], enabling a description of the 
socioeconomic characteristics of the population in which a Lyme disease case was resident. 
If no patient postcode was recorded, these cases were excluded from the analysis. 
Socioeconomic status is reported through the English Indices of Deprivation (EID) 2015 [167] 
and the Welsh Index of Multiple Deprivation (WIMD) 2014 [168]. 
The EID ranks 32,844 geographies (‘Lower super output areas’) containing between 1000 and 
3000 population and groups these in to deciles where 1 represents the areas with the highest 
levels of deprivation and 10 the lowest. The WIMD is ranked in a similar manner but is then 
grouped into the following categories; the 10% with the greatest deprivation, moving up 
through decreasing levels of deprivation in intervals from 10-20%, 20-30%, 30-50%, and the 
50% least deprived areas. The EID and WIMD categorize each geographical area with a 
variety of deprivation domain scores to build a summary index figure (Table 3.2). The ONS 
classifies these same geographies, in England and Wales, with a rural urban classification 
[169].  
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Table 3.2 Summary of the English Indices of Deprivation 2015 (156) and Welsh Index of Multiple Deprivation 
(157) domains, and their weighting to calculate an Index of Multiple Deprivation 
English Indices of 
Deprivation (EID) Domain 
Description Weighting for construction of 
Index of Multiple Deprivation 
(IMD) 
Income Deprivation 
Domain 
Proportion of population experiencing deprivation due 
to low income 
22.5% 
Employment Deprivation 
Domain 
Proportion of working age population excluded from 
the labor market 
22.5% 
Education, Skills and 
Training Deprivation 
Domain 
Measures the lack of attainment and skills in the local 
population 
13.5% 
Health Deprivation and 
Disability Domain 
Measures the risk of premature death and the 
impairment of quality of life through poor physical or 
mental health 
13.5% 
Crime Domain Measures the risk of personal and material 
victimization at local level 
9.3% 
Barriers to Housing and 
Services Domain 
Measures the physical and financial accessibility of 
housing and local services (schools, supermarkets, 
primary care and post offices) 
9.3% 
Living Environment 
Deprivation Domain 
Measures the quality of the local environment 
(housing, air quality and road traffic accidents) 
9.3% 
Index of Multiple 
Deprivation (IMD) 
Overall measure of deprivation constructed by the 
weighted sum of the above domains 
 
Welsh Index of Multiple 
Deprivation (WIMD) 
Domain 
Description Weighting for construction of 
Welsh Index of Multiple 
Deprivation (WIMD) 
Income Domain Proportion of population experiencing deprivation due 
to low income 
23.5% 
Employment Domain Proportion of working age population excluded from 
the labor market 
23.5% 
Health Domain Measures the lack of good health 14.0% 
Education Domain Measures the extent of deprivation relating to 
education, training and skills 
14.0% 
Access to Services Domain Measures deprivation due to a households inability to 
access services considered necessary for day to day 
living. 
10.0% 
Community Safety Domain Measures deprivation relating to living in a safe 
community 
5.0% 
Physical Environment 
Domain 
Measures factors in the local area that may impact on 
wellbeing or quality of life 
5.0% 
Housing Domain Measures deprivation through lack of adequate 
housing 
5.0% 
Welsh Index of Multiple 
Deprivation (WIMD) 
Overall measure of deprivation constructed by the 
weighted sum of the above domains 
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Postcode area case count data were matched independently to the EID and WIMD, and rural 
urban classification. As EID and WIMD were on a discrete ordinal scale, Spearman’s rank 
correlation was used to calculate the correlation between the number of cases and 
deprivation score. The proportion of cases with their home addresses located in either a rural 
or urban area, were compared to the national rural urban classification from the ONS [169]. 
This was performed using a Chi-squared test of independence for both English and Welsh 
data. 
3.2.2 SGSS Data Analysis 
A retrospective analysis was performed using data extracted from PHE’s Second Generation 
Surveillance System (SGSS) for notifications for Borrelia spp as a causal organism, with 
specimen dates between 1st January 2000 and 31st December 2016. Data was 
pseudoanonymised prior to extraction. Information captured included; organism name, 
specimen type, specimen date, local authority of patient’s residence, patient’s age in years, 
patient’s sex, and source lab name. Information relating to patient’s geography was limited 
to local authority level to maintain patient anonymity.  
Annual Lyme disease incidence estimates were calculated, using the Office for National 
Statistics (ONS) mid-year population estimates as the denominator population [159]. A Chi-
squared test for trend and a Chi-squared test for departure from the trend were used to 
analyse trends in incidence. Cases were stratified by age and gender. Using binomial tests, 
the null hypothesis that there was no difference in case numbers between males and females 
was tested within differing age bands, and overall. 
Geographical information was collated based on the local authority (or District Council for 
Northern Ireland) of a patient’s home address or residence. Northern Irish data was captured 
using the pre-2015 district boundaries (n=26). These were used to calculate average annual 
incidences for the whole study period.  
Information regarding source laboratory name and specimen type were described 
descriptively.  
All statistical and spatial analyses were carried out using R language (version 3.2.0) (R Core 
Team 2015). Results were deemed significant where p<0.05.  
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3.3 Results 
3.3.1 RIPL Results 
In total 3,986 unique cases (3,893 cases in England and 93 in Wales) meeting a serological 
diagnosis of Lyme disease were identified in the RIPL LIMS between 1st January 2013 and 31st 
December 2016. Of these, 98.7% (n=3,935) had complete records for date of submission, 
gender and age.  
The annual incidence of laboratory-confirmed Lyme disease cases in England and Wales rose 
from 1.62 per 100,000 population in 2013, to 1.95 in 2016. These figures are identical to 
PHE’s official incidence figures as they used the same data source [170]. There was evidence 
of an overall association between incidence and year (χ²=43.13, p<0.001). This association 
took the form of a trend with increasing incidence each year (χ²=30.17, p<0.001). Departures 
from the trend were significant (χ²=43.1-30.1=12.96, p<0.001), as shown by the fall in 
incidence in 2014. There was marked seasonality, with the peak numbers of cases being 
diagnosed in the summer months each year (Fig. 3.1).  
 
Figure 3.1 The annual incidence of laboratory-confirmed Lyme disease cases in England and Wales (2013 -2016), 
and the number of cases per month. 
Across all ages there were significantly more male (n=2,096) than female (n=1,839) cases 
(p<0.001), with a bimodal age distribution, with peaks at 6-10 and 61-65 year age bands (Fig. 
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3.2). Grouping the data in 5-year age bands, there were significantly more men than women 
in the 6-10 (p=0.03), 11-15 (p=0.03), 36-40 (p=0.01), 41-45 (p=0.02), and 46-50 (p=0.04) age 
groups.  
 
Figure 3.2 Population demographics of laboratory-confirmed Lyme disease cases in England and Wales, 2013-
2016. (Asterisks represent age bands with a significant difference between genders. Male = Blue, Female = Red) 
Data were available about PHE regions for 99.9% (n=3,985) of the study population (Fig. 3.3), 
and about patient residence postcode area for 58.2% (n=2,321). The South West PHE region 
had the highest incidence of Lyme disease in England and Wales; none of the PHE regions, 
nor Wales, reported zero cases. The postcode areas with the highest average annual 
incidence of Lyme disease were Southampton (11.65 cases per 100,000 per year), Salisbury 
(10.75), Bournemouth (5.62), Reading (4.59), Dorchester (4.57), Guildford (4.31), Taunton 
(2.79), Torquay (2.75), Brighton (1.96), and Bath (1.84) (Fig. 3.4). These areas are all in 
southern England. Only four postcode areas had no laboratory-confirmed cases in the four 
year surveillance period (Fig. 3.4), namely Dartford, Eastern Central London, Hull, and 
Western Central London.  
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Figure 3.3 The average incidence (cases per 100,000 per year) of laboratory-confirmed Lyme disease in England 
and Wales (2013-16) in Public Health England regions and Wales (n = 3,985) 
 
Figure 3.4 The average incidence (cases per 100,000 per year) of laboratory-confirmed Lyme disease in England 
and Wales (2013-16) by patient postcode area (n = 2,321). Highest postcode areas are labelled accordingly; SO-
Southampton, SP-Salisbury, BH-Bournemouth, RG-Reading, DT-Dorchester, GU-Guildford, TA-Taunton, TQ-
Torquay, BN-Brighton, BA-Bath. Areas with no cases are labelled in red; DA-Dartford, EC-East Central London, 
HU-Hull, WC-Western Central London. 
The smoothed data showed areas of highest incidence to be located in southern-central 
England (Fig. 3.5). There was significant spatial autocorrelation, the global Moran’s I was 0.56 
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(p=0.01), indicating that postcode areas with similar incidence are clustered together. LISA 
mapping identified six areas as significant clusters of high incidence (Fig. 3.6); Southampton, 
Salisbury, Bournemouth, Reading, Dorchester, and Guildford (for all p<0.001). 
 
Figure 3.5 The average incidence (cases per 100,000 per year) of laboratory-confirmed Lyme disease in England 
and Wales (2013-16) by smoothed patient postcode area. 
 
Figure 3.6 LISA map of significant incidence clusters of laboratory-confirmed Lyme disease in England and 
Wales (2013-16) 
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Using patient residence postcode data, it was possible to match 55.6% (n=2,165) of English 
records to the English Indices of Deprivation and 98.2% (n=92) of Welsh records to the Welsh 
Index of Multiple Deprivation (WIMD). An overall significant positive correlation between 
the number of cases and Index of Multiple Deprivation (IMD) decile was observed (ρ=0.96, 
p<0.001), with more Lyme disease cases found in less deprived areas (Fig. 3.7).  
 
Figure 3.7 Relationship between laboratory-confirmed Lyme disease case numbers (2013-2016) in England and 
the English Indices of Deprivation 2015. 
This significant positive correlation was seen across all domains of deprivation, except the 
‘Barriers to Housing and Services Domain’ where this trend was reversed (ρ=-0.88, p=0.002) 
and the ‘Living Environment Deprivation Domain’ where there was no significant correlation 
(ρ=0.2, p=0.58) (Fig. 3.8). An overall significant positive correlation between the number of 
cases and WIMD rank was observed (ρ=0.89, p=0.04), with more Lyme disease cases found 
in the least deprived areas. 
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Figure 3.8 Relationship between laboratory-confirmed Lyme disease case numbers (2013-2016) in England and 
the component measures of the English Indices of Deprivation 2015. 
When compared to the national population, the study population was disproportionately 
more likely to live in a rural area, for both English (p<0.001) and Welsh (p<0.001) sections of 
the study population (Table 3.3). 
Table 3.3 The rural urban classification of laboratory-confirmed cases of Lyme disease in England and Wales 
(2013-2016) compared to the national census population 
Category Percentage of English 
Study Population 
Percentage of Welsh 
Study Population 
Percentage of 2015 
census population 
Rural 34.3% (n=743) 47.8% (n=44) 17.9% 
Urban 65.7% (n=1,422) 52.2% (n=48) 82.1% 
 
3.3.2 SGSS Results 
In total 4,152 unique cases were identified in SGSS which had Borrelia spp as the causal 
organism between 1st January 2000 and the 31st December 2016. Of these, 3,802 (91.6%) of 
cases had the causal organism specifically named as Borrelia burgdorferi. The remaining 8.4% 
cases were defined simply as Borrelia spp and could be part of the relapsing fever group 
rather than Lyme disease [78]. Analysis was therefore restricted to Borrelia burgdorferi cases 
as these cases could be confirmed as having a Lyme disease causing pathogen. Complete 
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records were available for 97.7% (n = 3,715) of cases based on the key factors of specimen 
date, gender and age. 
The annual incidence of SGSS reported Lyme disease cases in England and Wales rose from 
0.21 per 100,000 population in 2000, to 0.78 in 2016. There was evidence of an overall 
association between incidence and year (χ²=903.41, p<0.001). This association took the form 
of a trend with increasing incidence each year (χ²=764.16, p<0.001). Departures from the 
trend were significant (χ²=139.25, p<0.001) (Fig. 3.9), most notably in 2011 and 2014.  
 
Figure 3.9 The annual incidence of Borrelia burgdorferi patients in England, Wales and Northern Ireland, based 
on SGSS data. 
There was marked seasonality, with the peak numbers of cases being diagnosed in the 
summer months each year (Fig. 3.10). 
43 
 
 
Figure 3.10 The number of Borrelia burgdorferi cases, by month, each year (2000 – 2016) within SGSS. 
There was no significant difference between the numbers of men (n=1,876) and women 
(n=1,839) (p=0.40), an age band comparison analysis was therefore not performed. A 
bimodal age distribution was seen with peaks at the 6 to 10 and 56 to 60 year age bands (Fig. 
3.11).  
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Figure 3.11 Population pyramid for Borrelia burgdorferi patients identified in SGSS (2000 – 2016), (Male = Blue, 
Female = Red) 
All records had local authority information relating to the patient’s place of residence (Fig. 
3.12). The local authorities with the highest incidence were Exeter with 9.29 cases per 
100,000 per year, West Dorset (8.87), West Somerset (7.01), East Devon (6.09), Taunton 
Deane (4.85), West Devon (4.54), Mid Devon (4.14), East Dorset (4.11), Camden (3.61), and 
North Devon (3.56). These are all, except Camden, found in south-west England. 
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Figure 3.12 The average annual incidence rate (cases/100,000/year) of Borrelia burgdorferi within SGSS, and 
the number of submissions per laboratory (2000–2016).  
(Local authorities with no submissions are in orange. E=Exeter, WDr=West Dorset, WS=West Somerset, 
EDv=East Devon, TD=Taunton Deane, WDv=West Devon, MDv=Mid Devon, EDr=East Dorset, C=Camden, 
NDv=North Devon) 
Fourteen (53.9%) of Northern Irish districts (n=26), seven (31.8%) of Welsh local authorities 
(n=22), and 100 (30.7%) of English local authorities (n=326) reported no cases through SGSS. 
49.4% (n=1,878) of specimens were blood, 46.2% (n=1,758) were serum, 0.7% (n=26) were 
cerebrospinal fluid, 3.5% (n=133) unknown, and 0.2% (n=7) were another specimen type. 
3.4 Comparison between the datasets 
Before a comparison can be made between the incidences and demographics of the Lyme 
disease populations in the SGSS and RIPL datasets, some important caveats most be 
highlighted. Firstly, RIPL only captures data from two nations, England and Wales, whereas 
SGSS additionally captures Northern Ireland. Secondly, they cover different, yet overlapping, 
time periods. RIPL covers 2013 to 2016, whereas SGSS covers 2000 to 2016. Finally, within 
the laboratories that submitted information to SGSS, which are a mix of NHS and private 
organisations, the diagnostic tests that are performed are not being reported. The 
recommended testing protocol for confirming a case of Lyme disease is a two-tier process, 
involving an initial screening test followed up with a confirmatory test as per current best 
guidance [23,41,44]. This is the process used by RIPL. If the precise test performed by the 
submitting lab is unknown, it is unknown what a positive case refers to, a screening test, the 
reporting lab’s confirmatory test, or a positive result of RIPL’s two tier test being reported by 
the reporting lab. Highlighting this, an internal PHE report assessed the reporting of SGSS 
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and its overlap with RIPL in 2015 [171]. They found that 54.4% of cases matched cases in RIPL 
and were positive confirmatory results, 36.0% of cases matched cases in RIPL and were 
confirmed as negative and therefore represented reporting of positive screening tests by the 
submitting lab, and 9.6% didn’t match with RIPL. This implies that submitting laboratories 
have very different habits around what they report to SGSS, thus bringing a high level of 
doubt to the validity and usefulness of the SGSS data regarding Lyme disease. However, it is 
still worth comparing the two datasets to see if any of the similarities or differences can aid 
in the improvement of the current reporting and surveillance of Lyme disease.  
Overall there were 184 less cases in SGSS than the RIPL dataset. Remembering that the 
assessment period for SGSS was twelve years longer than RIPL and included cases from 
Northern Ireland, this is a large overall underestimate of cases. The general bimodal shape 
of the population pyramid was similar between datasets, both having a pre-pubescent peak 
at the 6-10 year age band, and SGSS’s main peak was at 56-60, whilst RIPL peaked at 61-65. 
The main difference between the demographics was that RIPL has significantly more men 
than women, whilst in SGSS there were no significant differences. As previously mentioned, 
in England and Wales, Lyme disease incidence in men and women has historically been 
similar [154]. As the validity of SGSS is questionable little can be drawn between the 
differences in sex; other datasets within this project would be better placed to answer if 
there is any disparity between the sexes.  
When observing the difference between the PHE data (previously reported national figures, 
including RIPL data from 2012 [153]) and SGSS, the incidence of the PHE data is consistently 
higher. To compare this formally, a mean incidence rate ratio for the study period was 
calculated, 3.68 (95% CI 2.16, 5.21). The incidence rate ratio and its confidence intervals 
show that there is a large degree of variation between the incidences reported by both 
systems. The difference and variability are likely due to the inconsistent and varied reporting 
of submitting laboratories. The observed seasonality of SGSS matches that of RIPL, with 
peaks in summer months, usually peaking in August.  
Despite the two datasets reporting different geographical units, postcode area in RIPL and 
local authority in SGSS, marked differences can still be seen. Discussions will be based solely 
on England and Wales as there is no Northern Irish data captured by RIPL. In SGSS 30.7% of 
geographical units have no cases of Lyme disease, compared to 3.7% in RIPL. In SGSS, these 
are predominantly in the North of England and Midlands. The lack of reporting laboratories 
in these areas (Fig. 3.8), and the presence of cases in these areas in the RIPL dataset, suggest 
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that either they are not reporting any cases of their own diagnostic testing as per the Health 
Protection (Notification) regulations [77], or they are submitting samples to RIPL and 
assuming that RIPL will notify any resultant positive cases. The areas in SGSS that do have 
cases show a hot spot of higher incidence in southern England, but they lie further west than 
the hotspot seen in the RIPL data. It is likely that these areas do have a high incidence of 
cases, but there may be a degree of over-reporting compared to RIPL. It is possible that they 
are reporting the number of positives based on a screening test rather than a confirmatory 
test as RIPL does. Without an audit of the notification and diagnostic practices of all 
diagnostic laboratories it would be difficult to establish how reliable these incidence figures 
are.  
To explore the geographical relationships between the datasets further, the RIPL postcode 
data was transformed to local authority data. Average annual incidence of each local 
authority for each dataset was plotted against one another, with linear regression performed 
(Fig. 3.13). 
 
Figure 3.13 A comparison of average annual incidence of laboratory Lyme disease cases, at local authority 
resolution, between the RIPL and SGSS datasets 
A significant association between the two datasets was seen (p<0.05), however the r² value 
was low (r²=0.19). Geographical concordance of significant clusters of high and low incidence 
was explored by constructing a bivariate LISA (Local Indicators of Spatial Association) plot 
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[164,165] (Fig. 3.14). 
 
Figure 3.14 Bivariate LISA plot of Lyme disease laboratory cases incidence in the SGSS and RIPL datasets. 
A global Moran’s I score was calculated and tested for significance. This resulted in I=0.28, 
and p<0.05. This suggests that the spatial distribution of incidence were similar, with high 
and low values in the dataset being more spatially clustered than would be expected if 
underlying spatial processes were random. The plot shows significant concordance of high 
incidence clusters in southern England, with scattering of concordant low incidence areas 
across the country. The areas of statistically significant discordance are likely to do with 
differences in regional reporting habits in SGSS, as previously discussed. The large degree of 
non-significance shows that incidence for both datasets does not differ from a randomly 
generated distribution of incidence. 
One area of note with a high incidence, in the SGSS data, was Camden, a local authority in 
central London. The equivalent area in RIPL had a low incidence. On further examination of 
the data, almost all the samples were submitted from The Doctors Laboratory, a private 
commercial diagnostic laboratory [172]. They reported 132 cases from across England only 
in 2013 and 2015; 98 of these were from Camden. This laboratory performs both screening 
ELISAs and confirmatory immunoblot tests. If these are the same tests performed by RIPL, 
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and they are reporting confirmed positives to SGSS, then national incidence figures will be 
missing these patients, as PHE only reports cases from RIPL. If this is true, then it needs to be 
understood why and where patients in central London are acquiring Lyme disease. These are 
private (non-NHS) testing services; it could be concluded that patients submitting samples 
here are from a more affluent background. Lyme disease has been found to be present in 
ticks in London parks [173], these cases could represent this transmission. These cases may 
have also acquired infection on national or international travel. These cases need to be 
followed up, as they may represent transmission locations and cases that are unreported in 
the national literature.  
The majority of tissues sampled for diagnostics were appropriate following NICE diagnostic 
guidelines [23]. However, the non-recommended specimen types included were; skin 
biopsies, faeces, semen, sputum and urine. They are not recommended as tests relating to 
these tissue types have a very low sensitivity and specificity [23]. These samples come from 
a mix of NHS and private laboratories, and so the potential for the cynical use of unverified 
diagnostic tests for profit is limited. It is more likely that continued professional development 
is needed in some microbiological units to educate on the most appropriate procedures for 
Lyme disease, the publication of NICE guidelines should assist with this.  
3.5 Discussion of the RIPL dataset 
Between 2013 and 2016 there was a significant, but small, increase in annual incidence of 
cases of confirmed Lyme disease, with a seasonality that matched previous publications and 
has been well documented [174]. The observed seasonality closely matches I.ricinus tick 
population dynamics in the UK, which annually peak around June and July [24,142]. Concerns 
have been raised about how the expansion of tick habitats due to changes in land use and 
management, and climate change, may be increasing the risk of Lyme disease infection 
[26,175]. Although the incidence of confirmed cases increased over the study period, there 
was significant deviation from the trend, most notably in 2014. The reasons behind this 
variable, but increasing, incidence of Lyme disease are likely to be multifactorial and may 
include raised public and practitioner awareness, variable weather patterns causing 
alterations in tick abundance and/or carriage of B. burgdorferi s.l., and changes in human 
activity and behaviour. 
The RIPL data displayed a bimodal age distribution, with peaks at 6-10 and 61-65 years, and 
an overall predominance of males. This bimodal distribution has been reported in other 
European countries [176–178], and matches previous UK studies [154,179]. However, the 
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predominance of males in the current study population does not concur with other European 
studies, where women are over-represented [176–178]. In the USA, Lyme disease is more 
prevalent in males compared to females less than 60 years old, and equal or higher in women 
above 60 than among men [21]. In contrast, more men were hospitalised in France due to 
Lyme disease and more women were diagnosed by general practitioners [180]. Historically, 
in England and Wales, Lyme disease incidence in men and women has been similar [154,179]. 
The male predominance in the RIPL data may be due to the difference in health seeking 
behaviour between genders, with women more likely to seek healthcare at early stages of 
illness [109]. By presenting at later stages of Lyme disease, when pathognomonic signs may 
have waned, male cases may require laboratory confirmation more frequently. Further work 
is needed to establish the causes behind these gender differences and whether they are 
related to environmental or behavioral risk factors, such as occupation, leisure activities, or 
differences in health seeking behaviours.  
There was geographical variation in Lyme disease incidence across patient residence 
postcode area in England and Wales, based on 58.2% of laboratory-confirmed cases. The 
global Moran’s I statistic showed that there was significant positive spatial autocorrelation, 
and clusters of high incidence were found in southern England. This area includes the New 
Forest National Park, the South Downs National Park, Salisbury Plain, Cranborne Chase Area 
of Outstanding Natural Beauty (AONB), Dorset AONB and Purbeck Heritage Coast. These are 
all popular destinations for outdoor activities and are in southern England where the Lyme 
disease vector I.ricinus is most prevalent [24,137,175]. The exposure risk from ticks is likely 
to be higher in these areas than other parts of the country. It is interesting that previously 
observed Lyme disease hotspots, such as Thetford Forest [154], were not evident in the 
current study. This may be due to changing tick population dynamics and/or the prevalence 
of B. burgdorferi s.l. infection in host-seeking vectors, changing human behaviour, or the 
larger number of patients within the RIPL study population. It is also possible that awareness 
of Lyme disease is higher in these areas, and cases are successfully identified and managed 
in primary care without the need for serological diagnosis. Throughout the rest of England 
and Wales the incidence of confirmed Lyme disease cases remains relatively low (69.2% of 
resident postcode areas have an incidence of less than 1.0 per 100,000 population per year) 
compared to the majority of western Europe [66]. These data suggest that although I.ricinus 
ticks are widespread across England and Wales [24], the proportion that carry B. burgdorferi 
s.l. is relatively low, and a higher prevalence may only exist in the tick populations in the 
localities highlighted. Several studies would appear to support this hypothesis [36,181,182], 
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but further work is needed to compare the incidence of human cases, abundance of ticks 
and prevalence of B. burgdorferi s.l. in ticks in the same geographic area. The areas with high 
incidence are predominantly rural and this is reflected in the results where the study 
population were disproportionately more rural compared to the national population. 
Information about case locality represented by PHE region is reflective of the case’s referring 
hospital microbiology department rather than the cases’ residence, or location of exposure. 
In some instances, mainly in rural areas, this hospital may be a significant distance from the 
abode of the patient. This figure therefore is more reflective of the burden of Lyme disease 
on local microbiology departments.  
Information provided at postcode area level relates to the patient’s home address, and not 
necessarily to where the patient was bitten by a tick. Some patients are likely to have been 
bitten outside their resident postcode area. The further the exposure from home, the larger 
this spatial error will be. To date, no work has been done to quantify this error in the UK. The 
smoothed map (Fig. 3.5) attempts to account for this and shows an area of high incidence in 
southern-central England, centred around Southampton, Salisbury, and Weymouth and 
extends further west than the raw incidence data. This map highlights theoretical Lyme 
disease risk areas more accurately, as it accounts for the bite distance spatial error, and 
should be the map used for targeting public health strategies. The observed strong 
geographical clustering of positive cases (Fig. 3.6), suggests that patient residence postcode 
does correlate to some extent with disease risk.  
This is the first time that a cohort of laboratory-confirmed Lyme disease cases across England 
and Wales has been described in terms of the socioeconomic status of their residential 
postcode area. The results suggest that patients in England diagnosed with Lyme disease are 
more likely to live in areas which are more affluent, have high levels of employment and 
education, have a higher quality of life, are less exposed to crime, but have issues with access 
to housing and local services. This is in contrast to the classic income gradient of health [183–
185], where the lower an individual’s socioeconomic position the worse their health, but 
supports previous socioeconomic analyses of Lyme disease in the USA [156,157]. This study 
has not investigated why areas with higher socioeconomic status appear to correlate with a 
higher incidence of Lyme disease cases but it may reflect the type of leisure activities 
undertaken, available leisure time, access and attitudes to the countryside by this section of 
society [186]. Further research is needed to better define the population of cases diagnosed 
with Lyme disease and why there is an association with socioeconomic status.  
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The only negative association with Lyme disease in England was observed for the barriers to 
housing and services domain and is likely due to the rural nature of the areas with the highest 
incidence. Rural areas score poorly as the housing tends to be expensive in relation to income 
and houses are a greater distance from services such as hospitals, schools and post offices. 
It could be reflective of this population only accessing health care, and so needing serological 
diagnosis, once symptoms have progressed beyond the early stages of disease. The living 
environment deprivation domain is a mix of housing quality, air pollution and road traffic 
accidents, and it is unsurprising that no association with Lyme disease incidence was 
observed. 
In Wales, there was a significant positive correlation between case counts and the WIMD 
domain scores. There were an increasing number of patients living in more affluent areas. 
The reasons for this difference are likely to be similar to the English study population. 
The main limitation of this study is the use of patient residence postcode area as a proxy 
both for the place where Lyme disease was acquired and the socioeconomic status of Lyme 
disease cases. It is unknown how representative the socioeconomic characteristics of a 
postcode are of individual cases. Clear socioeconomic and demographic trends and 
associations have been identified; however, these factors cannot be disentangled using the 
current datasets and so the degree of bias inherent in them is unknown. Future studies 
should be designed, where a multivariable model can be created to identify any interaction 
or confounding effects of the variables under examination. 
Current guidance for Lyme disease state that an erythema migrans rash is pathognomonic 
and further laboratory diagnostics are not required [23]. An unknown proportion of cases 
will be clinically diagnosed and managed in early illness by primary care clinicians and will 
not make it in to this dataset. Laboratory-confirmed figures will therefore underestimate the 
true incidence of Lyme disease seen in the general population. Without surveillance of 
primary care presentations, it will be hard to establish a more accurate incidence figure.  
The majority of geographical data presented is reliant on case postcode data. Due to data 
attrition only 56.6% of cases in the dataset contained this data. Data attrition may have 
occurred in three ways; poor completion of the laboratory referral forms (something well 
documented for health professionals [187]), the non-notifiable status of clinical Lyme disease 
and the lack of statutory obligation to provide information about suspect cases, and the 
indirect route by which clinical samples are submitted for testing. Lyme disease testing is 
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usually requested in primary care and samples are routed through hospital laboratories 
before reaching RIPL. There is the potential that some cases are also missed due to some 
laboratories (both private and public) performing their own diagnostic testing without 
sending samples to RIPL, as the reference laboratory, for confirmation. Testing rates may 
also vary in different geographies dependent upon Lyme disease awareness of health care 
professionals.  
3.6 Conclusions and recommendations 
This chapter has shown that laboratory diagnosed Lyme disease cases in England and Wales 
have a bimodal age distribution and male predisposition. Geographical clustering of cases 
was seen and new insights into the socio-demographic nature of laboratory-confirmed Lyme 
disease patients were described. The incidence maps highlight areas where Lyme disease 
may place the highest burden on primary and secondary care, and therefore can be utilized 
by medical and public health professionals, and the general public, to raise awareness in 
these areas.  
SGSS has been shown to be flawed as a surveillance tool for Lyme disease. The incidence 
rates calculated are consistently different to those published by PHE and RIPL, there are large 
gaps in geographic coverage, it is unknown what test type is used to define a positive result, 
and inappropriate tissues have been sampled. Due to these problems, it would be 
recommended that RIPL is used as the primary surveillance tool for laboratory-confirmed 
cases of Lyme disease in England and Wales. 
Nonetheless, there are ways that SGSS could be improved so that meaningful Lyme disease 
surveillance data could be extracted from it. These include: 
• A compulsory audit of all (NHS and private) microbiological laboratories in England, 
Wales and Northern Ireland, to establish what Lyme diagnostic tests are being 
performed and what is being reported to SGSS. If any appropriate confirmation tests 
are being performed, their results could be included in national surveillance figures, 
something which isn’t currently occurring. Another option would be to legislate that 
all NHS confirmatory diagnostic tests for Lyme disease must be sent to RIPL. Thus, 
RIPL would report all NHS positive cases, and SGSS would collect all private 
laboratory positive cases.  
• Compulsory inclusion of identification method on the SGSS form. This would rule 
out any false positives received by the reporting of solely positive screening tests. 
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• Refresher courses for laboratories on the appropriate tests to use and the Health 
Protection (Notification) Regulations for appendix 2 organisms [77]. The importance 
of compliance must be stressed, to ensure complete coverage. This should be 
primarily targeted at laboratories that are reporting and testing inappropriately.  
• Establish whether a sample sent to RIPL and confirmed positive, needs to be 
reported to SGSS by the submitting laboratory.  
RIPL remains the “gold standard” surveillance system for recording laboratory-confirmed 
cases in England and Wales. There are understandable reasons that explain lower reporting 
of cases through SGSS. However, it is still likely to be an underestimate of national 
laboratory-confirmed incidence, as the SGSS data suggests that some laboratories (both NHS 
and private) are performing their own confirmatory tests. Understandably the incidence 
reported matches that of national surveillance publications and shows an increasing trend. 
It is the deeper analytics of patient demographics that offer new insight in to Lyme disease 
in England and Wales. There is strong clustering of cases, with significant proportion of cases 
being in rural areas, and most intriguingly the strong association between the level of 
deprivation and number of cases. 
The extent to which this work contributes to the overall aims of this thesis regarding Lyme 
disease surveillance can be summarised as follows: 
• Incidence: Increase (p<0.001) from 1.62 per 100,000 in 2013 to 1.95 per 100,000 in 
2016. Cases peaked in the summer. 
• Sociodemographics: Bimodal age distribution, with significantly more men than 
women. There was a significant socioeconomic trend, with the number of cases 
decreasing as societal deprivation increased. Cases were significantly more likely to 
occur in rural areas, compared to the national population.  
• Geographical hotspots: These were identified in southern England.  
• Patient presentation and management: No information about patient presentation 
and management was collected. 
• Additional information: By comparing RIPL and SGSS, it can be concluded that there 
is still an underreporting of laboratory-confirmed cases, as not all microbiology units 
send samples to RIPL, and no private laboratories do.  
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Chapter 4 Surveillance of Lyme disease in hospital datasets 
 
In Chapter 3 the demographics and geographic distribution of current national laboratory 
surveillance figures were presented and discussed. These potential trends may be seen in 
other datasets analysed throughout this thesis. As discussed in Chapter 2, laboratory data 
represents the traditional peak of a surveillance pyramid (Fig. 2.1). This chapter will discuss 
the second tier of the pyramid; secondary care. If this data were to follow the hypothetical 
norm of a surveillance pyramid one would expect a larger population to be represented, with 
a higher incidence and with demographics more characteristic of the diseased population 
than the top tier. This chapter will describe the hospital Lyme disease patient cohort, and the 
quality of the available datasets for analytics reviewed. 
The following content is currently in peer review as;  
Tulloch, JSP., Decraene, V., Radford, AD., Warner, JC., Christley, RM., Vivancos, R. 
Characteristics of Lyme borreliosis patients – retrospective analysis of hospital episode data 
in England and Wales; 1998 – 2015.  
4.1 Background 
Lyme disease is an important emerging tick-borne disease caused by members of the 
spirochaetal complex Borrelia burgdorferi sensu lato. The population-weighted incidence 
across Western Europe has been estimated to be 22.04/100,000 person-years [66]. In 
England and Wales the national incidence of laboratory-confirmed cases has risen from 0.38 
per 100,000 population in 1997 [174] to 1.95 per 100,000 population in 2016 [153]. Lyme 
disease is associated with a range of clinical presentations which may vary as infection 
progresses, though it commonly presents as erythema migrans with associated flu-like 
symptoms [23]. Other presentations include: borrelial lymphocytoma, Lyme 
neuroborreliosis, carditis, arthritis and acrodermatitis chronica atrophicans (ACA) [21]. This 
has resulted in broad and varied case definitions [23,39,40,43]. However, all case definitions 
agree that erythema migrans alone, without any laboratory confirmation, is sufficient for 
case confirmation. Considering this, current surveillance for England and Wales, which is 
based on laboratory diagnosis [174], is likely to underestimate the true incidence of disease. 
This resulted in the recent NICE (National Institute for Health and Care Excellence) guidelines 
explicitly stating that ‘there is a lack of robust epidemiological data on Lyme disease in the 
UK’ [23]. 
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Patients may present with Lyme disease in either a primary care or hospital setting, with an 
unknown proportion receiving confirmatory laboratory diagnosis. The relative proportion of 
patients presenting to either setting is currently unknown, as is the patient pathway between 
primary, secondary and tertiary care. Within England and Wales, studies that describe 
patients in a hospital setting have been either limited to one hospital [188,189], specialist 
referral centres [190–192], or one clinical presentation [179].  
Since 1989 Hospital Episode Statistics (HES) have recorded every ‘episode’ of admitted 
patient care (APC) delivered in National Health Service (NHS) hospitals in England [87]. 
Outpatient attendance (OA) and accident and emergency departments (A&E) datasets were 
added in 2003 and 2007. Patient Episode Database for Wales (PEDW) is a central 
administrative database that collects admissions data from NHS hospitals in Wales [92,93]. 
The primary use of these data is the calculation of health care costs and therefore mainly 
administrative data is collated. There is now an increasing body of medical research using 
the HES and PEDW databases; nevertheless, a recent systematic review highlighted that only 
seventeen out of 148 HES publications were related to the epidemiology of a specific disease 
[88].  
The aim of this study was to perform a retrospective analysis of HES and PEDW records to 
describe the incidence and demographics of Lyme disease patients in a hospital setting, and 
to describe their patient pathways through the NHS.  
4.2 Methods 
A retrospective search of both HES (including all datasets of APC, OA and A&E) and PEDW 
databases was performed to identify patients coded with Lyme disease. A case was defined 
as a patient with a Lyme disease diagnostic code drawn from the International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) (Table 
4.1)[23,39,40,43,86].  
Table 4.1 Lyme disease ICD-10 codes used to query hospital administrative data 
ICD-10 Code Description 
A69.2 Lyme disease 
M01.2 Arthritis in Lyme disease 
L90.4 Acrodermatitis chronica atrophicans 
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A list of variables for each dataset within HES and PEDW was constructed. These variables 
could be split into three categories; patient demographics, patient geography, and patient 
management (Table 4.2).  
Table 4.2 Variables queried of Lyme disease coded patients in hospital administrative data 
Hospital Episode Statistic 
variable codes 
Patient Episode Database for 
Wales variable codes 
Description 
HESID  Patient ID 
 
Unique pseudoanonymised patient 
identifier 
ADMIAGE Admitted Age Age on day of admission 
ADMIDATE Date first admitted Date of admission 
ADMISOURCE Admission Method Source of admission 
AEARRIVALMODE  Accident and emergency source 
AEATTENDDISP  Accident and emergency discharge 
destination 
APPTAGE  Age on day of appointment 
APPTDATE  Appointment date 
ARRIVALAGE  Age on arrival to accident and 
emergency 
ARRIVALDATE  Date on arrival to accident and 
emergency 
ATTENDED  Did or did not attend outpatient 
appointment 
DEPDUR  Time spent in accident and emergency 
until departure 
DIAG_CODE  Diagnose code searched in all diagnosis 
code fields 
DISDEST  Discharge destination 
EPIDUR  Duration of episode 
ETHNOS  Ethnicity 
IMD04  Index of Multiple Deprivation  
 Deprivation Index Welsh Index of Multiple Deprivation 
LSOA11 LSOA_Code Lower super output area – 2011 census 
REFSOURCE  Source of referral for outpatients 
RURURB_IND Urban Indicator Rural-urban indicator 
SEX Sex Sex 
TRETSPEF  Main treatment speciality 
 
Data were extracted for patients presenting between 1 January 1998 and 31 December 2015 
who had a Lyme disease code in any of the diagnostic fields. Data was cleaned by identifying 
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missing values and deduplication of records. Date of first appearance of a patient within any 
of the databases, based on pseudo-anonymised patient identifiers and admission date, was 
used for analysis. Using these index records, the incidence of Lyme disease coded patients 
was described for each dataset; mid-year population estimates provided by the Office for 
National Statistics (ONS) were used as the denominator population data [159]. Annual 
incidences were analysed using linear regression.  
Information on patient sex was stratified by age and compared using a binomial test. 
Ethnicity was compared to national figures available from the ONS using a Chi-squared test 
[159]. The average annual incidence was calculated at the geographical area of local 
authority. The rural-urban indicators of the study populations were compared to the national 
population using a Chi-squared test.  
Associations were assessed using linear regression for the Index of Multiple Deprivation 
(IMD) of English patients, whereas the Welsh Index of Multiple Deprivation (WIMD) of Welsh 
patients was assessed using a Chi-squared test for trend. Linear regression could not be 
performed on WIMD as the defined WIMD groups were of uneven proportion, unlike the 
IMD which is organised in equally sized deciles. Both were compared to the national 
populations using a Chi-squared test of independence. 
Information relating to patient management primarily was analysed descriptively. To 
determine if any ‘day of the week’ bias existed in the data, the number of cases per day was 
compared to the expected number of cases per day, using a Chi-squared test. This was 
performed for each dataset and by the admission method recorded in the APC dataset, with 
the null hypothesis being that there were an equal number of cases every day of the week. 
Pseudoanonymised patient identifiers were used to describe the patient pathway. Statistical 
analyses were carried out using R (version 3.2.0) (R Core Team 2015), and associations were 
deemed significant where a p value was less than 0.05.  
4.3 Results 
After de-duplication, 2,361 patients were identified with Lyme disease codes between 1998 
and 2015. Within English records (HES) 2,259 unique patients were identified, 2,045 of these 
were found in APC alone, 180 in outpatients, 13 in A&E, 18 were found in APC and 
outpatients, and three were found in APC and A&E. Within Welsh records (PEDW), 102 
patients were identified. Even though they could not be linked with the HES databases, these 
were likely to be unique patients, as none of them shared age, sex and lower super output 
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area (LSOA) of home address combinations with any HES patients. The combined results of 
both datasets were therefore described, unless otherwise specified. 
The annual incidence of Lyme disease coded patients rose significantly from 0.08 cases per 
100,000 population in 1998 to 0.53 in 2015 (r²=0.93, p<0.01; Fig. 4.1).  
 
Figure 4.1 Incidence of Lyme disease coded patients within hospital administrative records in England and 
Wales (1998-2015) 
This significant correlation was seen both in English (r²=0.93, p<0.01) and Welsh (r²=0.55, 
p<0.01) populations. There was marked seasonality, with peak number of cases recorded in 
August (Fig. 4.2).    
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Figure 4.2 Lyme disease patient monthly count, within hospital administrative records in England and Wales 
(1998-2015) 
4.31 Demographic characteristics 
In England and Wales, 70.9% (n=1,673) of records contained information on the patients’ age 
and sex. When stratified by country, English records contained 69.5% (n=1,571) of this 
information, and Welsh 100% (n=102). There were significantly (p<0.01) more female 
patients than male in England and Wales 60.1% (n=1,005), displaying a bimodal age 
distribution, with peaks at 6-10 and 61-65 year age bands (Fig. 4.3). 
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Figure 4.3 Population demographics of Lyme disease patients within hospital administrative records in England 
and Wales (1998-2015). Asterisks represent a significant difference (p<0.05) between sexes. 
This sex ratio held true in England (60.5%, p<0 .01), in Wales there were more female patients 
52.9% (n=54), however this was not significant (p=0.62). Ethnicity information was available 
for 79.5% (n=1,877) of records in England and Wales. Of these records, 96.1% (n=1,803) of 
patients were recorded as identifying with being white. Using a Chi-squared test to assess 
white ethnicity vs other ethnicities, a significantly (p=0.01) greater proportion of this 
population was white compared to the 2011 Census population [193].  
4.32 Geographical distribution 
Over two thousand (2,078; 88.0%) records contained geographical information (Fig. 4.4).  
62 
 
 
Figure 4.4 The average incidence rate of Lyme disease in English and Welsh local authorities (n=348), (1998-
2015). These data were based on hospital administrative records, and incidence measured as number of cases 
per 100,000 per year. Black areas recorded no cases over the study period. P = Purbeck, ED = East Dorset, NF = 
New Forest. 
The areas with the highest incidence were located in the south west of England. The local 
authorities with the highest incidence were Purbeck with 3.13 cases per 100,000 per year, 
New Forest (2.58), and East Dorset (2.32), with the incidence in neighbouring areas in central 
southern England also with high rates. Thirty-four (9.8%) local authorities recorded no 
hospital cases assessed for Lyme disease. 
Analysis of rural-urban indicators showed a significant difference between the study 
population (n = 2,292) and the national population, where Lyme disease patients were more 
likely to live in rural (37.4%) rather than urban areas, compared to the national population 
(17.9% live in rural areas) (p<0.01). 
4.33 Sociodemographic characteristics 
Information on IMD deciles was available for 96.7% of English patients (n=2,186). There was 
a significant difference (p<0.01) between this population and the national English 
population, with a significant linear trend showing that patients were found in increasing 
numbers in less deprived areas (r²=0.87, p<0.01). Information on WIMD was available for 
90.1% (n=92) of Welsh patients; using Chi-squared tests, there was a significant difference 
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(p<0.01) between this population and the national Welsh population, and there was a 
significant linear trend, with increasing number of patients found in the least deprived areas 
(p<0.01). 
4.34 Patient Management 
There were significant differences between the daily cases in APC (p<0.01), OA (p<0.01), and 
Welsh admissions (p=0.01), compared to the expected number of cases per day of the week. 
For these three datasets, there were fewer cases at the weekend, and the APC dataset had 
a high number of cases on a Monday (Fig. 4.5).  
 
Figure 4.5 Proportional daily Lyme disease case attendance, in English and Welsh hospital administrative 
records (1998-2015). Asterisks represent a significant difference (p<0.05) compared to the expected proportion 
of daily cases. 
There was no significant difference between daily case numbers for the A&E dataset 
(p=0.72). Within the APC dataset, there were significant differences between the daily cases 
admitted via the elective (p<0.01), GP (p<0.01), and other (p<0.01) routes, compared to the 
expected number of cases per day of the week. There were fewer cases admitted via these 
routes at the weekend. There was no significant difference between daily case numbers for 
patients admitted through A&E (p=0.67) (Fig. 4.6). 
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Figure 4.6 Proportional daily Lyme disease case admission routes, in English and Welsh hospitals (1998-2015). 
Asterisks represent a significant difference (p<0.05) compared to the expected proportion of daily cases 
In table 4.3, coding patterns, department of treatment, bed days, number of appointments, 
and length of time in A&E for HES data, are shown.  
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Table 4.3 Patient management statistics for Lyme disease coded patients in Hospital Episode Statistics (1998-
2015) 
 Admitted Patient Care (APC) Outpatients Accident and 
Emergency 
(A&E) 
ICD-10 Codes    
Lyme disease 91.5% (n=1,891) 27.8% (n=55) 100% (n=16) 
Acrodermatitis chronica 
atrophicans 
8.0% (n=166) 71.4% (n=142) 0 
Lyme Arthritis 0.1% (n=2) 0.5% (n=1) 0 
Lyme and LA 0.3% (n=7) 0 0 
Number of Departments of 
Treatment Recorded 
63 (2,065 patients) 20 (198 Patients) N/A 
Top 5 Departments of 
Treatment 
General medicine        28.9% 
Paediatrics                    14.7% 
Neurology                     10.8% 
Gynaecology                  4.8% 
Infectious disease         4.5% 
Dermatology                  70.7% 
Rheumatology                5.6% 
Neurology                        5.1% 
Infectious disease           4.0% 
General medicine           3.0% 
N/A 
Mean number of episodes 
per patient 
1.72 episodes (range: 1-50) N/A N/A 
Mean number of bed days 
with patients with one 
episode  
(n=1,638, 79.3% of APC 
patients) 
4.47 days (range: 0-137) 
733 (35.5%) with one episode and 
no bed days. 
258 (12.5%) with one episode and 
one bed day. 
N/A N/A 
Mean number of total bed 
days for patients with  
more than one episode 
(n=427, 20.7% of APC 
patients) 
11.2 days (range: 0-315) N/A N/A 
Mean number of 
outpatient appointments 
(n=308, 24 cancelled) 
N/A 1.5 (range: 1-25) NA 
Mean time in A&E 
(minutes) 
N/A N/A 140 (32-237) 
 
Lyme disease was the predominant code in admissions (91.5%) and A&E (100%) data, where 
as it was ACA (71.4%) in outpatients. Data on patient management for PEDW data was 
limited to patient admission method; 67.6% (n=69) of Welsh patients were admitted through 
the A&E department, the remainder were electively admitted.  
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Patient pathways were described using the source of the patient and their discharge method 
(Fig. 4.7).  
 
Figure 4.7 The pathway of Lyme disease coded patients through the NHS, based on hospital administrative 
records 
There was no discharge information for OA, and information for APC was excluded as 
discharge destination codes did not explicitly describe whether patients were to receive 
primary care on discharge or whether patients were referred to an outpatient or inpatient 
clinic. 
4.4 Discussion 
This study provides an in-depth description of Lyme disease patients seen in English and 
Welsh hospitals, and addresses some of the NICE guidelines calls for new epidemiological 
data [23]. Incidence rose over the study period, showing a similar trend, but at lower levels, 
to officially published figures based on laboratory-confirmed cases [153,174]. This 
discrepancy is to be expected, as national laboratories will receive samples from both 
hospital and primary care patients, and will therefore have a higher incidence. Not all cases 
would need to be referred to a hospital clinician from primary care, as the majority of cases 
are likely to present with an uncomplicated erythema migrans rash [23]. The cause for the 
increase in incidence is unknown, but may be the result of, among other causes: increased 
awareness by the public and/or hospital clinicians, increase in referrals by clinicians in 
primary care, or a true increase in incidence within England and Wales. Further research is 
needed to understand the drivers for this increase in incidence. Compared to other European 
countries the incidence described is lower. In France the annual hospitalisation rate due to 
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Lyme diseases is 1.55 cases per 100,000 [180], with an estimated average national incidence 
of 42 cases per 100,000 population. Whereas in Germany the inpatient incidence was 9 cases 
per 100,000 population, but with large regional variation [194]. The reasons for this are 
mixed, and are likely due to: differences in Ixodes spp prevalence and Borrelia spp carriage 
rates, different levels of exposure to ticks by the general population, and differences in how 
patients access healthcare.  
The seasonality observed here supports the known risk factors and epidemiology of Lyme 
disease. Tick populations in the UK have been shown to peak in June or July each year 
[24,28,142]. One would therefore expect to see tick bite incidence and exposure to Lyme 
disease to peak similarly. Clinical signs will appear anywhere from several days to a few 
weeks after a tick bite [40]. Previous work in England and Wales showed a peak of 
serologically confirmed cases in August and September, with an assumed peak of symptoms 
earlier in the summer [154]. This work would support this conclusion. This mirrors other 
Northern European countries, such as Finland and Germany, where clinically diagnosed cases 
peak throughout July and August [67,176]. 
The age structure of this population compares closely with a recent study performed in 
England and Wales [179]. It shows the classic bimodal age distribution seen with Lyme 
disease, with an initial peak incidence in pre and peri-pubescent children, followed by a 
second larger peak from late middle age. The reasons for this age structure haven’t been 
formally assessed, however there is agreement that it likely reflects an increased exposure 
to tick habitats due to leisure behaviour rather than occupational exposure [67]. These data 
display a predominance of female cases, unlike the study referenced above. The reasons for 
this are hard to explain, but could be related to differences in health seeking behaviour [109]. 
Ninety-six percent of patients identified as being white, compared to 86% in the 2011 
national census [159]. There is no clear reason why ethnicity has any impact on a person’s 
susceptibility to Lyme disease. Instead, this apparent association is most likely due to 
sociocultural and behavioural reasons. Patients were found, in increasing numbers, living in 
less deprived areas. It must be noted that all ethnic minority groups were more likely to live 
in areas of higher deprivation than the white population [195], and this could explain the 
higher proportion of white patients within this population. Lyme disease patients were more 
likely than the national population to live in rural areas. The characterisation of Lyme disease 
patients as white and from suburban or rural areas with low deprivation may be explained 
by a complex combination of risk factors related to access to habitats which support ticks 
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(either through work or recreation), and access to health care [196]. Further research is 
required to understand the link between ethnicity, deprivation, area of residence and 
presentation to hospitals with Lyme disease.  
There is clear geographical variation in incidence between local authorities. The highest 
incidence is in southern-central and western England, which has traditionally been seen as a 
Lyme disease hotspot [154]. Areas with no cases are unlikely to be due to an absence of 
disease but may reflect differences in case management or hospital coding practices. The 
remainder of England and Wales is a patchwork of low incidence with no obvious hotspots 
of disease. Interestingly, there are no clear foci of infection observed in either the Thetford 
Forest, the Lake District or the North Yorkshire Moors as identified previously by Public 
Health England (PHE) [174]. In these areas the awareness, diagnosis and management of 
Lyme disease may differ from other areas, perhaps with primary care clinicians treating cases 
in the community and with fewer subsequent cases referred to hospitals. The geographical 
data collected by HES and PEDW is based upon the patient’s home address and no 
information is recorded on recent travel history or where a tick bite may have occurred, and 
so there may be an element of bias in the results.  
Bed day analysis showed three distinct populations; those with one episode who weren’t 
admitted (35.5% of patients) or stayed for one night (12.5%), those with multiple episodes 
and a low number of bed days and those with one or many episodes that had a large number 
of bed days (Table 4.3). The first group is likely to represent patients with uncomplicated 
cases of Lyme disease. The second group often had consecutive daily episodes totaling 
fourteen to twenty-one days, which could be consistent with daily intravenous doses of 
antibiotics as recommend by the British Infection Association and National Institute for 
Health and Care Excellence (NICE) guidelines [23,39]. The final group appear to represent 
complicated cases of Lyme disease that require prolonged stays in hospital. It was not in the 
scope of this project to see whether any clinical presentations predisposed patients to these 
three groups, but further investigations are recommended.  
Analysing the patient flow through the datasets has enabled better understanding of the 
care pathway for Lyme disease infected patients. Thirty percent of Lyme disease admissions 
in England, and 67.6% in Wales, originate from the A&E department. To place this into 
context, in 2011 69% of all NHS England admissions originate from A&E [197]. The same 
report saw a decline in admissions through primary care referral and an increase through 
A&E between 2001 and 2011. It would be unlikely that the numbers of patients admitted in 
69 
 
this study have more acute/severe presentations of disease that require immediate hospital 
attendance, however this cannot be ruled out. A combination of two factors possibly result 
in this finding; the lack of knowledge of the recommended care pathways for symptoms 
associated with Lyme disease (such as flu-like illness and rashes), and the difficulty in getting 
a prompt appointment in primary care [190,197–200]. Peak non-urgent attendance at NHS 
emergency departments has been recorded at weekends [201], which may be due to the lack 
of access to primary care at the weekend [190,198–200,202]. However, the data shows that 
the number of cases appearing in A&E is relatively evenly distributed throughout week, 
suggesting that the lack of knowledge of where to seek help with Lyme disease symptoms 
may be the predominant cause of the above findings. Further work is needed to explore why 
so many patients would seek treatment at a hospital when, for the majority of cases, 
management could occur at primary care level. By linking with primary care electronic health 
records, one may be able to see whether they had sought help first in primary care before 
arriving at A&E. 
The major limitations of this study revolve around the use and validity of ICD-10 codes. A 
case of Lyme disease can be defined without laboratory confirmation, so there is no way to 
independently validate the accuracy of diagnostic coding in this context [23,39]. Previous 
work has shown that coding practices in hospitals are not infallible, but are steadily 
improving; quality issues were primarily focused on patient management variables, rather 
than demographics and geography [203]. Without such an audit, any potential 
inconsistencies in coding behaviour cannot be fully understood or quantified. Subjectively, 
admissions data in HES and PEDW were the most robust. As such, further work on the Lyme 
disease patient hospital population should primarily focus on admissions data. 
Sixty-three treatment departments were recorded, some of which have no discernible link 
to Lyme disease. This may represent simple coding errors or that the code has been added 
for completeness when the primary reason for admission was unrelated to Lyme disease. 
The outpatient dataset was significantly overrepresented by two hospitals; both had the 
main treating department as dermatology and resulted in a high number of ACA codes. This 
is further seen by the large number of outpatients seen on a Monday. These cases were all 
from one hospital, and likely represent one dermatology clinician’s outpatient clinic. This 
suggests that outpatient departments across England and Wales were not coding 
consistently and episodes may be being lost. The A&E dataset contained very low numbers 
of patients, in stark contrast to the large number being admitted through A&E as recorded 
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in the APC dataset. The main reasons for these low numbers is not through lack of 
attendance but how coding is encouraged. Within A&E, coding is not required to be as 
specific as the admissions data, and is just needed to code a generalised condition, sub-
analysis of more serious conditions and anatomical area involved [204]. This results in Lyme 
disease potentially falling into multiple categories depending on symptoms, such as 
“Infectious disease”, “Local infection”, “Dermatological conditions” and “Facio-maxillary 
conditions”. This has been seen in previous work on arthropod bites, where all cases were 
recorded as “Bites/Stings” and routinely didn’t specify the causal arthropod [205].  
PEDW only collects admission data and so some of the issues discussed above for the English 
dataset were negated. Unfortunately, linkage between the PEDW and HES datasets was not 
possible; though, for reasons described above, these patients were likely to be unique. 
Without linkage there still is the potential of duplication of patients within the records and 
therefore there is a small degree of uncertainty attached to these results.  
4.5 Conclusions 
This chapter has described the demographics of hospital patients who are coded with Lyme 
disease, across England and Wales. The demography of this population poses some 
interesting questions, especially around female predominance, the relative lack of ethnic 
diversity and the trend towards habitation in areas of low deprivation. This chapter provides 
a platform to inform future work on Lyme disease patients within hospital settings. Analysis 
of secondary care data can inform and help target health promotion messages, and as this is 
an ongoing dataset, interventions relating to Lyme disease could be formally assessed.  
The extent to which this work contributes to the overall aims of this thesis regarding Lyme 
disease surveillance can be summarised as follows: 
• Incidence: Increase (p<0.001) from 0.08 per 100,000 in 1998 to 0.53 per 100,000 in 
2015. Cases peaked in the summer. 
• Sociodemographics: Bimodal age distribution, with significantly more women than 
men. They were more likely to identify with being white than the national population 
There was a significant socioeconomic trend, with the number of cases decreasing 
as societal deprivation increased. Cases presenting in secondary care were 
significantly more likely to occur in rural areas, compared to the national population.  
• Geographical hotspots: These were identified in southern England, particularly in 
the south-west.  
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• Patient presentation and management: No information about patient presentation 
was collected. Cases tended to be admitted during weekdays. A single admission 
averaged 4.5 days in stay length. Admissions to hospitals are evenly distributed 
between accident and emergency departments, GP referrals, and elective lists. 
• Additional information: The APC dataset provided the most robust resource to use 
for analysis. The A&E, and outpatients data sets had significant flaws. A 
recommendation from this work would be for future research to focus solely on the 
APC dataset. 
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Chapter 5 Surveillance of Lyme disease in a primary care dataset 
 
The results from the hospital datasets (Chapter 4) are suggestive that the theoretical 
surveillance pyramid model may not accurately reflect the Lyme disease population, as the 
hospital dataset represents a smaller population of patients than that found in laboratory 
surveillance data (Chapter 3). The implications of this will be discussed more thoroughly in 
Chapters 9 and 10. The next tier in the surveillance pyramid (Fig. 2.1) represents Lyme 
disease patients that present to primary care. This chapter will discuss the analysis of a 
primary care electronic health records datasets to describe the incidence and 
sociodemographics of patients coded with a Lyme disease related Read code. 
The following content is currently in peer review as;  
Tulloch, JSP., Christley, RM., Radford, AD., Warner, JC., Beadsworth, MBJ., Beeching, NJ., 
Vivancos, R. The incidence of Lyme disease cases in a UK primary care cohort, 1998-2016.  
5.1 Introduction 
Lyme disease, caused by some members of the spirochaetal genospecies complex Borrelia 
burgdorferi sensu lato, has been the topic of much debate and created many headlines in 
the United Kingdom (UK) [12,54,206]. It is transmitted by the bite of an infected Ixodes spp 
of tick, and is the most common zoonotic disease transmitted by ticks in the Northern 
Hemisphere [21]. It has a variety of clinical presentations, most usually including erythema 
migrans, flu-like symptoms, and joint and muscle pain, or more uncommonly neurological 
and cardiac presentations [18,21,23,152]. Current recommendations are to treat patients 
presenting with an erythema migrans rash with antibiotics. Laboratory diagnostic tests are 
recommended when erythema migrans is absent and if there is clinical suspicion and a strong 
supportive history of Lyme disease [23]. However, as the (National Institute for Health and 
Care Excellence) NICE guidelines state, ‘there is a lack of robust epidemiological data on Lyme 
disease in the UK’ [23]. This lack of knowledge includes incidence data in different health 
care settings, basic patient demographic information, and an understanding of current case 
management strategies by health care professionals. 
As notification of clinical cases is not required, national incidence figures in the UK are based 
on reports of laboratory confirmed cases from the reference laboratories of Public Health 
England and Health Protection Scotland [82,153]. In 2016, the national incidence reported 
was 1.95 cases per 100 000 population in England and Wales, and 3.15 cases per 100 000 in 
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Scotland. Over the last decade, cases in England appear to be rising, whilst the incidence in 
Scotland is reported to be stable [76,82,153]. A 2016 review compared reported incidence 
across Western Europe and calculated a population-weighted average incidence rate of 
22.05 cases per 100 000 person-years [66]. In the United States of America, a study of the 
incidence of clinician-diagnosed Lyme disease calculated an annual incidence of 106.6 cases 
per 100 000 persons [64]. These differences in incidence are likely due to a combination of 
differing surveillance methods and differences in true incidence. Without a comprehensive 
surveillance system and an internationally standardised case definition, comparisons 
between nations prove challenging.  
Within a health care system, primary care manages the greatest number of Lyme disease 
patients [21,23,64,176,177,180,207]. No work has examined UK Lyme disease patients that 
accesses primary care. Without understanding the potential burden for general practitioners 
(GPs) and the demographics of these patients, it is difficult to shape policy, deliver targeted 
education to the general public and clinicians, perform financial assessments, or to 
understand case management strategies. The incidence of Lyme disease identified within 
primary care in the UK remains unknown, and no population-based UK study has been 
previously performed. There are two methods of recording primary care data; Read codes 
representing presenting symptoms or diseases, and free-text narrative. Read codes are a 
coded thesaurus of clinical terms that are used in primary care electronic health records in 
the UK and New Zealand [101]. A narrative analysis of health record free text, on a national 
scale, would prove ethically challenging due to difficulties in data anonymisation. On the 
contrary, primary care databases coded via Read codes are pseudo-anonymized and capture 
a large sample of the UK population. The aim of this ecological study was to describe the 
incidence and demographics of Lyme disease as recorded in primary care between 1998 and 
2016 in the UK using Read code analysis. 
5.2 Methods 
5.2.1 Data Source 
Population-based primary care data from The Health Improvement Network (THIN) were 
used to identify patients with Lyme disease, suspected Lyme disease or Lyme disease related 
conditions. The design of this study was approved by the THIN Scientific Review Committee 
(16THIN103).  
THIN represents 11.1 million patients with around 4.0 million active patients, collected from 
over 700 general practices. An active patient is defined as one being registered to a general 
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practice currently supplying data to THIN, who is not dead and has not left the practice since 
the last data collection point. THIN has representative coverage of 6.1% of the UK population, 
and is representative in terms of demographics, major condition prevalence and adjusted 
death rates [118]. All patients and general practices are pseudoanonymised and 
demographic information is available at patient level for: age, sex, ethnicity, and nation of 
residence. The representativeness of ethnicity data within THIN has been questioned, as the 
level of missingness at case-level is high. Between 2000 and 2013, 60% of THIN patient 
records had missing ethnicity information [208]. Ethnicity data are based upon patient-
provided information categorised into the following 2011 census groups; ‘White’, ‘Mixed’, 
‘Asian’, ‘Black’, and ‘Other’ [193,209]. 
The remaining sociodemographic variables under assessment were Townsend scores (an 
indicator of material deprivation) [210], and rural urban classification. Within THIN these 
data are not related directly to the case but are based upon the case’s resident postcode, 
and then linked to 2001 census data [159]. These data are therefore not a direct measure of 
the case’s sociodemographics, but rather a proxy, and reflect better the area that cases 
reside in. Townsend scores were converted, by THIN, from exact scores in to quintiles of 
equal size. The quintile of 1 includes patients living in the lowest 20% of Townsend scores 
(i.e. the least deprived areas), whereas the quintile of 5 includes the highest 20% and the 
most deprived areas.  
5.2.2 Participants and statistical analysis of the data 
In primary care the presenting symptoms of a patient are coded with Read codes. Currently 
we do not know which set of symptoms clinicians identify to code the patient as ‘Lyme 
disease’. Our case definition was therefore restricted to Read codes specific solely to Lyme 
disease and suspect Lyme disease (Table 5.1). The ‘Suspected Lyme disease’ and ‘Suspected 
erythema migrans’ codes were only introduced as Read codes in 2014 [211]. Conditions with 
multiple aetiology, such as Bell’s palsy, were not included. This strict definition was chosen 
to minimise the number of false positives identified. Choosing strict case definitions will likely 
underestimate the number of cases and sensitivity may be lost, as cases of mixed non-
specific clinical signs could be missed. These codes were used to identify patients accessing 
primary care between 1st January 1998 and 31st December 2016. No other exclusions were 
placed on the patients. The index episode was taken as the first occurrence of any one of the 
Read codes identified in a patient’s record. All calculations and demographic information 
were derived from this date.  
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Descriptive statistics were used to summarise the epidemiology of Lyme disease by 
demographic factors. Overall incidence rates, and incidence rates and ratios by sex, country, 
and Read code per 100 000 person-years were calculated. Incidence rates were constructed 
using patient-level data from THIN. This was defined as the number of cases divided by the 
sum person-time contributed by all patients in THIN between 1998 and 2016.  
Age-standardised incidence rates per year were calculated for the whole dataset, and were 
stratified by, sex, country and Read code. Denominators were calculated as the mid-year 
population of the THIN database. These annual incidence rates were assessed for trend using 
linear regression. Crude monthly incidence rates per year were calculated for the whole 
dataset and stratified by nation. 
Due to the poor recording of ethnicity within THIN, the complete electronic health record of 
each identified case was read to visually confirm ethnicity status, rather than constructing a 
Read code search. It was not in the remit of this project, or feasible, to perform this for the 
remainder of the THIN population. As such, incidence could not be calculated, and 
proportions of case ethnicity classification were compared with the national population. 
Ethnicity was compared to the national population using a Chi-squared goodness of fit test.  
The crude incidence rates of rural and urban place of residence were calculated. An incidence 
rate ratio was calculated to compare whether statistically significant differences in incidence 
existed between urban and rural areas. The crude incidence rate of each Townsend quintile 
was calculated. A Chi-squared test for trend and a Chi-squared test for departure from the 
trend were used to analyse trends in the incidence of cases across the Townsend quintiles. 
The study was designed as an ecological study and it was felt that the creation of a 
multivariable model, based on demographic variables, would not be statistically appropriate. 
This was due to the inability to calculate incidence for ethnicity, and that the incidence for 
rural urban classification and Townsend quintiles were based upon proxy geographical units 
rather than on individual case data, thus leading to issues of ecological fallacy. These 
variables were therefore assessed descriptively.   
All statistical analyses were carried out using R language (version 3.2.0) (R Core Team 2015), 
and results were deemed significant where p<0.05. 
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5.3 Results 
In total 3,725 unique patients were identified with a Read code for Lyme, suspected Lyme 
disease, or related conditions Read code between 1st January 1998 and 31st December 2016 
(Table 5.1).  
Table 5.1 Read codes used to identify Lyme disease patients in The Health Improvement Network (THIN) 
dataset (1998 - 2016) 
Description THIN Read 
Code 
Number 
of 
patients 
Lyme disease 
Erythema migrans 
Suspected Lyme disease 
Suspected erythema migrans 
Acrodermatitis atrophicans chronica 
Lyme arthritis 
Lyme neuroborreliosis 
Borrelial lymphocytoma 
Lyme carditis 
A871000 
AA41.00 
1JN1.00 
1JN2.00 
M21y000 
N010A00 
A871100 
A871300 
A871200 
2,386 
992 
233 
50 
30 
21 
8 
5 
0 
Total  3,725 
 
The most frequently used Read codes (‘Lyme disease’ and ‘Erythema migrans’) represented 
89.1% (n=3,318) of all Read codes identified with Lyme disease. The suspected Lyme disease 
codes only represented 7.6% (n=283) of all codes.   
The overall incidence rate was 4.42 per 100,000 person-years (95% CI 4.23-4.63). Incidence 
rates and incidence rate ratios between sexes, countries and Read codes for patients with 
Lyme disease in the UK are presented in Table 5.2.  
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Table 5.2 The incidence of Lyme disease cases by demographic factors and Read codes in The Health 
Improvement Network (THIN); 1998 – 2016 
Demographic Category n Person-years 
Incidence rate (per 
100 000 person-
years) (95% CI) 
Demographic 
Comparison 
Incidence rate ratios 
(95% CI) 
p 
value 
Sex       
Female 
Male 
1,907 
1,818 
43,109,106 
42,534,510 
4.42 (4.23-4.63) 
4.27 (4.08-4.47) 
Female versus male 1.04 (0.97-1.10) 0.29 
Country       
England 
Northern Ireland (NI) 
Scotland 
Wales 
 2,055 
50 
1,455 
165 
60,016,197 
3,781,630 
13,508,169 
8,337,619 
3.42 (3.29-3.56) 
1.32 (0.99-1.74) 
10.77 (10.23-11.34) 
1.98 (1.69-2.23) 
England vs NI 
England vs Scotland 
England vs Wales 
2.59 (2.00-3.43) 
0.32 (0.30-0.34) 
1.73 (1.48-2.03) 
<0.01 
<0.01 
<0.01 
Read Code       
Lyme disease  
Erythema migrans 
Acrodermatitis atrophicans chronica 
Lyme arthritis 
Lyme neuroborreliosis 
Borrelial lymphocytoma 
2,386 
992 
30 
21 
8 
5 
85,643,615 
85,643,615 
85,643,615 
85,643,615 
85,643,615 
85,643,615 
2.79 (2.68-2.90) 
1.16 (1.09-1.23) 
0.04 (0.02-0.05) 
0.02 (0.02-0.04) 
0.009 (0.004-0.02) 
0.006 (0.002-0.01) 
 
 
 
  
All Lyme codes 3,442 85,643,615 4.02 (3.89-4.12)    
Suspected Lyme disease 
Suspected erythema migrans 
233 
50 
85,643,615 
85,643,615 
0.27 (0.24-0.31) 
0.06 (0.04-0.08) 
   
All suspected Lyme codes 283 85,643,615 0.33 (0.30-0.37) 
All Lyme codes vs all 
suspected Lyme codes 
12.16 (10.77-13.73) <0.01 
Rural Urban Status – Only available for English and Welsh cases 
Rural 623 11,129,541 5.60 (5.17-6.05) Rural vs Urban 1.92 (1.75-2.11) <0.01 
Urban 1,450 49,793,661 2.91 (2.77-3.07)    
No status recorded (including all of 
Scotland and Northern Ireland) 
1,652 N/A     
Townsend Quintiles – a measure of material deprivation    
1 (least deprived) 916 18,632,692 4.92 (4.61-5.24)    
2 1,081 16,365,633 6.61 (6.22-7.01)    
3 787 16,076,059 4.90 (4.56-5.25)    
4 452 14,223,891 3.18 (2.90-3.48)    
5 (most deprived) 221 9,986,715 2.22 (1.94-2.52)    
No score recorded 287 N/A     
       
There was an increase in incidence for both sexes across the study period, however there 
was no significant difference in incidence rate between sexes. There was a significant 
difference between countries, with Scotland having the highest incidence of 10.77 per 100 
000 person-years (95% CI 10.23-11.34). This was more than three times higher than in 
England; the country with the next highest incidence of 3.42 per 100 000 person-years (95% 
CI 3.29-3.56). There was a significant increase in the age-standardised incidence of Lyme 
disease coded patients in primary care in the UK between 1998 and 2016 (Fig. 5.1-3). This 
rise was seen in all nations except Wales. 
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Figure 5.1Age-standardised incidence rates of Lyme disease coded patients in The Health Improvement 
Network (THIN) during 1998-2016, with smoothed lines of best fit (95% CI represented by shaded areas). 
Presented by UK and constituent nations 
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Figure 5.2 Age-standardised incidence rates of Lyme disease coded patients in The Health Improvement 
Network (THIN) during 1998-2016, with smoothed lines of best fit (95% CI represented by shaded areas). 
Presented by sex. 
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Figure 5.3 Age-standardised incidence rates of Lyme disease coded patients in The Health Improvement 
Network (THIN) during 1998-2016, with smoothed lines of best fit (95% CI represented by shaded areas). 
Presented by the four most prevalent Lyme disease Read codes 
Across the UK, cases displayed a seasonal pattern, with the highest incidence in the summer 
and peaking in July and August (Fig 5.4).  
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Figure 5.4 Box and whisker plots of monthly incidence rates of Lyme disease coded patients in The Health 
Improvement Network (THIN) during 1998-2016. A – UK, B – Constituent nations 
This seasonality was seen in England and Scotland with incidence peaking in July and August 
respectively. In Northern Ireland and Wales no obvious trends were seen.  
There was a high degree of missing data for ethnicity, with only 35.1% (n=1,306) of cases 
providing information. Of these, 73.5% (n=960), had an ethnicity description that matched 
the ethnicity categories defined in the UK 2011 census [209]; the remaining 346 all identified 
with being ‘British/Mixed British’. There was a significant difference in ethnic diversity 
(p<0.01), with a higher percentage of the Lyme disease coded THIN patients (96%) identifying 
with being white compared to the national population (87%).  
Information relating to Townsend score was available for 93.6% (n=3,487) of cases. Quintile 
five, that with the highest levels of material deprivation, had the lowest incidence rate, 2.22 
cases per 100,000 person-years (95% CI 1.94-2.52) (Table 5.2). The highest incidence rate 
was reported in the second quintile, 6.61 cases per 100,000 person-years (95% CI 6.22-7.01). 
There was evidence of an overall association between incidence rate and Townsend quintile 
(χ²=336.99, p<0.01). This association took the form of a trend of decreasing incidence with 
each increase in quintile number (χ²=197.38, p<0.01). Departures from the trend were 
significant (χ²=139.61, p<0.01).  
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Rural urban classifications were only available for English and Welsh cases, as Scottish and 
Northern Ireland authorities do not record this measure. Of the 2,220 of English and Welsh 
cases, 93.4% (n=2,073) had useable data. The incidence rate of cases living in rural areas, 
5.60 cases per 100,000 person-years (95%CI 5.17-6.05), was significantly higher than those 
cases living in urban areas, 2.91 cases per 100,000 person-years (95% CI 2.77-3.07).  
5.4 Discussion 
This study describes the incidence and demographics of Lyme disease coded patients using 
primary care data in the UK, fulfilling one of the key research needs identified by the NICE 
guidelines [23]. There has been a significant increase in the annual incidence of Lyme disease 
coded patients in UK primary care between 1998 and 2016. Incidence rates varied between 
nations, with Scotland experiencing the highest incidence of disease. There was a higher 
incidence of Lyme disease coded THIN patients living in rural areas and within areas of lower 
deprivation. 
European studies using similar data from primary care sentinel practices have described a 
large range in incidence [176,212,213], from 42 cases per 100,000 per year in France [180], 
to 148 per 100,000 per year in Norway [177]. The UK had a much lower incidence rate across 
the study period; 4.23 cases per 100,000 person-year. The UK had its peak age-standardised 
incidence in 2015, 7.10 per 100,000 population (Fig. 5.1). The annual incidence significantly 
varied between nations; Scotland peaked in 2015 with an incidence of 16.40, England in 2015 
with 5.23, Northern Ireland in 2015 with 2.94, and Wales in 2016 with 3.21. Even in Scotland, 
the incidence of Lyme disease is lower than in most areas of continental Europe. The reasons 
for this are likely to be multiple and need to be further explored. They may include: a lower 
prevalence of Ixodes spp of ticks, a lower prevalence of Borrelia spp carriage by ticks (4.2% 
in southern England [214], 0-8.2% in northern England [182], and 10.2% in Scotland [37], 
compared to 13.6% across Europe [215]), and different levels of exposure of the general 
populace to ticks, possibly due to differences in occupational and/or recreational 
dispositions. One possible explanation is lower awareness about Lyme disease in the general 
population and primary care in the UK, compared to the rest of Europe. This would result in 
fewer presentations to primary care, the potential for mis-diagnosis and a resultant 
underreporting of cases. 
The incidence figures are notably higher than those reported in current surveillance figures 
based on laboratory confirmed cases. The laboratory confirmed incidence of Lyme disease 
in England and Wales in 2016 was 1.95 cases per 100,000 (95%CI 1.84-2.06) [76,82,153], 
83 
 
whilst that identified in THIN was 3.77 (95% CI 3.62-3.94). The laboratory confirmed 
incidence of Lyme disease in Scotland in 2016 was 3.15 cases per 100,000 (95% CI 2.70-3.65) 
[76,82,153], in THIN it was 12.86 (95% CI 11.93-13.84 The laboratory confirmed incidence of 
Lyme disease in Northern Ireland in 2016 was 0.21 cases per 100,000 (95% CI 0.07-0.52) 
[76,82,153], in THIN it was 1.29 (95% CI 0.85-1.89). The large non-overlapping differences 
suggest that the incidence described in primary care data, for each country of the UK, was 
significantly larger than that described by official laboratory confirmed cases. This was to be 
expected as not all cases of Lyme disease (in particular those with erythema migrans) require 
confirmatory diagnostic laboratory tests. 
These differences between nations are notable and likely to be multifactorial. Scottish GPs 
may be more confident in diagnosing a case of Lyme disease, due to the higher prevalence 
of Lyme disease compared to England and Wales [153], and so manage more patients within 
primary care without submitting samples for serological testing. Conversely English and 
Welsh GPs could be more reluctant to diagnose and treat Lyme disease cases and may refer 
cases to secondary care sooner than their Scottish equivalents. There may be differences in 
patient access to primary care or differences in health-seeking behaviour between the 
different nations, dependent on differing clinical presentations. Further analysis of the THIN 
database may provide information about case referrals, and differences in case presentation 
and management. However, the exploration of differences in GP recording or patient 
behaviour would best be conducted through qualitative research.  
The rise in annual incidence of Lyme disease, and the differences in incidence with the 
laboratory datasets, could be a result of a real increase in disease, an increasing awareness 
of the disease in the general public, a change in general practitioners’ behaviour resulting in 
the submission of fewer diagnostic samples, or a combination of the above. Further work is 
needed to understand how general practitioners diagnose and manage Lyme disease cases. 
Wales is the only country that does not have a significant increase in cases, which may be 
due to, at least in part, a low number of cases (n=165) and registered THIN practices in Wales. 
The peak number of cases we observed in summer months is consistent with other studies 
[75,153,154]. This peak occurs slightly earlier in England than in Scotland. This is likely due 
to latitudinal, climatic and ecological differences between the two nations impacting on the 
emergence and peak numbers of nymphal ticks [216]. The low case numbers in Wales and 
Northern Ireland (n=50) likely explain the lack of an obvious seasonal trend. 
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The Lyme disease patient demographic have shown predominance in either sex in various 
settings in the UK [76,153,154,179]. In comparison to other national primary care datasets, 
Switzerland and France have no statistical difference between sexes, but numerically have 
more women [180,212]. Finland and Norway have significantly more women [176,177]. The 
results from THIN indicate no difference in the incidence between sexes (Table 5.2, Fig. 5.2), 
however, local differences may exist relating to differences in tick exposure or presentation 
to health services [109].  
A few papers have suggested that areas with higher Lyme disease incidence are likely to be 
less deprived [156,157]. The results presented here support this evidence and build on 
previous hypotheses that use and access to the countryside is a driver of Lyme disease risk. 
In England 45% of all outdoor visits were to the countryside, 68% of these were within two 
miles from their starting point (usually a home address), and that people were less likely to 
visit if they were from a BAME (Black, Asian, minority ethnic) background, or from a ‘DE’ 
social group (i.e. semi-skilled and unskilled occupations, unemployed and lowest grade 
occupations) [217]. In Scotland, 50% of outdoor visits were taken in the countryside, the 
average distance travelled from home being 4.8 miles, and that people were less likely to 
visit if they lived in the 15% most deprived areas, and were of ‘DE’ social grade; no difference 
in regards to ethnicity was identified [218]. All ethnic minority groups are more likely to live 
in areas of higher deprivation compared to the white population, and there is a lack of ethnic 
diversity in wealthy areas [195]. Taking this into consideration, we believe that members of 
the general population who live in areas of low deprivation, predominantly rural locations 
[167,168], are more likely to identify with a white ethnicity, and due to their residential 
location have greater and closer access to the countryside. This increased potential access 
to the countryside enables increased risk of a tick bite and therefore subsequent risk of 
developing Lyme disease. The lack of representation of non-white ethnicity patients may also 
be due to inadequate healthcare access, lack of Lyme disease awareness, or simply that EM 
rashes are harder to identify on non-white skin colour [219,220]. The latter assumption 
would not hold true with other clinical presentation, and it is recommended that ethnicity 
should be explored in relation to clinical presentation prevalence. 
There is obviously a complex interplay between ethnicity, socio-economic status and place 
of residence of a case, probably related with either outdoor employment or leisure activities. 
The current descriptive analysis only provides baseline exploratory information on these 
variables. The ethnicity data has a high degree of missingness, 74%, more so than prior 
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analyses, 60% [208]. Its representativeness must therefore be questioned; our data only 
provides a general indicator of the true situation. Our characterisation may be simplified, but 
the structure of the dataset negates multivariable analysis of these potential risk factors 
associated with Lyme disease. Future work should be designed to take this into account and 
allow for the identification of any confounding and interaction between these variables.  
With this large scale work we provide UK specific baseline data that is greatly needed for 
further epidemiological research around Lyme disease, and have fulfilled one of the NICE 
guidelines identified research needs [23]. We have highlighted new insights into the 
demographics of Lyme disease patients in primary care. THIN has been shown to be 
representative of the UK population and, as such, the results are likely to be representative 
of the Lyme disease cases seen in primary care. However, there are some limitations that 
must be highlighted. The majority of research investigating conditions within a primary care 
database also try to validate the Read codes investigated. This is usually via the result of a 
diagnostic test or a questionnaire of general practitioners [106,221]. Validation of Read 
codes relating to Lyme disease therefore proves a challenge, as if there is an uncomplicated 
clinical presentation the clinician is recommended to prescribe antibiotics without 
performing subsequent diagnostic tests [23]. Therefore, matching a Read code case with a 
positive test result may be a fruitless exercise. Instead, validation through a GP questionnaire 
would be recommended. In the majority of cases there will be no confirmatory diagnostics, 
so GPs would have to confirm a case by remembering the exact consultation, as the 
information collected by THIN does not substantially differ from what is in the practices’ 
clinical records. Hence, there would be scope for considerable error. Methodology for 
validating conditions with broad clinical presentations needs to be explored, but this was 
beyond the scope of this study.  
One of the largest limitations of this study is the absence of knowledge about GP coding 
practices and changes in their coding behaviour. Further work is required to better 
understand coding practices and how they may vary. The Read codes used by clinicians were 
consistent until 2010, with the majority being ‘Lyme disease’ and ‘Erythema migrans’, at 
which point the use of these terms started to decline (Fig. 5.3). A year after the introduction 
of the ‘suspected’ case codes in 2014, the ‘suspected’ codes were already more prevalent in 
use than ‘Lyme disease’ and ‘Erythema migrans’. The reasons for the changes in GP coding 
behaviour, potentially indicated by changes in code incidence, are unknown; the change may 
be due to the increasingly politicised landscape of Lyme disease and the debate around 
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‘chronic Lyme disease’ [54,222]. We need to know what symptoms are identified to code a 
patient with ‘Lyme disease’; this could be only an erythema migrans rash or another 
presentation described by NICE [23]. Qualitative research around general practitioners’ 
recognition and coding behaviour regarding Lyme disease would help answer these 
questions. Only 25.8% (n=960) of the study population had information that could be 
analysed around ethnicity. We assumed that the trends seen in this subset of patients is 
representative of the THIN population as a whole; further work is needed to verify this.  
Finally, the geographical resolution of THIN only allows us to carry out analysis to the level 
of the constituent nations of the UK, so analysis of the spatial distribution of incidence with 
this dataset is not possible. Previous research in the UK has shown clear clustering of cases 
both from laboratory confirmed cases [23,76,153,154], and hospital admissions [179]. The 
largest number of identified cases will be in primary care, because not all cases require 
diagnostics or hospital admissions. Therefore, without greater resolution, we cannot see 
whether the observed hotspots of disease in laboratory surveillance systems are reflected in 
primary care activity. 
The NICE guidelines highlighted the ‘lack of robust epidemiological data’ on Lyme disease in 
the UK, and called for research in this area [23]. This research provides a description of the 
demographics and incidence of a representative UK primary care population. This work will 
help ensure the appropriate public health prioritisation of Lyme disease in the UK, however, 
many basic epidemiological questions remain unanswered. These mainly revolve around 
person-tick interaction and include; the Borrelia spp seroprevalence of the UK population, 
the total exposure of tick bites to the UK population, and the risk of contracting Lyme disease 
after a tick bite in the UK. These final two points could be explored using the THIN dataset.  
Our data provides the primary care practitioners with basic sociodemographic information 
about the type of patient who is more likely to present with Lyme disease. This information 
can be used to raise awareness of increasing Lyme disease presentations in primary case and 
their seasonality in the UK. This information is critical to their diagnostic clinical decision 
making and ensures that their clinical suspicion of Lyme disease is increased in suitable 
situations. This research, alongside the NICE guidelines [23], will raise Lyme disease 
awareness amongst primary care clinicians and thus ensure that Lyme disease is aptly placed 
on their differential diagnosis list. Patients are therefore less likely to be misdiagnosed and 
will be managed more appropriately. This will only enhance Lyme disease patient care. 
Comparing Lyme disease presentations in primary care with incidence in laboratory 
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surveillance systems can highlight areas where differences exist regarding awareness, 
reporting, and management of Lyme disease. These differences would require further 
investigation. Future research using Lyme disease coded patients within THIN, will 
investigate concurrent symptoms, and treatment and referral choices as part of case 
management plans. This study provides a platform to describe patient management in the 
UK primary care setting and enables ongoing epidemiological analysis of Lyme disease.  
5.5 Conclusions 
This chapter has described the demographics of primary care patients who are coded with 
Lyme disease, across the United Kingdom. The demography of this population poses some 
interesting questions about the relative lack of ethnic diversity and the trend towards 
habitation in areas of low deprivation, and in rural areas. This chapter provides a platform to 
inform future work on Lyme disease patients within primary care. Analysis of primary care 
data can inform and help target health promotion messages, and as this is an ongoing 
dataset, interventions relating to Lyme disease could be formally assessed.  
The extent to which this work contributes to the overall aims of this thesis regarding Lyme 
disease surveillance can be summarised as follows: 
• Incidence: An overall incidence rate of 4.42 cases per 100,000 person-years (95% CI 
4.23-4.67). There was an increase (p<0.05) from 2.07 cases per 100,000 in 1998 to 
6.05 per 100,000 in 2016. Cases peaked in the summer. 
• Sociodemographics: A slight bimodal age distribution, with no differences between 
sexes. They were more likely to identify with being white than the national 
population. There was a significant socioeconomic trend, with the incidence 
decreasing as societal deprivation increased. The incidence of cases in rural areas 
was almost double (1.92 per 100,000 (95% CI 1.75-2.11)) that of cases residing in 
urban areas.  
• Geographical hotspots: No fine geographical resolution data was available. Scotland 
had the highest incidence (10.77 cases per 100,000), followed by England (3.42), 
Wales (1.98), and Northern Ireland (1.32).  
• Patient presentation and management: No information about patient presentation 
and management was analysed. Such data were available in THIN and were 
extensive. This meant that it was beyond the scope of this thesis. However, it would 
be critical for the data to be analysed so that the current management of Lyme 
disease patients in primary care could be understood.  
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• Additional information: Read codes have been identified that can be used to identify 
Lyme disease patients. These codes could be used in other primary care datasets for 
further research purposes or for the surveillance of Lyme disease in primary care. 
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Chapter 6 The validation of Lyme disease Read codes through 
blinded interviews with primary care clinicians 
6.1 Introduction 
In Chapter 5 the wealth of information that can be extracted from primary care electronic 
health records was discussed. However, when a disease does not require a confirmatory 
diagnostic test, how do we know the reliability of Read code defined cases? (Read codes are 
a standardised coded thesaurus of standard clinical terminology used in primary care 
electronic health records in the United Kingdom.) Essentially, what is the positive predictive 
value (PPV) of the Read codes that were used to define a case of Lyme disease?  
Many research projects have tried to validate their Read codes and calculate a PPV for them. 
Two systematic reviews have been performed on this topic [221,223]. To date, no evidence 
could be found of research into the negative predictive value of Read codes. This would be 
challenging research, as it would be exceptionally difficult to identify true false negatives in 
datasets of this scale, based solely on Read codes. Until a robust methodology is designed to 
calculate negative predictive values for Read codes, interpretation of Read code based 
incidence studies must bear this in mind. The two systematic reviews reported four ways of 
calculating a PPV and validating Read codes: comparing incidence figures to a national 
database: requesting the health records of identified patients to confirm the diagnosis 
themselves, using questionnaires to general practitioners (GPs) to confirm cases, or a 
mixture of the above.  
An example of the comparison validation methodology is a study which observed the 
national rates of suicide and self-harm [107]. This compared the incidence described in a 
primary care database to official figures (Office for National Statistics - ONS). It was 
concluded that the primary care figures were unreliable, as there was significant under and 
over-reporting of cases. Another study explored the quality of recording for a QOF (“quality 
and outcomes framework” introduced in 2004 as part of the contract for general practices 
in England) dementia record in primary care. The QOF financially rewards primary care 
practices for the ‘provision of quality care’ to ‘help standardize improvements in the delivery 
of primary medical services’ [224]. Certain clinical conditions, and their associated Read 
codes, are deemed “QOF-able” if they are of high importance to the health and well-being 
of the nation. Dementia is one of these QOF-able areas, and practices are paid for the 
recording of all dementia cases. One would therefore expect a high level of reporting 
accuracy. Russel et al [225] initially found 1,007 cases on the QOF dementia records, but on 
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further examination of the practice Read codes, they found an extra 132 patients. This 
significant difference suggested that the QOF records underreported primary care cases by 
12% [225]. A further study described the incidence of non-fatal acute myocardial infarctions 
in primary care records, hospital records, and a national disease registry [226]; 63.9% of cases 
were found in at least two sources, with the crude incidence being 25% lower if based solely 
on primary care records rather than all three data sources. 
If it is possible to link cases across multiple databases, one has a much greater ability to get 
closer to the true incidence of disease. This methodology relies on a reliable national 
database to work effectively. This proves a challenge with Lyme disease, as most patients are 
only likely to present in primary care and not appear in another database. Hence, this 
methodology for validation had to be ruled out for the current study.  
The remaining methodologies of sending GPs questionnaires or requesting health records 
are the commonest approaches, and have been performed for at least forty different 
diseases [223]. Often studies use a combination of both. There is, however, a huge range of 
PPV, ranging from 16.5% to 100%. On the questionnaires the GPs are usually asked how they 
confirmed a case. This can be through hospital confirmation letters, clinical notes, hospital 
records, electronic health records or laboratory reports[106,221,223,227,228]. Independent 
validation of the health records can be performed by the research team and has been 
described as the most robust method, but this will come with a cost, averaging around £70 
per clinical note [221]. It has been described that questionnaires alone have a PPV of 91.7%, 
record request alone, 82.7%, and a combination as 90% [221]. Due to the high expense and 
ethical challenge of requesting clinical notes, most studies solely use a questionnaire [221]. 
Within these, the most common methods of case validation is firstly a consultant’s letter, 
followed by clinical notes, and electronic health records [106,221,223,227,228]. 
Interestingly, one study found high PPVs for cataracts (92%) and glaucoma (84%) based on 
questionnaires; however, there were huge discrepancies (20-33% accuracy) between 
reported timings of diagnosis in the primary care database and the questionnaire response 
[228]. This clearly shows the disparity in how certain elements of clinical notes are recorded 
with differing amounts of rigour and accuracy.  
All the studies captured within these systematic reviews had narrow case definitions, and 
the cases often involved referral or contact with hospital consultants. One suspects that, due 
to this, GPs are comfortable assigning a specific Read code to the patient. Lyme disease 
differs to all of these previous studies in that the case definition is very broad, and the 
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majority of patients are likely to be managed in primary care without contact from either a 
hospital or laboratory [23]. If validation is performed through questionnaires, it is likely that 
confirmation will occur via clinical notes. Therefore, the best method for validation would be 
requesting the clinical records of each patient identified through our analysis. To do this 
properly was too costly (estimated at over £210,000) and would exceed the time constraints 
of this PhD.  
Only one primary care database study utilising Read codes shared similarities with Lyme 
disease, in that it had a vague case definition, and diagnosis does not always require 
laboratory diagnostics. This was a 2013 study investigating the prevalence of irritable bowel 
syndrome (IBS) [229]. IBS is a functional bowel disorder whose presentation includes 
abdominal pain, discomfort with defaecation, and changes in bowel habit and defaecation, 
amongst other symptoms. This study was unable to validate their codes but found a much 
lower prevalence in GP coded records compared to the literature. It was also noted that most 
patients coded with IBS had no other codes relating to gastrointestinal symptoms. The 
authors noted a few interesting reasons why there is a disparity in prevalence, firstly that; 
‘Read Codes used to code a consultation are at the discretion of the individual 
clinician, which means that there can be considerable variation in their use to 
describe the same set of symptoms in practice (particularly for conditions not 
incentivised in the Quality Outcomes Framework (QOF))’ 
They describe how IBS is not a priority for GPs, and that GPs appear reluctant to code patients 
for IBS and thus recording is patchy [230]. The same authors stated that; 
 ‘GPs reported that they did not initially add a Read code for IBS to the patient 
record, but delayed until they were more confident in the diagnosis. [230]’ 
The authors hypothesised that IBS patients did not feel that primary care can offer help, and 
that patients felt that doctors were unsympathetic, ignorant about IBS and believed that IBS 
is psychosomatic. Overall the authors suggested that the alienation felt by some IBS patients 
meant that they were not accessing health care, resulting in underreporting of cases. They 
suggest that this shares 
 ‘similarities with many other medically unexplained symptoms which are typically 
difficult to diagnose in clinical practice.’ 
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Even though Lyme disease’s case definition is broad [23], it is subjectively more clearly 
clinically defined than that of IBS. However, one can hypothesise that the potential reasons 
for underreporting is likely to be similar, with GPs not being incentivised to consistently code, 
GPs not coding Lyme until a definitive diagnosis is reached, and some patients reluctant to 
see GPs. The question, therefore, is not how we validate patients coded for Lyme disease, 
but ‘How do GPs code patients with Lyme disease presentations?’ If we can understand this, 
we may have a better understanding of the level of underreporting of Lyme disease cases. It 
was felt that this question could best be addressed by using a questionnaire.  
The decision-making behaviour of GPs regarding the selection of Read codes is poorly 
understood [231]. It has been acknowledged that the primary care consultation is a complex 
social and professional interaction and that the recording of electronic and written clinical 
notes is an important part of this [232]. However, barriers to coding consultations have been 
acknowledged and these include; the perception that coded data is unimportant, codes 
having a predominant biomedical focus and are difficult to use in complex clinical 
presentations, the difficultly in creating a high quality clinical record as well as leading a 
patient-centered consultation, and that targets and financial incentives drive and distort 
coding behaviour [231]. It has been reported that clinicians do not see a direct patient benefit 
to coding their records [231–233]. In addition, if an electronic health record receives a 
‘definitive diagnosis’, via a Read code, it can be harmful to the patient and damage the 
patient-clinician relationship [233,234]. Through questioning GPs on a disease with a non-
specific presentation there is an opportunity to understand some of the motivators and logic 
behind Read code selection.  
Many other studies have used a questionnaire design focused on Lyme disease. None of 
these have focused on primary care coding, but instead have focused on clinician knowledge 
and management of Lyme disease cases. In France, overall 50% of clinicians believe that 
serology is needed to confirm a case; however, if they have training, 72% believe than an 
erythema migrans (EM) rash is diagnostic [46,235]. A Belgian study found that 17.5% of GPs 
would offer Lyme disease serology for a tick bite and 9% would prescribe antibiotics. If they 
identified an EM rash 54% would order serology and 91% would prescribe antibiotics [236]. 
Dutch GPs had highly varied approaches about when they ordered Lyme disease serology 
even though national guidelines exist [237]. In the USA, clinician beliefs are very varied on 
how they manage cases in terms of antibiotic choices, and length of treatment for both tick 
bites and erythema migrans rashes [238]. One study found that 31% of GPs give antibiotic 
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prophylaxis for tick bites. When presented with EM with a tick bite history 70.6% prescribe 
antibiotics and perform a serological test, 18.7% only prescribe antibiotics and 4.3% perform 
only a serological test [239]. Two separate studies in Quebec found inconsistencies in how 
GPs manage tick bites and EM rashes [240,241]. A more controversial paper that has 
provoked extensive commentary [242], found that 2% of GPs believe in and treat ‘Chronic 
Lyme disease’, 48.1% are unsure of its existence, and 49.8% don’t believe it exists [243].  
The two most relevant papers, with very similar methodologies, examined GP beliefs and 
practices in an endemic area (New Hampshire) [244] and a non-endemic (British Columbia) 
area [245]. In New Hampshire, 93.9% of GPs knew the causal pathogen, and 52.4% knew EM 
was diagnostic. When presented with an EM rash, 85.5% would prescribe antibiotics, 13.1% 
would order Lyme disease serology, 0.6% would do nothing and 0.6% would refer. When 
presented with a tick bite, 12.9% would prescribe antibiotics, 28.8% would order serology, 
57.7% would do nothing, and 1.1% would refer. With a Lyme arthritis presentation, 13.7% 
would prescribe antibiotics, 48.2% would investigate without serology initially, 4% would do 
nothing, 7% would order serology, and 29.6% would refer. Overall 89.7% of GPs believe that 
patients that requested a Lyme disease diagnostic test have another cause of their symptoms 
other than Lyme disease [244].  
In contrast, in the non-endemic area of British Columbia, 98.2% of GPs knew the causal 
pathogen, and 26% knew EM was diagnostic. When presented with an EM rash, 58.3% would 
prescribe antibiotics, 36% would order Lyme disease serology, 0.2% would do nothing and 
3.4% would refer. When presented with a tick bite, 7.5% would prescribe antibiotics, 40.2% 
would order serology, 51.3% would do nothing, and 1% would refer. With a Lyme arthritis 
presentation, 11.1% would prescribe antibiotics, 40.8% would investigate without serology 
initially, 1.5% would do nothing, 5.7% would order serology, and 40.8% would refer. In 
consults were Lyme disease was mentioned, patients would initially raise it rather than GPs 
57.8% of times. Overall 78.7% of GPs believe that patients that requested a Lyme disease 
diagnostic test have another cause of their symptoms other than Lyme disease. Thirty one 
percent of GPs prescribed antibiotics due to Lyme disease related patient concerns, even 
though they didn’t believe the patient had Lyme disease [245]. 
These studies show the varied approaches of Lyme disease case management in primary 
care. The inconsistencies are not only present in non-endemic areas but also in endemic 
areas, and very few GPs appear to be following their nation’s guidelines. As this study was 
designed to capture how GPs code for Lyme disease, it was felt appropriate to also ask 
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questions about case management. The above studies were used to inform the design of 
case management questions in our research; the results of which will help inform us about 
the current management of Lyme disease patients within a primary care setting. This will 
highlight any need for the future education of GPs in Lyme disease, so that their patients 
receive the best and appropriate care. 
6.2 Aims 
To investigate how well GPs recognise the various clinical presentations of Lyme disease, and 
what Read codes they would use to record those presentations within patient electronic 
health records. To understand what ideas and motives help shape primary care clinicians 
coding behaviour.  
6.3 Methods 
Through discussions with the Royal Liverpool and Broadgreen University Hospitals NHS Trust 
(RLBUHT) research team, it was decided that the project was to be split in to two phases. 
These were (a) semi-structured interviews of GPs, as a pilot study, followed by (b) a national 
blinded online questionnaire.  
A pilot study was run for two main reasons. Firstly, no questionnaire-based studies were 
found where GPs were blinded to the researchers’ motives, and it was unknown how GPs 
would react to being blinded. Secondly, no previous study had attempted to understand 
coding habits based on case studies. There was therefore a need to ensure the questionnaire 
worked and that the correct questions were being asked. The feedback from the GPs in the 
pilot study would enable the design of a better questionnaire and provide ideas on the most 
successful distribution route for a national online questionnaire.   
6.3.1 Semi-structured interviews of GPs 
In all the studies mentioned in section 6.1, the GPs knew they were being asked about Lyme 
disease. This may cause bias through GPs answering with what they perceive to be the 
correct answer, rather than what they clinically do. In addition to this concern, if the GPs 
knew what the aims of the study were they may not answer the coding questions honestly, 
due to Lyme disease being at the forefront of their clinical decision making process. This 
would impact the validity of any results generated. The GPs were therefore blinded to the 
fact the study was about Lyme disease; aiming to make their decision making process as close 
to an unbiased clinical consultation as possible.  
Interviews commenced with the presentation of a ‘Participant Information Sheet’ (Appendix 
1), in which the study was entitled ’Understanding the decision making process of general 
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practitioners (GPs) presented with non-specific conditions’. Thus, answers generated from 
the questionnaire should reflect GPs coding practices and case management strategy closer 
to what they would do in a clinical setting. It was felt that through this design, information 
garnered from this study could help inform future research studies, of not only Lyme disease, 
but other conditions with a similarly vague presentation.  
Eleven clinical cases were constructed based on current clinical case definitions [23,39] and 
through discussions with infectious disease consultants based at the RLBUHT (Table 6.1). 
The cases were loosely based on real cases. Most had vague symptomology that could have 
easily been attributed to a variety of causes other than Lyme disease. 
Table 6.1 A summary of clinical cases presented to GPs, for full details see Appendix III 
Case Further details 
1 – Classic erythema migrans (EM) rash Initial presentation of EM. A photo used 
by multiple organisations, so GPs likely to 
be familiar with. Then patient revealed to 
have been bitten by a tick.  
2 – Borrelial lymphocytoma Borrelial lymphocytoma of the ear lobe. 
3 – Acrodermatitis chronica atrophicans 
(ACA) 
With associated peripheral neuropathy 
4 – Bell’s palsy Later revealed to have insect bite on 
scalp. 
5 – Recurrent synovitis of knees N/A 
6 – Multiple EM rashes Patient had been walking in Dartmoor 
7 – Heart rhythm abnormalities N/A 
8 – Fatigue, post-exertional malaise, 
anxiety, headaches, and memory issues 
Later patient reveals an international lab 
report saying she has Lyme disease, and 
she demands long term antibiotics. 
9 – Fatigue, arthralgia, poor ability to 
concentrate, myalgia, mood swings 
N/A 
10 – Non-engorged tick attached to scalp N/A 
11 – Poor fine motor movements, rash two 
months previously at scout camp. This had 
been treated with erythromycin. 
N/A 
 
For each case, a series of questions were constructed regarding the GPs’ differential 
diagnoses, how they would code their patient (using Read codes) on the patient’s electronic 
health record, and decisions around diagnostics, prescriptions and referrals. To reduce 
cognitive bias (recollection of previous cases in the questionnaire could impact their answers 
to the current case), the cases were presented in a random order, determined by a random 
number generator. 
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At the start of the interview, the basic demographic information of each GP was collected. 
The GPs were told that all patients presented in the cases were otherwise healthy with no 
other known health problems, prior to the symptoms and history presented to them. The 
cases were then presented, with answers and comments transcribed. On completion of the 
cases, the GPs were handed the ‘Exit Information Sheet’ (Appendix IV), which revealed the 
purpose of the study. Questions were then asked about the blinding process and whether 
they found it acceptable. Questions were also asked around the questionnaire structure and 
how it would work online. Guidance was sought for the best online distribution channels for 
phase 2, to maximize participation rate. Finally, information was collected regarding their 
basic knowledge about Lyme disease. The GPs were then provided with resources to learn 
more about Lyme disease. The questionnaire pack used in the interviews is included in 
Appendices I to IV. 
The interviews were recorded on a dictaphone and transcribed, this enabled the analysis of 
any discoursive elements of the participants answers to the questionnaire. A thematic 
approach was taken to explore coding behaviour of the GPs [246]. The transcribed 
manuscripts were read multiple times to allow thorough immersion of the data. The 
transcripts were then coded using an inductive approach, this allows for thematic codes to 
emerge from the data rather than from pre-planned codes. The resultant codes were reread 
and combined into a set of themes. The themes were then checked with the coded extract 
and the main corpus. To ensure reliability and repeatability of the results, these themes were 
then refined with members of the research team until a consensus was reached. The themes 
identified were then organised and quotations selected to highlight the main themes. 
Interpretation of the themes occurred to theorize the explanatory causes behind them.  
The interviews took place at the GPs’ practices and were designed to last between 30 and 45 
minutes. On arrival they signed a consent form and were given the opportunity to opt out at 
any point during the process. They were also given the option to end the interview if it was 
taking too long, but still allow their results to be used for research. They could also opt out if 
they felt uncomfortable with the blinding process.  
The aim was to identify ten GPs in the Merseyside area, chosen on a purely convenience 
basis, who would be willing to participate in the study. However, when initial recruitment 
began in July 2017, there were zero responses. This meant engaging with the Clinical 
Research Network (CRN) to aid recruitment, and with a resulting larger recruitment area. 
Recruitment was not complete until August 2018. Recruitment had to stop in November 
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2017; it would not resume until May 2018. The pilot project was granted REC (NHS Research 
Ethics Committee) and HRA (Health Research Authority) approval under the IRAS (Integrated 
Research Application System) project ID: 208815. 
The severe delays and challenges faced getting the pilot phase started (Figure 6.1), resulted 
in Phase 2 not being undertaken as part of this PhD, due to restrictive time constraints. These 
issues will be further debated in the discussion of this chapter.  
 
Figure 6.1 Timeline of GP validation study: from study protocol design to end of recruitment. (ID – Infectious 
disease, RLBUHT – Royal Liverpool and Broadgreen University Hospital Trust, PHE – Public Health England, UoL 
- University of Liverpool, IRAS  - Integrated Research Application System, REC – NHS Research Ethics Committee, 
HRA – Health Research Authority, RCGP – Royal College of General Practitioners, CRN – Clinical Research 
Network) 
 
6.4 Results 
Ten GPs in the Clinical Research Network (CRN) North-West Coast region were approached 
to take part in the interviews. All ten responded that they were willing to take part. However, 
one GP failed to attend multiple appointments, and another never set a date for the 
interview. The remaining eight GPs had similar enough responses that we felt that data 
saturation was reached for the purposes of this project [247,248], and further recruitment 
was not needed. 
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Five (62.5%) of the GPs were male. The GPs had a mean age of 46 (range: 38-53). The mean 
time in clinical practice was 16 years (range: 10-26). Three (37.5%) were a GP with a specialist 
interest. These interests were, diabetes, ear, nose and throat (ENT), and one GP whose were 
substance misuse, and sexual and reproductive health.    
The study area that CRN North West Coast covers includes the regions, South Cumbria, 
Lancashire, Merseyside and Cheshire (Figure 6.2).  
 
Figure 6.2 The clinical research networks (Image from the UK Clinical Research Collaboration) 
None of the GPs were based in South Cumbria, five were based in Lancashire, two in 
Merseyside and one in Cheshire (Figure 6.3). These areas all have a low incidence of 
laboratory-confirmed cases of Lyme disease and hospital admissions (Chapters 3-4). 
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Figure 6.3 The study area (CRN North West Coast), with the number of GPs interviewed in each subdivision. 
(Image from the Clinical Research Network North West Coast)  
The participant GPs took, on average, 43 minutes (range 20-60) to complete the interview. 
None opted out at any point of the process. Four of the GPs were able to complete all 11 
cases, three completed 10 cases, and one GP was only able to complete two questions. This 
variability was due to time constraints in their professional schedule. The responses to the 
cases are summarised in table 6.2, for more detailed responses see Appendices V to XV. 
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Table 6.2 Summary of key results of a blinded case-study questionnaire about coding and diagnosis regarding Lyme disease. If the case had split sections, the cells in the table are similarly 
split.  
Case, and number of 
GPs presented with it 
Top three differential diagnosis, 
where n>2, and any mention of a 
Lyme disease diagnoses 
Top three Read Codes, where n>2, 
and any Lyme disease Read Codes 
Diagnostics
(Y/N)  
Prescription 
(Y/N)  
Referral 
(Y/N)  
1: Erythema migrans 
(EM) rash (n=7) 
See Appendix V 
Lyme disease   
Bite  
(10 differentials were 
mentioned in total) 
71.4% 
28.6% 
Rash  
Lyme disease  
Erythema migrans   
Suspected Lyme disease  
(5 Read codes were mentioned 
in total) 
42.6% 
28.6% 
14.3% 
14.3% 
71.4% 71.4% 57.4% 
Lyme disease  
(3 differentials were 
mentioned in total) 
85.7% 
2: Borrelial 
lymphocytoma (n=7) 
See Appendix VI 
No differential was mentioned 
more than once. 
(13 differentials were mentioned in 
total) 
Ear swelling  
(5 Read codes were mentioned 
in total, and one GP wouldn’t 
code the case) 
28.6% 28.6% 42.9% 57.1% 
3: Acrodermatitis 
chronica atrophicans 
(n=8) 
See Appendix VII 
Alcohol related issue 
Vitamin B12 deficiency  
(19 differentials were 
mentioned in total) 
50% 
37.5% 
Peripheral neuropathy  
Sensory loss  
(4 Read codes were mentioned 
in total, and one GP wouldn’t 
code the case) 
37.5% 
25% 
100% 25% 50% 
4: Bell’s palsy (n=7) 
See Appendix VIII 
Bell’s palsy  
Brain tumour  
Space occupying lesion  
(9 differentials were 
mentioned in total) 
100% 
42.9% 
28.6% 
Bell’s palsy  
Nerve palsy  
(5 Read codes were mentioned 
in total) 
57.1% 
28.6% 
71.4% 14.3% 85.6% 
Bell’s palsy  
Brain tumour   
Lyme disease  
(7 differentials were 
mentioned in total) 
100% 
28.6% 
14.3% 
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5: Recurrent synovitis 
of knees (n=7) 
See Appendix IX 
Osteoarthritis   
Rheumatoid arthritis  
Gout  
(9 differentials were 
mentioned in total) 
71.4% 
57.1% 
42.9% 
Knee pain  
Synovitis  
(4 Read codes were mentioned 
in total) 
42.9% 
28.6% 
100% 100% 42.9% 
6: Multiple EM rashes 
(n=7) 
See Appendix X 
 
Insect bite  
Fungal infection  
Lyme disease  
(11 differentials were 
mentioned in total) 
85.7% 
42.9%
42.9% 
 
Non-specific rash  
Erythema migrans 
(6 Read codes were mentioned 
in total, and one GP wouldn’t 
code the case) 
28.6% 
14.3% 
42.9% 85.7% 0% 
7: Heart rhythm 
abnormalities (n=7) 
See Appendix XI 
Arrhythmia  
Palpitations  
(11 differentials were 
mentioned in total) 
57.1% 
42.9% 
Palpitations  
(2 Read codes were mentioned 
in total, and one GP wouldn’t 
code the case) 
71.4% 85.7% 28.6% 28.6 
8: Fatigue, post-
exertional malaise, 
anxiety, headaches, 
and memory issues 
(n=5) 
See Appendix XII 
Thyroid problems  
Chronic fatigue 
syndrome  
Depression  
(8 differentials were 
mentioned in total) 
80% 
60% 
 
60% 
Tired all the time  
(3 Read codes were mentioned 
in total, and one GP wouldn’t 
code the case) 
60% 100% 20% 60% 
Thyroid problems  
CFS  
Depression  
Lyme disease  
(7 differentials were 
mentioned in total) 
60% 
40% 
40% 
20% 
9: Fatigue, arthralgia, 
poor ability to 
concentrate, myalgia, 
mood swings (n=7) 
See Appendix XIII 
Depression  
Anaemia  
Thyroid problems 
(13 differentials were 
mentioned in total) 
71.4% 
42.9% 
42.9% 
Fatigue 
Polyarthralgia   
(4 Read codes were mentioned 
in total, and one GP wouldn’t 
code the case) 
42.9% 
28.6% 
100% 71.4% 14.3% 
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10: Non-engorged tick 
attached to scalp 
(n=6) 
See Appendix XIV 
Cutaneous horn  
Foreign body 
Skin lesion  
Tick 
(10 differentials were 
mentioned in total) 
33.3%
33.3% 
33.3% 
33.3% 
Skin lesion  
Tick bite  
(4 Read codes were mentioned 
in total) 
33.3% 
33.3% 
66.7% 16.7% 0% 
11: Poor fine motor 
movements, rash two 
months previously 
(n=8) 
See Appendix XV 
Depression   
Neurological condition  
Lyme disease  
(18 differentials were 
mentioned in total) 
50% 
50% 
12.5% 
Feeling low  
Low mood  
Neurological symptoms  
(4 codes were mentioned in 
total, and one GP wouldn’t 
code the case) 
25% 
25% 
25% 
87.5% 0% 37.5% 
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All the GPs had heard of Lyme disease. Two (25%) correctly gave the causal pathogen as 
Borrelia burgdorferi, five (62.5%) said it was caused by tick bites, and one (12.5%) did not 
know what the cause was. One (12.5%) knew that there was a national reference laboratory 
at the Rare and Imported Pathogens Laboratory (RIPL), Porton Down, one (12.5%) thought 
that it was at the Liverpool School of Tropical Medicine, and one thought it was at the Royal 
Preston Hospital. The remaining five (62.5%) did not know that there was a reference 
laboratory. Five (62.5%) GPs felt that current testing available on the NHS was reliable, two 
(25%) did not know, and one (12.5%) thought that it was not reliable. Six (75%) GPs thought 
that chronic Lyme disease exists, and all eight GPs recognised that Chronic Fatigue Syndrome 
exists. Four (50%) of the GPs would seek advice about Lyme disease from an infectious 
disease consultant, three (37.5%) from a consultant microbiologist, and one (12.5%) from a 
Lyme disease specialist. 
6.4.3 Thematic analysis results 
Thematic analysis of the interview transcripts yielded five main themes relating to coding 
behaviour; personal experience of the GP, evidence-based medicine, diagnostic uncertainty, 
professional integrity and defensive practice, and patient and primary care politics. The 
personal experience of the GP underpins the other four themes and is the central core that 
runs through each of the other themes. Due to this, examples of this core theme will be 
illustrated with quotations nested amongst the other themes’ quotations.  
Evidence-based medicine and diagnostic uncertainty 
Primary care clinicians are taught to diagnose and manage patients in an evidence-based 
manner [249]. This can mean that without any strong diagnostic or clinical evidence, the GP 
may have diagnostic uncertainty and choose a Read code that is relatively non-specific. 
 ‘I think first, ‘What is the primary complaint?’, and unless there is something 
definitive, I tend to code with the primary complaint or not code at all. So for this 
patient, what is the primary complaint? Numbness, dropping things, or is it his blue 
hands?’ [GP5, case 3] 
Here we can see that GP 5 is unsure of the diagnosis and does not have the prior personal 
experience or strong evidence base to choose ACA as the definitive diagnosis. They therefore 
suggest that they will adopt a highly generic code for this patient. 
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GP 3 showed similar behaviour. They wanted a stronger evidence base, and lacked personal 
experience, this resulted in diagnostic uncertainty. They would choose not to use any Read 
code at all for the patient. 
‘If I can’t diagnose, I will pick the main symptom to code. I will always do this unless 
I’m almost a hundred percent positive of the diagnosis. Sometimes, if I’m really not 
sure, I will write everything in free text and not code anything.’ [GP3, case 2] 
GP 6 shared the same feelings very succinctly;  
‘If I don’t know what it is, then I won’t code it. Otherwise it gives the appearance of 
certainty, where there isn’t.’ [GP6, case 6] 
The need to build a strong evidence base was strengthened by multiple GPs enquiring 
whether the patient in case 1 had a significant travel history, and that some would perform 
internet searches or ask their colleagues about unusual rashes. In all instances the GPs asked 
for a better description, about the firmness and texture of the tick (case 10). 
This shows that GPs need a certain level of supportive evidence, which will vary for each 
condition and for each GP, to have certainty and confidence in their diagnosis. This can be 
clearly seen in the results of case 1 (Appendix V) where the majority of GPs thought the case 
was Lyme disease, but then coded the patient with a rash. This suggests that without 
diagnostic certainty a non-specific presenting symptom will be chosen as a Read code rather 
than one with a definitive diagnosis.  
This is exemplified by several GPs who noted that they had heightened diagnostic 
uncertainty regarding Lyme disease, and without sufficient confirmatory evidence, would 
not code it as such. This may be due to a lack of personal experience, 
‘Lyme disease is a possibility here. But I wouldn’t leap to it without a history of a 
tick bite.’ [GP5, case 11] 
If they had had more supportive evidence or personal experience, they may have been more 
confident in their diagnosis and then coded Lyme disease. In many of the cases, Lyme disease 
was never discussed. It is probable that either the GPs’ knowledge of Lyme disease’s various 
presentations is poor, or that GPs do not think of Lyme disease as a differential diagnosis 
until they have a greater evidence base, or that Lyme disease only enters their differential 
list through a diagnosis of exclusion.  
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However, at times personal experience can become its own form of evidence base, and when 
this occurs diagnostic certainty improves and the Read code selected becomes highly 
relevant. 
‘This is a tick; I’ve been bitten many times before.’ [GP 4, case 10] 
GP 8 had recently been involved in the recent management of a Lyme disease case; 
‘I had a patient diagnosed in the last couple of months; a child with non-specific 
knee pain. We initially suspected an infected knee joint. He’s now been successfully 
treated and has been fine since.’ [GP8] 
This resulted in this GP having much greater personal awareness of Lyme disease 
presentations; this GP confidently placed Lyme disease on their differential lists and chose 
relevant Read codes.  
Professional integrity and defensive practice 
Professional integrity drives certain coding behaviour. Here we see a GP showing frustration 
around how other members of their practice don’t respect practice policy nor understand 
the need for appropriate coding;  
‘We’re told off if we don’t code all patients. Others in the practice use the code ‘chat 
with patient’, it drives me mad!’ [GP7] 
This was seen more acutely where a GP felt hindered in coding Lyme disease due to both a 
lack of diagnostic evidence, and the desire to protect themselves and their colleagues from 
litigation; 
‘I would never write Lyme disease on a patient’s record until I had a positive lab 
diagnosis. I’m wary because of potential litigation, and I don’t want to cause 
problems for future doctors treating that patient.’ [GP 2] 
Patient and primary care politics 
The current political landscape around Lyme disease and the lack of trust in certain evidence 
bases results in a diagnostic uncertainty, 
‘I won’t code Lyme disease until they’d seen a NHS specialist. I’d be very suspicious 
if it [laboratory results] was a ‘high street’ or ‘internet’ lab, so I would arrange 
serology to be sent to a local lab.’ [GP 4, case 8] 
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‘I would be very suspicious of results from a non-NHS supported lab. She also has 
no supportive history for Lyme disease.’ [GP3, case 8] 
One of the GPs helped place this landscape in context by discussing their own experiences 
with a cohort of patients in their practice; 
‘We’ve had a few patients, around five, who have formed a little chronic Lyme 
disease group. All white middle aged, very wealthy women. They have spent 
thousands at the Breakspear [250] [a private clinic and laboratory offering 
unvalidated testing and treatment for Lyme disease] and claim to have Lyme 
disease, but present more with ME [myalgic encephalomyelitis] or not coping with 
life. They don’t believe that Porton do their tests properly, and they are now majorly 
concerned about getting Anaplasma too.’ [GP5] 
This political landscape is the framework in which all coding behaviours are contained. It will 
vary for every disease and medical condition, and with the awareness that patients can ask 
for direct access to their health records. For example, depression is a mental health condition 
that is QOF-able [224] and is on PHE’s [251] and the UK governments policy agenda [252]. 
There is heightened awareness of this condition and its QOF-able nature, which could lead 
GPs to have confidence in diagnosing and coding their patients with a ‘depression’ read code. 
In contrast, cancer is also QOF-able and is a series of conditions with huge awareness 
amongst the general public. However, it is likely that a GP would not code a suspected patient 
with cancer, unless they had confirmation from a referral department. The consequences of 
misdiagnosis could be severe, and a GP would not want to place ‘cancer’ on a patient’s health 
record without any pathological evidence first as it could lead to litigation and unwarranted 
medical and legal investigations. 
Lyme disease sits within a very confused political landscape. On the one hand NICE guidelines 
[23] have recently been published and the national incidence is low [70]. GPs should 
therefore have confidence in making a diagnosis and should not feel the need for laboratory 
diagnostics for the majority of cases, who are likely to present with an EM rash. On the other 
hand, there are now multiple patient groups and charities raising awareness about Lyme 
disease, but also discussing ‘Chronic Lyme disease’, a condition not currently accepted by 
any medical organisation [21,23,39,43,53–55]. ‘Chronic Lyme disease’ is the narrative that is 
often portrayed in the media rather than that of research or medical organisations 
[12,13,253]. These contrasting narratives make it a challenge for both the GPs and patients 
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to sift through scientific fact and fiction [254]. This was made evident by two of the GPs 
interviewed 
‘Loads of people [patients] are asking about it [Lyme disease] in the practice, 
through I’ve only seen four or five over my career’ [GP 5] 
There are so few [Lyme disease] specialists across the country [in fact, there are 
none]. A friend of mine has Lyme, so I know the difficulties.’ [GP 4] 
These issues have now been potentially confounded by the Medical Defense Union offering 
specific advice about Lyme disease [255], something which is rather unusual for a disease 
that is, in general, readily treatable and has a low incidence. This complex political landscape 
could result in GPs being hesitant to diagnose and code a patient with Lyme disease without 
confirmation from a laboratory or referral unit. 
6.4.2 Study design feedback 
Three (37.5%) GPs realised that the case series were about Lyme disease. GP 2 said they 
suspected this on their third case; case 11 (fine motor movement issues and rash). This was 
self-confirmed when the following case was case 1 (the classic EM rash). GP 3 suspected it 
on their final case; case 1 (the classic EM rash), and GP 6 suspected it on their eighth case; 
case 6 (multiple EM rashes). 
All the GPs did not mind being blinded and felt that unless several stereotypical Lyme disease 
cases were presented sequentially, they would likely remain blinded in a future 
questionnaire. To improve the blinding they suggested shortening the questionnaire to five 
random cases, with additional dummy cases and to finish the case series with the most 
obvious case (case 1). 
All GPs requested a more thorough case history to be included for each case. General 
feedback that was mentioned by many GPs, was to add the following questions after being 
unblinded;  
‘Have you seen Lyme disease in your practice, if so how many?’  
‘How many chronic Lyme disease patients have you seen?’  
They also requested that the number of clinical questions were reduced and to ask more 
questions about coding, for example:  
 ‘Why did you choose that code over another?’ 
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‘Why did you have that diagnosis on your differential list but not select it as the 
Read code?’ 
To aid recruitment the GPs suggested that it should be advertised as a continuing 
professional development (CPD) learning exercise, with official Royal College of General 
Practice (RCGP) accreditation. A couple said that they would not have done it online as they 
prefer doing this type of research in person. And another GP said that the only way to attract 
GPs to the study was via compensation for their time.  
Regarding the distribution of the questionnaire online at a national level, there was no 
overwhelming consensus. Organisations that were suggested as distributions channels were; 
the RCGP (2 GPs mentioned), the University of Liverpool (2), the local Clinical Commissioning 
Group (CCG) (2), the local primary care network (2), a local NHS leader (1), the Clinical 
Research Network (1), and any organisation with an NHS badge or affiliation (1).  
6.5 Discussion  
This study has provided insight not only in to the coding behaviour of GPs in relation to Lyme 
disease, but coding behaviour in general. The results and feedback from the questionnaire 
will help shape the design of a more detailed Read code validation study for Lyme disease. 
In Chapter 5, ‘Lyme disease’ and ‘Erythema migrans’ represented 89.1% of all Lyme disease 
related Read codes, and suspected codes represented 7.6%. In this validation pilot study, GPs 
only used the codes, ‘Lyme disease’, ‘Erythema migrans’ and ‘suspected Lyme disease’. This 
appears to be reflective of the codes used in Chapter 5. The remaining 3.3% of codes 
identified in Chapter 5 were not mentioned by the GPs in this study; this likely relates to the 
small sample size of GPs interviewed, and the rarity of the general usage of these codes in 
primary care. Only two cases were coded with Lyme disease codes. To formulate an idea of 
the sensitivity and specificity of these codes is difficult, as so few GPs utilised the Lyme 
disease codes, and the study size is small. One could speculate that the specificity is likely to 
be high as Lyme disease codes were only used in the ‘textbook’ clinical presentations, and 
there are likely to be very few false positive codes, given the case descriptions. It is therefore 
possible that the positive predictive values of the Lyme disease Read codes are high. The 
sensitivity of the codes is likely to be low, with a lot of false negatives with cases not being 
coded at all; reasons for this are discussed above. If these conclusions are true it means that 
our incidences calculated in Chapter 5 are likely to be an underestimate of the clinical 
incidence of Lyme disease. Phase 2 of the project needs to progress, in order to take this 
theory beyond conjecture. 
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The thematic analysis suggests that when a GP is presented with a case of vague 
symptomology or there is diagnostic uncertainty, they will not code with a highly specific and 
definitive code such as ‘Lyme disease’. They prefer to code the patient’s primary complaint, 
the main symptom, or not to code at all. They will only code with a definitive diagnosis code 
if the evidence base or personal experience is strong enough to justify it. Harkness et al’s 
[229,230] investigation of GPs’ perspectives on IBS, appears to support the identified 
themes. The GPs in that study were constrained by the politics of giving a patient an IBS label, 
and they wanted to have confidence in their diagnosis (through an evidence base, and 
personal experience) before coding with IBS. For most cases they would code with symptoms 
of IBS. Both their data and this work suggest that for these diseases a surveillance system 
based upon specific Read codes is likely to underreport cases. This may also be relevant to 
other diseases with either a non-specific presentation or with certain political constraints.  
Some of the themes identified match those identified in previous research about coding 
behaviour [231–234]. These include diagnostic uncertainty and a GP’s personal experience. 
In these studies, the GPs state that they were fearful of the potential negative impact of 
giving a patient a definitive diagnosis through a Read code. This is something that we had 
speculated in relation to Lyme disease but was not explicitly stated by the GPs in our 
research. Previous research has also identified that the GPs personal experience and 
‘emotional motives’ can drive decision-making behaviour [233]. This can be based simply on 
the recognition of a similar case or on the previous negative experiences of an incorrect or 
missed diagnosis of a patient. These works and our study highlight that human emotion and 
experience may be a larger driving force, in some instances, of decision-making behaviour 
than the medical evidence base alone. 
Themes that had been identified in other studies but not in this chapter include; the lack of 
direct patient benefit, targets and financial incentives driving coding, and the negative 
impact coding can have whilst trying to lead a patient-centred consultation [231]. These may 
not have been discussed by the GPs in this chapter as no questions were directly asked about 
coding behaviour. It may also be due to the small biased population of GPs that were 
interviewed and that they may not be representative of the UK GP population. However, a 
targets and incentive theme could mirror or reside in the professional integrity theme 
identified in this research. This chapter builds on previous evidence and supports the 
evidence that diagnostic uncertainty and personal experience are critical elements of a GPs 
coding behaviour. The other three themes of evidence-based medicine, professional 
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integrity and defensive practice, and patient and primary care politics, need to be explored 
to assess whether they can be generalised across the UK primary care clinician population.  
Syndromic surveillance, using a variety of Read codes to build a case definition, may offer an 
alternative approach for primary care disease surveillance. However, problems identifying 
cases could still remain if the presentation is relatively non-specific. Take, for example, case 
6 in which the following non-Lyme disease Read codes were mentioned; rash, insect bite, 
non-specific dermatitis and skin lesion. In isolation, or in combination, these codes are still 
non-specific and the potential differential list is so long that it would be very difficult to 
conclude that this patient actually had EM rashes. The budgetary requirements to request 
the medical free text notes of all patients that presented like this, to identify a definitive 
diagnosis, would be very large. Challenges still remain regarding surveillance of conditions 
with a non-specific presentation.   
The thematic analysis highlighted that the GPs personal experience core theme driving 
coding behaviour. The data from the exit interview questions showed that this group of GPs 
had limited clinical exposure to cases of Lyme disease. This should not result in poor clinical 
and case management knowledge. Some acknowledged their lack of personal experience 
and did mention that they would enhance their evidence base (through internet searches 
and discussing cases with colleagues). If this had been done in reality, maybe diagnostic 
certainty would have improved, and more cases would have been coded with Lyme disease. 
This lack of knowledge needs to be explored at a national scale to evaluate the potential for 
regional biases. A recommendation resulting from this work is the provision of a national 
programme of CPD (continued professional development), promoting NICE (National 
institute for health and care excellence) guidelines and aiming to arm GPs with the 
appropriate knowledge to manage cases of Lyme disease. 
GP 5 was the most vocal about their views on Lyme disease. They had the strongest views 
on the demographics of chronic Lyme disease patient groups and discussed their symptoms 
in what may be perceived to be a condescending or dismissive manner. They tried to clarify 
why they do not believe that this sub-set of patients do not have chronic Lyme (they believed 
the symptoms were psychosomatic) and what they perceive to be the case definition of 
chronic Lyme disease. GP 5’s opinions were likely constructed through the themes described, 
but with the greatest weight attached to personal experience and the politics of patients and 
primary care. It is essential to remember that both the BIA (British Infection Association) and 
NICE guidelines do not recognise chronic Lyme disease as a clinical entity [23,39]. These 
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views were given anonymously and in confidence, so they may not be reflective of the terms 
and tone used when consulting and managing these patients directly. However, even taking 
this in to consideration, it mirrors the opinion and experience of some patients that a 
proportion of GPs do not believe them and that they are quickly dismissed, something also 
seen in the IBS study [230]. This has been nicely summarized previously,  
‘To make matters worse, some [Lyme disease patients] have grown frustrated or 
cynical with the medical profession because of ineffective treatments, unsatisfying 
explanations and fruitless testing. A commonly expressed perception is that 
physicians become impatient or dismissive once it becomes apparent that a 
patient’s symptoms are medically inexplicable. In other words, a dominant feeling 
is that the suffering of these patients is not effectively heard or validated. [54]’ 
In contrast to North American studies [244,245], the responses to the diagnostics and 
treatment option questions were often very generic. However, the referral location was 
often very specific. As the interview was supposed to replicate the online experience 
proposed for phase 2 of the study, the interviewer could not ask for a more specific response 
in relation to what blood test would be used or which drug would be prescribed. The reasons 
for the generic responses could be due to diagnostic uncertainty and a lack of personal 
experience. The fact that they knew where to refer suggests that they have an idea of the 
disease pathology even if they do not know the exact cause. Hence, GPs’ responses were not 
necessarily indicative of them not knowing the recommended care pathway for Lyme disease 
patients, but rather show a reluctance to commit to a specific treatment plan without 
diagnostic certainty and an evidence base supportive of the cause of an unfamiliar or vague 
clinical presentation. These questions did not provide much insight in to how GPs manage 
Lyme cases, and therefore should not be included in phase 2 of the project. However, they 
could form the basis of a separate non-blinded study about how GPs manage cases of Lyme 
disease, similar in design to studies mentioned in the introduction.  
The feedback on study design will prove useful to the design of the questionnaire for phase 
2 of this project. Unfortunately, there was no consistent distribution channel that the GPs 
preferred. This indicates that to achieve the highest penetration and response rate of an 
online questionnaire, a multi-channel and multi-organisational approach is needed. The 
overwhelming response of the GPs was that they preferred doing the questionnaire face-to-
face and may not have even responded or would have engaged less if they had been sent it 
online. This poses a fundamental research problem, which is well beyond the scope of this 
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project; how do researchers increase engagement rates with GPs? Their own suggestions 
involved financial or CPD incentives. The creation of a successful national questionnaire may 
need large financial and time commitments, especially if face-to-face interviews are 
required. For Phase 2 of this project to go ahead very careful planning is needed to ensure 
that resources are used as efficiently as possible.  
6.5.1 Limitations 
The two main limitations of this work were the potential impact of selection bias and the 
small sample size. As this was a pilot project for a proposed national study, the GPs were 
chosen for convenience and were unlikely to be representative of the national GP 
population. The GPs that were recruited were from a biased population as they were drawn 
from those GPs showing an interest in taking part in research. They had a narrow age range, 
and even within the small recruitment area were predominately based in Lancashire, with 
only one GP from a rural practice. The practices were all in areas with a low laboratory-
confirmed incidence and a low number of hospital admissions for Lyme disease (Chapters 3-
4). The GPs therefore may reasonably not recognise a relatively rare disease, for their 
location, and any of its varied presentations. Hence why they were reluctant to code. This 
inherent bias could be reversed if the study was performed in an area of high incidence. If 
GPs had higher awareness and saw more cases, they may feel more comfortable coding a 
Lyme disease patient. If this study had been performed at a national scale, these biases could 
have been examined and explored in more depth, providing greater insight in to coding 
behaviours. 
However, as this was a pilot study and the main aim was to test the questionnaire structure 
and blinding format, these biases and small sample size could be, in the main, overlooked. 
The objectives were achieved and additional insight in to GPs coding and views about Lyme 
disease were gained, which will help inform the design of phase 2 of this project. Due to the 
above, the themes identified have the potential to be unrepresentative of the national GP 
population. Although it is encouraging that the results from Harkness’s work [230] appear to 
support the themes. They provide a theoretical template that need to be tested in future 
research studies and on a larger scale.  
The most substantial issue faced during this project was not inherent in the design or conduct 
of the study, but rather was the result of the logistics necessary to gain NHS ethical approval 
and recruit the GPs, as outlined in Figure 6.1. Tradition dictates that a scientific manuscript 
should be an impersonal document; however, science is a discipline that involves a huge 
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amount of personal investment. The adoption of the ‘scientific style’ can sometimes mask 
fundamental constraints to a project, and I want to briefly give my personal reflections on 
the logistics of this project. I feel that this is important as these issues should be formally 
documented, so that lessons can be learnt, and processes adapted. I want no other 
researchers to go through the same frustrating process that I did.  
On completion of the design of our study, no one within the research team, including myself, 
were fully aware of the required research ethics for the project. I contacted the Central 
Research Ethics Support team at the University of Liverpool, who were unable to offer any 
support other than to say that NHS ethics would be needed, and that this would supersede 
University ethics. No clear pathway was given, and I was given contacts to seek help, which 
led to a fruitless chain of emails eventually ending up with the original contact provider. The 
University Clinical Governance Team was then contacted who again provided no clear route 
or advice on how to gain ethical approval. After three months of no progress, one of my 
supervisors mentioned meeting with the Royal Liverpool Hospital’s research team. They had 
a wealth of experience and knew the requisite requirements and documents needed to gain 
successful ethical approval. They were extremely helpful and guided me through getting the 
study registered and sponsored by the Royal Liverpool and Broadgreen University Hospitals 
NHS Trust. The ethics team at the hospital were surprised that the University were unable to 
provide assistance, as they believed my request was very straight forward. Their help meant 
the relatively speedy sponsorship of the project. The project then ground to a halt with a 
disagreement between PHE and the University about who was responsible for the project in 
terms of insurance and indemnity. This is a fundamental issue that could have been agreed 
upon before the creation of the Heath Protection Research Units (HPRU). Once this was 
resolved, the IRAS document took longer than expected to be signed off. On reflection, not 
all supervisors should have been listed on the project documentation, but I had not been 
advised to the contrary. Once the IRAS document had been submitted a year had elapsed. 
The project’s REC and HRA approval was smooth and very quick and the initial recruitment 
phase began. The University provided no support of how best to recruit GPs and I was left to 
contacting all GP practices in Merseyside by phone, email and in person. After this 
recruitment drive, not one GP was willing to take part in the research. It appeared that the 
non-medical staff in the practices worked as such good gate-keepers that researchers were 
effectively denied access to GPs. Even with the Merseyside RCGP’s branches help I was 
unable to recruit. This suggests that more needs to be done to train non-clinical members of 
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primary practices about the importance of research. One supervisor then informed me of 
the existence of the CRN-North West Coast, whom they had only recently learnt about. In 
hindsight, the CRN-North West Coast should have been involved with the project from the 
beginning. The CRN-North West Coast agreed to help, but to get their assistance I went 
through a labourious six-month process of increased bureaucracy and delays. Once 
everything had been signed off they were exceptionally helpful in providing contact details 
of GPs who were willing to take part in the project. From completion of the study design to 
the end of recruitment took 27 months.  
This whole process involved a vast amount of administrative paperwork and multiple email 
chains with a wide range of organisations; there appeared to be a significant lack of training 
provided by any organisation. The Royal’s research team provided support in gaining 
sponsorship and IRAS submission. However, if I had not had a member of their staff on the 
research team I would have been unable to utilise their services. I was one of the first 
University of Liverpool students that they had worked with. The CRN were exceptionally 
useful once the paperwork was completed. Their system for project adoption was very 
complicated and the same documents were sent to them multiple times, with a large number 
of people involved. For example, proof of funding was sent to five separate people within 
the same organisation. The University and PHE also struggled initially to find this 
documentation, which resulted in one supervisor writing a letter to confirm my funding. 
During this 27 month period it was discussed at multiple supervisor meetings whether we 
should drop this part of thesis. I felt that this chapter was important in placing Chapter 5 in 
context and would benefit other researchers; if it was not for my personal tenacity phase 1 
would not have been completed. The organisation that I feel the most let down by is the 
University of Liverpool; the fact that the main assistance I received came from outside of the 
University framework is unfortunate.  
The time taken from project planning to interview completion has meant that phase 2 of the 
project could not be done within the time period of this PhD. It remains to be seen whether 
this can be picked up as either part of a post-doc or via PHE. The ratio between the volume 
of paperwork needed and time invested, compared to the resultant eight interviews is 
undesirable. There is a substantial failing of the system to support qualitative or mixed-
methods researchers embarked in NHS based research. I have spoken to other researchers 
and colleagues working in human health about these issues, based both in the Institute of 
Infection of Global Health (Epidemiology and Population Health department) and Institute 
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of Psychology Health and Society, and in the HPRU’s Emerging and Zoonotic Infections, and 
Gastrointestinal Infections research units. It appears to be a consistent problem when the 
project is not a hospital-based study, does not involve patients but NHS staff, or there are 
elements of qualitative research involved. This one project, that should have been a small 
part of the PhD both in terms of time and results, has proved to be the most frustrating part 
and one of the biggest users of my time. My feelings have been succinctly summarised by 
another researcher experiencing the same problems at a different University, highlighting 
that this appears to be a universal problem; [256] 
‘This [emotional] exhaustion was exacerbated by the insufficient acknowledgement of, 
planning for or engagement with the emotional labour required in conducting this type of 
research.’ 
Considering all of the above, I have four recommendations: 
• The University of Liverpool ethics team and Clinical Research Governance team need 
to be trained in how to approach NHS ethics, with a focus on how to deal with non-
clinical trial, non-hospital based qualitative research. They need to be able to 
appropriately train/inform early career researchers in this process and have this 
service fully signposted. 
• The University of Liverpool and the CRN need to have a more cohesive relationship, 
with the CRN’s profile heightened within the University. 
• Researchers, and especially post-graduates, need to be made aware of the ethics 
pathway to be taken and the time needed for a successful project. Ideally a map or 
standard operating procedure should be created. 
• Supervisors and funders should be made aware of the potential time taken to start 
these projects and be provided with training. This would enable them to aid in the 
efficient use of an early career researcher’s time and be aware of the difficulties and 
frustrations in the process of being able to perform qualitative or mixed-methods 
research. Finally, they should be able to assess whether small projects (like this one) 
are achievable and worthwhile in the context of a PhD or Master’s thesis.  
The University of Liverpool needs to urgently address these issues if it wants to produce 
timely and relevant research and continue to be seen as a leader in health care research.  
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6.6 Conclusions 
There is reluctance by GPs to code with specific diagnostic Read codes when they are 
presented with a patient with either a vague or unfamiliar symptomology. This needs to be 
explored further through additional qualitative research, and through the testing of our 
identified themes. In relation to Lyme disease Read codes, it is likely that the codes have a 
high specificity, a low sensitivity, and a high positive predictive value. This pilot project has 
been successful in amending the design of a future national survey to investigate coding 
behaviour. 
In relation to the aims of this thesis, this project does not provide epidemiological data 
regarding Lyme disease. However, it places the results of the primary care dataset in context; 
and suggests that it probably underestimates the real incidence of disease. This poses many 
problems for surveillance in general, not just for Lyme disease, and research is greatly 
needed to understand what drives GPs’ coding behaviour.  
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Chapter 7 Scoping the potential of Twitter as part of a Lyme 
disease surveillance system 
 
Previously in this thesis, multiple routinely collected health data have been reviewed for the 
information they contain about Lyme disease cases. These are likely to form the basis of any 
future Lyme disease surveillance system. The progression downwards through the Lyme 
disease surveillance pyramid (Fig 2.1), from laboratory cases, to hospital cases, to primary 
care cases, has now reached the level of unreported cases in the general population. As 
discussed in Chapter 2, describing and identifying cases that have no contact with National 
Health Services is challenging, and validating these cases even harder. However, there is an 
opportunity to use novel and unexplored datasets and research methods to attempt to 
describe this population. In the next two chapters such attempts are described. Firstly, the 
analysis of a social media platform, Twitter, to understand how its temporal and spatial 
trends may match those of the known epidemiology of Lyme disease. In Chapter 8, the 
analysis of companion animal electronic health records are explored to provide insight into 
tick activity across the UK.  
7.1 Introduction 
Social media are websites and applications that allow users to share and create content, and 
to participate in building social networks [130]. In the United Kingdom (UK) two thirds of 
adults now use social media, and 22% of over 15 year-olds (roughly 14.6 million people) use 
Twitter as a social media platform [257]. Twitter is a micro-blogging website and application 
that allows users to post messages of up to 280 characters (tweets), and to then share and 
interact with other users’ tweets [258]. Users can ‘retweet’, repost or forward a tweet of 
another user, with or without their own comments. Users can also show their appreciation 
for a tweet by ‘liking’ it, by selecting a heart-shaped icon alongside the tweet. Tweets not 
only contain user-composed written information but also data about the time and location 
of when and where the tweet was sent. Twitter users in the UK are more likely to be male, 
and from a managerial, administrative or professional occupation [259]. In the Republic of 
Ireland, 28% of the population over 15 years old use Twitter, this represents around 1.3 
million people [260]. Users of Twitter use this platform to network and to discuss a wide 
range of topics, including aspects of human health [261]. Twitter therefore has the potential 
to be a large, data-rich resource for research. 
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In a questionnaire-based study, the reasons for the general public and health professionals’ 
use of social media in a health related context were explored [261]. Patients predominantly 
used Twitter to stay updated on new healthcare developments, increase knowledge, express 
emotions, and compare themselves to other patients, in relation to a specific disease or 
condition affecting them. Conversely, health professionals used it to extend their 
professional network, self-promote their work, promote their workplace, or share 
information from medical conferences. It has been hypothesised that by observing the 
patterns of tweets and their content, one may be able to use Twitter as a disease surveillance 
tool, and understand patients concerns and emotions regarding a disease [129,133,136]. 
Many studies have explored Twitter as a surveillance tool [129,133–135]. However, due to 
methodological restrictions exercised by Twitter these studies have focused on very specific 
diseases, for a set period of time, in a specific location. Due to the large scale nature of 
Twitter’s data, Twitter only allows free access to a certain number of tweets in a specific time 
period [262]. If this set limit is exceeded, only a random selection of tweets will be displayed; 
how these tweets are chosen is unknown to the general public [263]. There are two ways of 
dealing with this problem; firstly to pay for all tweets resulting from a specific search query; 
which can be costly. Alternatively, queries must be restricted, via content, geography or time, 
to avoid reaching the maximum number of tweets allowed. A team at San Diego State 
University has worked in-depth to develop improved methodologies for surveillance of 
influenza and pertussis [264,265]. They were unable to perform surveillance at a national 
level and resorted to performing multiple searches in different cities. This suggests that 
Twitter surveillance may only be feasible in restricted geographical areas.  
To date, the diseases explored using Twitter have had a very high public health importance 
and tend to have a high incidence or awareness in the researched areas. If the number of 
tweets is relative to incidence or awareness, then these prior projects had a heightened risk 
of reaching the tweet collection limit. By investigating Twitter surveillance methodology on 
a disease of a relatively low incidence, information may be able to be collected at a national 
level, without reaching the tweet collection limit. A disease that potentially fulfills these 
criteria is Lyme disease. 
In Chapters three to five, the incidence and geographic distribution of Lyme disease has been 
described through a variety of routinely collected health records. In the Republic of Ireland, 
only the neuroborreliosis presentation of Lyme disease is under surveillance by the Health 
Protection Surveillance Center (HPSC) [266]. Whilst the incidence of the more common 
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erythema migrans presentation is unknown, the HSPC reports an annual incidence for Lyme 
neuroborreliosis of 0.44 cases per 100,000 population in 2016 [267]. In contrast the 
incidence of neuroborreliosis in the UK is unknown. The HSPC has produced one map of 
cumulative crude incidence rate of Lyme neuroborreliosis from 2012-2016, which shows the 
highest incidence of disease being located in the south-west of the country [268]. Since Lyme 
disease has a relatively low incidence, social media surveillance, utilising Twitter data, may 
be achievable for the entirety of the United Kingdom and the Republic of Ireland. 
Previous research has been performed utilising social media regarding Lyme disease; 
however, no studies have been exclusive to the UK and the Republic of Ireland. Two studies 
have explored the content of YouTube videos, but were primarily focused on content analysis 
on who influences public health messages [269,270]. Two papers discussed the potential of 
using Google Trends for understanding seasonality [271,272], and another looked at 
physicians’ browser search history in relation to seasonal trends [273]. No published research 
to date has focused on Twitter data and considered the extent to which the spatio-temporal 
data generated through Twitter matches the known epidemiology in a given territory. If 
Twitter data were to match epidemiological data, it would have the potential to show 
temporal and spatial trends in real-time and potentially identify new geographical areas with 
disease. 
The aim of this chapter was to explore whether the tweeting habits of British and Irish Twitter 
users matches the known spatio-temporal epidemiology of Lyme disease in these respective 
countries. 
7.2 Methods 
Methodological design was inspired by the work of Nagel et al, and Allen et al [264,265]. 
Tweets were collected through the TwitteR package [274] in R, for the keyword ‘Lyme’ using 
the Twitter Search and Streaming Application Programming Interfaces (APIs). Tweets were 
collected daily from the 1st of July 2017 till the 30th June 2018 inclusively. To collect tweets 
that were sent from the UK and the Republic of Ireland, the query was geographically 
restricted to a 375 mile radius around the geographical centre of Great Britain (Whitendale 
Hanging Stones: 54.016674, -2.566153) (Fig. 7.1). 
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Figure 7.1 The search area queried for ‘Lyme’ in tweets between 1st July 2017 and 30th June 2018. The search 
area was centred on Whitendale Hanging Stones. 
This did include a small section of northern France, Belgium, and The Netherlands. The query 
was therefore further restricted to tweets written in English. It unfortunately excluded the 
Shetland Isles, as to include these islands would have meant expanding the search area to 
include even larger parts of continental Europe and Scandinavia, increasing the chance of 
geographical based errors.  
Data collected with each tweet included: the user name of the tweet’s author, the time and 
date of the tweet, if the tweet is either a retweet or an original tweet, and the tweet location. 
The tweet location is based upon the latitude and longitude of where the tweet was sent 
from a GPS-enabled device. Researchers can only access this information if the user has 
allowed this data to be shared publicly (i.e. the Twitter account was location enabled). In this 
study, the users’ self-identified location was additionally collected from their user profile. A 
user’s profile location can be any alphanumerical combination; it can therefore be as specific 
as a grid reference or as vague as ‘Planet Earth.’  
From this database, tweets were removed which referred to locations that included ‘Lyme’ 
within their name, for example Lyme Regis and Newcastle-under-Lyme. This was done to 
exclude any irrelevant tweets and minimise geographical bias. Time series of daily and 
monthly count data of both original tweets and retweets were constructed. These were 
visually compared to the reported seasonality of Lyme disease incidence (Chapters 3-5). 
The users’ self-identified location was matched with local authority areas in England (n=326), 
Scotland (n=32), Wales (n=22), and the Republic of Ireland (n=31), and local government 
districts in Northern Ireland (n=11). Using the Office for National Statistics (ONS) [159] and 
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the Republic of Ireland’s Central Statistics Office (CSO) [275] population data as the 
denominator population for each area, incidence was calculated. This was defined as the 
number of users per 100,000 population per local authority per year. Choropleth maps were 
plotted for the incidence of original tweet users and combined original and retweet users. 
Exploratory spatial data analysis (ESDA) [164,165] was used to explore the geographical 
association between the laboratory-confirmed incidence of Lyme disease (Chapter 3) and 
Twitter user incidence data at local authority level. This analysis had to be restricted to 
England and Wales as the available laboratory-confirmed incidence data (RIPL) contained 
data for only these nations. The bivariate global Moran’s I value, and a bivariate Moran’s I 
scatterplot, were created to assess the relationship between each dataset in each local 
authority. A bivariate LISA (Local Indicators of Spatial Association) plot was constructed to 
identify spatial clusters and geographic outliers in both datasets. 
All statistical and spatial analyses were carried out using R language (version 3.2.0) (R Core 
Team 2015). Results were deemed significant where p<0.05. 
7.3 Results 
Between the 1st of July 2017 and the 30th June 2018, 56,402 tweets containing the word 
‘Lyme’ were collected through the Twitter API. Data were collected on 98.6% of study period 
days; connectivity issues with the API led to five days of missing tweets (13th July 2017, 29th 
July 2017, 30th July 2017, 1st May 2018, and 2nd May 2018). Tweets which included place 
names relating to the word ‘Lyme’ were removed; Lyme Regis (n=13,266), Newcastle-under-
Lyme (n=9,191), Lyme Bay (n=2,922), Lyme Park (n=1,641), and misspellings of Ashton-
under-Lyne (n=61). This led to 49% of tweets being removed, leaving 29,321 to take forward 
for analysis. Of these tweets, 46.9% (n=13,757) were original, the remaining (n=15,564) were 
retweets. 
7.3.1 Temporal Analysis 
To allow a time series of the data to be constructed, the five missing daily tweet counts 
needed to be imputed. As the level of missingness was small, it was deemed appropriate to 
use a mean imputation approach. The missing value was estimated to be the mean of the 
daily tweet count for the month the missing data was located in. The resultant mean number 
of total daily tweets was 81, the median 65, with a minimum of 15, and maximum of 643. 
The mean number of original daily tweets was 38, median 33, a minimum of 12 and 
maximum of 276. The total daily tweets showed some degree of seasonality, with the 
smallest number in winter (Fig. 7.2). This seasonality was harder to identify when just the 
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daily original tweets were considered. There was a locus of extreme outliers in both total and 
original tweets between 21st and 23rd August 2017. 
 
Figure 7.2 Number of daily tweets mentioning ‘Lyme’ between 1st July 2017 and 30th June 2018. Smoothed 
lines of best fit (with grey 95% confidence intervals) were fitted with the LOESS method. Red- All tweets, Blue 
– Original tweets only. 
Total tweets and original tweets were aggregated to produce a monthly time series (Fig. 7.3). 
This suggested a clearer seasonality with peaks in summer months for both datasets. 
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Figure 7.3 Monthly count of tweets mentioning ‘Lyme’ between July 2017 and June 2018. The smoothed lines 
were produced using the Loess method. Red- All tweets, Blue – Original tweets only. 
7.3.2 Geographical analysis of original tweets 
There were 5,212 Twitter users who tweeted original tweets about Lyme disease in the study 
period, with a mean number of 2.64 tweets per user. Eighty-nine percent (n=4,662) of users 
had a self-identified location on their user profile that could be matched to a real-world 
location. The remainder either did not provide a location or were fictional locales; for 
example, locations mentioned included, Narnia, Westeros, and Gallifrey. Out of the location 
data, 1.35% (n=63) were outside of the UK and the Republic of Ireland; the top three 
locations were the USA (n=31), Germany (n=4) and The Netherlands (n=4). In addition, 
40.54% (n=1,890) of users had a location in the UK and the Republic of Ireland, which could 
not be matched to an administrative area as the location was too broad (Table 7.1). 
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Table 7.1 Number of Twitter users, per broad geographical area, that couldn’t be matched to a local authority 
area 
Location All tweets Original tweets 
UK 836 570 
England 342 225 
London 1012 767 
South 158 109 
North 109 57 
Midlands 26 45 
Scotland 128 48 
Wales 86 48 
Northern Ireland 20 11 
Republic of Ireland 37 11 
Jersey 4 10 
Guernsey 3 1 
Isle of Man 10 4 
 
The remaining 58.1% of tweets (n=2,709) had a location that could be matched to a local 
authority. There were 6.9% (n=27) local authorities in the UK, and 25.8% (n=8) local 
authorities in the Republic of Ireland, that had no Twitter users who tweeted about Lyme 
disease. Users who identified their location with a ‘Lyme’ related place name, where also 
removed in case they biased the results; 53 from Lyme Regis and 71 from Newcastle-under-
Lyme. There was a mean of 3.7 Twitter users tweeting about Lyme disease per 100,000 per 
local authority, a median of 2.1 and a maximum of 50.8. Only 110 (0.8%) of all original tweets 
were location enabled, allowing the exact co-ordinate plotting of where the tweet was sent 
from. There appeared to be a higher incidence of users in the south-west England and the 
Highlands of Scotland. Location enabled tweets tended to be in the south of England (Fig. 
7.4).  
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Figure 7.4 The incidence of Twitter users per 100,000 population who tweeted about ‘Lyme’, and the location 
of location enabled tweets (in orange) that mentioned ‘Lyme’. Black areas had no Twitter users who tweeted 
about ‘Lyme’ 
When the user locations were compared to the disease incidence of the RIPL dataset for 
England and Wales (Chapter 3), there was a significant Global Moran’s I of 0.17 (p=0.002), 
indicating an overall significant positive spatial correlation between the two datasets (Fig. 
7.5a). 
 
Figure 7.5a Bivariate Moran’s I scatter plot between Lyme disease incidence and original tweets in England and 
Wales local authorities. 7.5b Bivariate LISA cluster map between RIPL laboratory-confirmed (RIPL) Lyme 
disease incidence and original tweets 
This shows a positive linear relationship, in which local authorities (and their neighbours) 
with a higher laboratory-confirmed incidence tend to have a higher incidence of Twitter 
users creating original tweets about Lyme disease, and vice-versa. This overall correlation is 
seen on the bivariate LISA plot (Fig. 7.5b), which shows significant concordant high incidence 
clusters in the south-west of England.  
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7.3.3 Geographical analysis of all tweets (i.e. including retweets) 
There were 12,168 Twitter users who tweeted or retweeted about Lyme disease in the study 
period, with a mean number of 2.4 tweets per user. Seventy-six percent (n=9,214) of users 
had a self-identified location on their user profile that could be matched to a real-world 
location. Out of the location data, 17.0% (n=1,562) were outside of the UK and the Republic 
of Ireland, the top three locations were the USA (n=688), Canada (n=181) and Australia 
(n=76). Almost one-third, 31.8% (n=2,928), of users had a location in the UK and the Republic 
Ireland, which couldn’t be matched to an administrative area (Table 7.1). 
The remaining 51.3% of tweets (n=4,724) had a location that could be matched to a local 
authority. There were 3.1% (n=12) local authorities in the UK, and 9.7% (n=3) local authorities 
in the Republic of Ireland, that had no Twitter users who tweeted about Lyme disease. Users 
who identified their location with a ‘Lyme’ related place name, where also removed; 75 from 
Lyme Regis and 99 from Newcastle-under-Lyme. There was a mean of 2.0 users per 100,000 
per local authority, a median of 1.1 and a maximum of 82.5. Only 110 (0.4%) of all original 
tweets were location enabled. There appeared to be a higher incidence of users in south-
west England and the Highlands of Scotland. Location enabled tweets tended to be located 
in the south of England (Fig. 7.6).  
 
Figure 7.6 The incidence of Twitter users per 100,000 population who tweeted or retweeted about ‘Lyme’ (i.e. 
All tweets), and the location of location enabled tweets (in orange) that mentioned ‘Lyme’. Black areas had no 
Twitter users who tweeted about ‘Lyme’ 
When the user locations were compared to the disease incidence of the RIPL dataset 
(Chapter 3), there was a significant Global Moran’s I of 0.18 (p<0.001), indicating an overall 
significant positive spatial correlation between the two datasets (Fig. 7.7a). 
127 
 
 
Figure 7.7a Bivariate Moran’s I scatter plot between Lyme disease incidence and all tweets in England and 
Wales local authorities. 7.7b Bivariate LISA cluster map between RIPL laboratory-confirmed Lyme disease 
incidence and all tweets 
This shows a positive linear relationship, in which local authorities (and their neighbours) 
with a higher laboratory-confirmed incidence tend to have a higher incidence of Twitter 
users, and vice-versa. This overall correlation is seen on the bivariate LISA plot (Fig. 7.7b), 
which shows significant concordant high incidence clusters in the south-west of England.  
7.4 Discussion 
Previous studies have demonstrated that Twitter data has the potential to mirror disease 
seasonality and outbreak data [134,135,264]. Here we provide further evidence that Twitter 
can be used for the temporal estimation of disease incidence. However, it is the identification 
of concurrent disease hotspots, potentially in real-time, that provide exciting new avenues 
of research that could influence future disease surveillance strategies.  
Analysing tweets at a daily resolution level offers only a small insight into seasonal trends. 
As suggested be Nagel et al [265], analysis of only the original tweets appears more robust 
as the range of the daily tweet count is much smaller and original tweet datasets appear less 
susceptible to outliers than the combined dataset. However, both original tweets and 
retweets have extreme outliers in August 2017. These coincide with a high profile press 
release, which gained significant media attention, as part of a pharmaceutical company’s 
campaign to raise awareness about ticks and to sell a pet ecto-parasiticide [276]. This 
campaign involved utilising a celebrity sportsman’s own case of Lyme disease to raise 
awareness of Lyme disease and the risk that ticks pose to people and animals [12,277–279], 
despite the lack of an evidence base for a high incidence of clinically affected pets with Lyme 
disease in the UK [280]. This shows that Twitter data can be easily skewed by high profile 
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media and/or celebrity events; this must be considered if Twitter data is used for modelling 
and surveillance purposes. There were parallels in the research on Lyme disease videos on 
YouTube, which found that the most viewed and liked videos had included a celebrity 
component [269,270]. Hence, high levels of disease-related tweets may result from a range 
of stimuli; these may include increased disease occurrence but may reflect other social 
signals.  
When aggregated to monthly counts, the data showed strong seasonality, with peaks in the 
summers of 2017 and 2018. Monthly counts were chosen, so that if monthly national figures 
are released, these figures can be compared. This matches the known seasonality of Lyme 
disease in the UK (Chapters 3-5). This data currently cannot be matched to the monthly 
disease incidence, as the UK and Irish governments have not released data covering the 
entirety of this period and they only record quarters rather than monthly data. Without 
content analysis the drivers of tweet seasonality remain unknown. It is likely to be 
multifactorial and to be reflective of, among other things, users tweeting about being 
diagnosed, the general public’s concern, media stories and awareness, and public health 
awareness campaigns. 
One of the exciting potentials of Twitter-derived data is the exploration of the geographical 
distribution of Twitter users tweeting about a disease. The fact that the user incidence maps 
produced here reflected the known spatial epidemiology of Lyme disease closely is highly 
interesting, as no known publications have described this for any infectious disease. The 
majority of users in the present study had location information that could be matched with 
a local authority area. The bivariate plots and global Moran’s I figures showed a strong spatial 
agreement with laboratory-confirmed cases for England and Wales. This highlights that 
Twitter has the potential to map the geographical distribution of an infectious disease, and 
that it could be used in real time, to identify suspect disease hotspots. By focusing on the 
LISA cluster map of the original tweets (Fig. 7.6) an understanding can be gained of the 
relationships between Twitter data and national Lyme disease incidence figures. The 
majority of the map is covered in non-significant local authorities, showing that in these 
localities the incidence for both datasets does not differ from a randomly generated 
distribution of incidence. The high-high areas represent concordant clusters of high 
incidence. Except one area in the Midlands, these are all neighbouring areas in the south-
west of England, an area already identified as a potential hotspot of Lyme disease in this 
thesis. Whether the higher number of Twitter users tweeting about Lyme disease is due to 
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increased awareness in the area or due to it reflecting actual cases in the area, or a mixture 
of the two is unknown. The reverse of this reasoning would explain the low-low areas. 
Only seven (2%) local authority areas showed significant discordance between the location 
of Twitter users who tweeted about Lyme disease and laboratory-confirmed cases of Lyme 
disease. The areas that have high levels of cases and low level of users could have a low level 
of awareness of Lyme disease, or simply the Twitter user population is not representative of 
the general population in these areas. The areas that have a high level of Twitter users and 
a low level of cases are harder to explain. Reasons for users tweeting about Lyme disease in 
areas of low incidence are unknown and need to be explored. It could be due to an 
underreporting of cases, or due to prominent Lyme disease advocates being based in these 
areas. It must be noted that three of these areas neighbour the main high-high area in 
southern England. These areas are significant clusters because the incidence is high within 
their area and in the neighbouring areas. Therefore, these low-high areas in the south-west 
of England, are still likely to be representative of areas with a higher than average incidence 
of laboratory-confirmed Lyme disease. Content analysis of the tweets originating from 
discordant areas may be able to shed light on some of the reasons behind the discordance.  
Incidence data at local authority level is unfortunately lacking for Scotland, Northern Ireland, 
and the Republic of Ireland. Its therefore unknown whether Twitter data matches the known 
epidemiology of Lyme disease in these areas. However, reports suggest that the incidence is 
high in the Highlands and Western Isles of Scotland [76] and is high in the west of the 
Republic of Ireland [268,281]. Better incidence data in these areas would be valuable, 
although Twitter data for the Republic of Ireland collected in this study was sparse, which 
limits further research using the methodology described here. The Twitter data has the 
potential to match the geographical distribution in Scotland and should be explored.   
7.4.1 Limitations and future research 
The largest limitation of the data presented here is the potential unreliability of the user 
location data. The search query utilised aimed to identify tweets sent from within a defined 
geographical area, however it appears that tweets were collected outside of this area. The 
algorithm for the collection of tweet location is not public, and it can be hypothesised that 
this is based on a combination of device/GPS co-ordinates (not shared through the API) and 
network/ (Internet Protocol) IP address location. If this assumption is correct, then all tweets 
collected should have been posted within the search area. It cannot be ruled out that an IP 
address is registered in the UK and the Republic of Ireland, but the user posted the tweet or 
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is based in a location outside of the search area. Only a small fraction of the study tweets 
were publicly location enabled, however all of these did have a location within the search 
area. The majority of the tweets locations were derived from the user profile stated location. 
There are obviously issues with this methodology as a person’s location may not be always 
reliable. This can be as extreme as giving a falsified location, forgetting to update a profile 
location, or as in the author’s case, using a place of work as their location rather than their 
place of residence. This could account for the number of countries outside of the study 
location identified as locations. The other alternative is that a Twitter user based outside the 
UK and the Republic of Ireland sent a tweet in the study area when they were visiting. 
However, the fact that maps were produced that had significant similarity to the known 
epidemiology of Lyme disease suggest that unreliability may be less than initially perceived; 
given the analyses undertaken. By attempting to reduce bias by removing place names with 
‘Lyme’ in them from the analysed datasets, bias may have been introduced by excluding any 
trends from these areas. This could especially be true for Lyme Regis, which is a town in an 
area of high incidence. Places that included ‘Lyme’ in their name may have also been 
included, despite the thorough search. This problem is potentially not unique just to Lyme 
disease. Other diseases with location specific names include, among many others; Rocky 
Mountain spotted fever, Ross River Fever, Omsk haemorrhagic fever, and Zika. The 
methodology developed to adapt to this issue is fairly rudimentary and a more robust 
methodology needs to be explored to reduce this problem.  
Two separate studies show that Twitter users are more likely to be male and young adults 
(15-34) compared to the national population [257,259]. They also tend to be of the upper 
and middle class demographic, and occupy managerial, administrative, and professional 
roles. In previous social media health research, it was additionally found that the 
communities that drive messages and information on social media are often grouped in 
polarized subsets. Within each subset similar views are shared that reinforce their own 
beliefs, and act as echo-chambers [282]. The content shared may not stand up to scientific 
scrutiny, and therefore the spread of false information can be exacerbated [283]. As such, 
the degree of representation of this study population is uncertain. The views of each Twitter 
community, and identification of the ‘experts’, can only be explored through network 
analysis of Twitter users and qualitative analysis of the tweet content. 
One of the assumptions of this research is that the Twitter users are being honest both about 
themselves and their commentary or information that they are sharing. As shown by the 
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fictional locales in the user location data, not all users of this platform are always honest, 
and some want to deceive. This may be for comedic purposes, as was likely in the case in the 
highlighted users, or for strategic enhancement of self-presentation, or for more malevolent 
purposes. A study evaluating deception in online dating found that 81% of users had 
deceptive information on their profile and 18.7% intentionally deceived, all with the aim of 
strategic enhancement of their self [284]. The author could not find literature discussing 
malevolent deception, however one could hypothesise that the perceived anonymity of 
users, and the relative lack of accountability provides a platform where the spread of false 
information is enabled. The retweet functionality can therefore perpetuate the spread of 
false information if a user is unaware of the credibility of the information contained within 
the original tweet. Without in-depth content analysis of the tweets the level of deception 
and the amount of false information contained within this dataset remains unknown.   
This research has focused entirely on the spatial-temporal distribution of tweets relating to 
Lyme disease; however, the main reason for tweeting is to share information or views. 
Therefore, the majority of the data contained within a tweet has not been analysed. There 
is scope for further research on this dataset to explore content analysis through a thematic 
approach, and to perform a network analysis of the tweeters. This research could provide a 
deeper understanding of what is being publicly shared about Lyme disease and what type of 
individual or organisations are the main drivers of this information. This could be used to 
inform future public health campaigns for Lyme disease and other conditions.   
7.5 Conclusions 
Twitter has the potential to be used as an adjunct to traditional surveillance methods to 
understand people’s concerns, and to identify seasonal trends and identify geographical 
activity hotspots in real time. Further analysis is needed to explore its robustness. Future 
research is also needed to analyse the content of the tweets, and to see whether they can 
utilised for public health messaging.  
The extent to which this work contributes to the overall aims of this thesis regarding Lyme 
disease surveillance can be summarised as follows: 
• Incidence: Disease incidence cannot be defined from Twitter. There were, on 
average, 38 original tweets a day in the UK and the Republic of Ireland. There were 
signs of seasonality, with tweets peaking in summer months. 
• Sociodemographics: No data could be garnered.  
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• Geographical hotspots: These were identified in south-west of England, and the 
Highlands of Scotland.  
• Patient presentation and management: No data could be garnered. 
• Additional information: Twitter offers some scope as a future ‘measure of concern’ 
surveillance tool; however, it can be easily biased by the users (both intentionally 
and unintentionally). Content and network analysis of the tweets is needed to 
understand who is tweeting and what is being discussed within the tweets. The 
potential of using this in conjunction with Lyme disease incidence and tick activity 
surveillance systems to inform health promotion campaigns merits further 
investigation.  
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Chapter 8 Companion animal electronic health data as a 
surveillance tool for tick activity 
 
In the preceding chapter, Twitter data was explored as an adjunct for traditional surveillance 
systems and showed promise for matching temporal and geographical trends associated 
with Lyme disease. Another proxy data resource worth exploring is national data on the 
geographic distribution and temporality of ticks, in particular Ixodes ricinus. This data could 
provide information needed for a formal risk assessment of Lyme disease acquisition in the 
UK. The Small Animal Veterinary Surveillance Network (SAVSNET) has the potential to 
provide this information through the analysis of small animal primary care veterinary 
consultations as recorded in electronic health records. SAVSNET also collects laboratory 
diagnostic data but unfortunately this was not currently suitable for analysing tick-borne 
diseases, despite this data being greatly needed [280]. This chapter uses these companion 
animal primary care electronic health records to describe the incidence and geographic 
distribution of ticks found on companion animals. It’s future potential as a Lyme disease risk 
resource will be discussed.  
The following content was published as: Tulloch, J., McGinley, L., Sánchez-Vizcaíno, F., 
Medlock, J., & Radford, A. (2017). The passive surveillance of ticks using companion animal 
electronic health records. Epidemiology and Infection, 145(10), 2020-2029.  
8.1 Introduction 
Ticks are effective vectors of zoonotic pathogens, and tick-borne diseases (TBDs) can be 
severely debilitating to both humans and companion animals, in some cases leading to death. 
Lyme disease is the most common TBD in the Northern Hemisphere with, in Western Europe, 
an unweighted mean for annual incidence rate of 56.3/100,000 persons per year [66]. Tick 
borne diseases can pose a large burden on health services; a recent study of Lyme borreliosis 
inpatients in Germany estimated an annual cost in excess of 30 million Euros [194]. Due to 
this, and increasing public concern, governments and research organisations are trying to 
heighten and improve their understanding of risk models of ticks [285]. The responses to this 
call have largely fallen into three categories: the active and passive collection of ticks, the 
utilisation of digital applications, and the monitoring of electronic health records.  
In Great Britain, Public Health England (PHE) coordinates the Tick Surveillance Scheme (TSS) 
[28,286], which relies on passive submission of ticks by members of the public as well as 
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medical / veterinary professionals. Between 2005 and 2016 the TSS received a total of 18,000 
ticks, primarily found on companion animals and humans (PHE unpublished). Similarly, ‘The 
Big Tick Project’, collected data on ticks found on dogs in the United Kingdom (UK) [137,287]; 
in their most recent study, 6,555 ticks were actively collected from dogs attending select 
veterinary clinics over a 16 week period from April to July 2015 [137]. Since such systems 
collect the actual tick, they are able to both identify the ticks and describe their spatial 
distributions. However, they are labour and time intensive, relying on large amounts of 
public engagement and involvement and, in the case of the Big Tick Project, do not provide 
continuous surveillance data. 
A very different approach has been developed by the National Institute for Public Health and 
the Environment (RIVM) in The Netherlands. The Tekenradar website and digital app allows 
members of the public to record when they have been bitten by a tick (and send it to RIVM), 
or develop an erythema migrans rash which is pathognomonic for Lyme disease [288,289]. 
This enables ‘live’ reporting of tick bites and identifies areas of tick bite and Lyme disease 
risk. Due to its presence on multiple digital platforms it facilitates easy promotion for public 
health messaging. It has also been promoted as a resource for researchers of ticks and TBDs 
[289]. However, the success of such a system is largely reliant on the accurate diagnosis and 
identification of ticks, tick bites and erythema migrans by members of the public, rather than 
qualified health care professionals. 
In Switzerland, the government has set up a voluntary surveillance system of 150 primary 
care physicians called Sentinella [212], recording 1,644 cases of tick bites from 2008 to the 
end of 2011. Rather than collecting and submitting ticks for further analyses, this system 
relies on the accurate diagnosis and recording of tick bites by medical practitioners within 
their patients’ electronic health records (EHRs), without the actual visualisation or collection 
of the tick. In a similar way, PHE use routine passive syndromic surveillance based on a 
predetermined list of clinical codes to monitor the incidence of arthropod bites in near real-
time across various clinical settings including general practitioner consultations, emergency 
department attendance and telephone helplines [205]. However, constraints of the clinical 
diagnostic codes being used mean tick bites cannot be analysed separately from those of 
other arthropods. 
While each of these systems contribute to different aspects of tick surveillance, none of them 
currently provide a surveillance system that is low cost and in sufficient temporal and spatial 
135 
 
resolution in near real-time to quickly and efficiently provide large sets of data about generic 
tick activity. 
According to the most recent estimates, there are 11.6 million dogs and 10.1 million cats 
kept as pets in the UK, with 30% and 23% of households owning a dog and cat respectively 
[290]. These species have the potential for greater exposure to tick habitats than humans, 
and often without measures to prevent tick contact. It has been shown that dogs that are 
regularly walked are likely to acquire ticks, and it is well established that dogs have the 
potential to act as sentinels for ticks and TBDs [137–141]. Due to owner concern, companion 
animals with ticks are often presented to veterinary clinics, with the veterinary practitioner 
frequently recording the presence of ticks within an individual animal’s electronic health 
record (EHR) [145]. The aim of this chapter is to explore the feasibility of using such EHRs 
from a large sentinel network of veterinary clinics as the basis of a novel surveillance system 
to provide efficient temporal and spatial estimates of tick activity risk in Great Britain that 
complement existing tick surveillance schemes. 
8.2 Methods 
EHRs were collected through the Small Animal Veterinary Surveillance Network (SAVSNET) 
from volunteer veterinary clinics using a compatible practice management system; currently 
Teleos ™ and RoboVet™. This study uses over two years of data gathered from 192 veterinary 
clinics across the UK between 31st March 2014 and 29th May 2016 (Fig. 8.1). 
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Figure 8.1 The distribution of participating SAVSNET veterinary clinics (red dots), and the total number of 
electronic health records collected between April 2014 and May 2016 by owners’ postcode area. 
Each EHR was collected at the end of a veterinary consultation in real-time and included the 
following data; date of the consultation, postcode of the owner, species of the animal in the 
consultation and the clinical narrative, which would have been written by the consulting 
veterinary surgeon or nurse. Whilst data on ecto-parasiticide treatments were collected, 
they were not included in further analysis; many are active against multiple arthropods and 
routine prophylactic prescription by veterinarians results in a low specificity for tick 
infestation.  
Initially, a simple free text analysis approach was developed to identify EHRs containing the 
word ‘tick’ in the clinical narrative field, whilst excluding records where only the terms ‘tickl’, 
‘ticki’ and ‘sticki’ were used. To increase the specificity of such an approach, the resulting 
EHRs were subsequently read by two domain experts (JT and LM) who verified the reference 
to ticks based on a strict case definition. A tick was only deemed present in a consultation if, 
within the associated EHR, ‘a veterinary surgeon or nurse confirmed visual sighting or 
removal of a tick within the consultation.’ This case definition was used to avoid any 
misidentification errors of ticks by owners, or any historical identification of ticks being 
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included in the current analysis (e.g. tick removed last week). To verify concordant 
interpretation of the case definition, the two domain experts manually classified a random 
sample of the EHRs. The amount of agreement (i.e. inter-rate reliability) was measured by 
Cohen’s kappa coefficient (R package ‘psych’) [291]. Each EHR where an agreement was not 
achieved was re-examined by both domain experts to develop a more consistent 
interpretation of the case definition. This process was repeated until an ‘almost perfect’ level 
of agreement was achieved, at which point the remaining EHRs were randomly divided 
between the two domain experts and categorised [292]. 
Results of these analyses were used to calculate the number of consultations where a tick 
was recorded in the EHR per 10,000 consultations. This is assumed to be a proxy for activity 
of ticks and for brevity, refer to this measure as “tick activity”. Relative risks were calculated 
between the two predominant host species (i.e. dogs and cats) with statistical significance 
(P<0.05) measured by a Chi-squared test.  
Time-series plots (based on the time of the consultation as recorded in the EHR) were used 
to identify temporal trends in tick activity and to compare temporal trends by host species. 
The temporal pattern of tick activity was smoothed using a nonparametric method, the 
LOESS (locally weighted regression) technique (R package ‘ggplot2’) [293,294]. Outliers were 
identified as those outside the smoothed line’s 95% confidence intervals. All proportions and 
95% confidence intervals (CIs) were calculated using robust standard errors to account for 
intragroup correlation within veterinary clinics. Statistical analyses were carried out using R 
language (version 3.2.0) (R Core Team 2015). 
Maps were used to describe the spatial distribution of tick activity during each season. 
Seasons were defined as winter (December-February), spring (March-May), summer (June-
August) and autumn (September-November). The spatial distribution of tick activity was 
stratified by owner’s given address. SAVSNET receives full owner postcode for each EHR, 
which locates each address to one of 1.75 million locations [295]. However, at such 
resolution it is possible to identify some individual properties, particularly in rural areas. 
Therefore, postcode area (first half of postcode; n=124) was used to maintain owner 
confidentiality when presenting the results. When displaying the data, a cautious approach 
was taken and areas with less than 200 EHRs in each season were excluded, as they were 
less likely to be representative. A map was constructed displaying all EHRs, aggregated by 
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owner’s postcode area, to show the underlying population distribution (Fig. 8.1). The data 
was depicted using QGIS version 2.8.2-Wien. 
8.3 Results 
In total 1,658,857 EHRs were collected during the study period, consisting of 70.5% dogs and 
26.4% cats. Of these, 10,155 (0.61%) had a clinical narrative containing the word ‘tick’. The 
two domain experts first independently read and applied the case definition to 365 randomly 
selected EHRs from these 10,155. After adjusting by the amount of agreement which would 
be expected by chance, a ‘substantial agreement’ (K= 0.7; 95% CI: 0.63-0.78) with 305 EHRs 
agreed was achieved. After reappraising this first data set, the exercise was repeated on a 
new random sample of 365 EHRs, this time achieving an ‘almost perfect’ agreement (K= 0.82; 
95%CI: 0.77-0.88) with 332 EHRs agreed; the remaining EHRs were therefore categorised 
independently by the two authors. 
In total, 2,180 EHRs were confirmed as having a tick present, equating to 0.13% of the total 
1,658,857, and 21.5% of the 10,155 automatically identified EHRs. Of these 2,180 EHRs, 
1,421 were from dogs (65.2%), 728 from cats (33.4%), and 17 from other species (which only 
included ferrets, rabbits and guinea pigs; 0.8%), with the remaining 14 EHRs lacking an 
identifiable species label (0.6%). The relative risk of a dog being recorded as presenting with 
a tick compared to that for a cat was 0.73 (95% CI: 0.67-0.80, p<0.005). The main reasons for 
EHRs being identified by the free text analysis but failing to meet the case definition included; 
misidentification of ticks by owners (e.g. skin tags, nipples, tumours), ticks observed by 
owners before the consultation and not confirmed by a veterinary surgeon or nurse within 
the consultation, and discussions held in the consultation about ticks and TBDs without a tick 
being present. Only five of the 2,180 (0.2%) EHRs identified as relating to ticks included 
information at genus and species level; two referring to Ixodes spp, one to I.ricinus, one to 
Dermacentor spp and one EHR referring to both Dermacentor and Rhipicephalus spp. 
The mean weekly rate of tick reporting in this population over the entire study period was 
15.3 tick based EHRs per 10,000 EHRs. The temporal pattern was similar in both calendar 
years, with peak tick activity between May and July each year, and highest levels recorded in 
mid-June (Fig. 8.2). 
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Figure 8.2 Time series plot showing the weekly number of tick based electronic health records (EHRs) per 
10,000 EHRs between April 2014 and May 2016 
Minimum tick activity was between December and February, with the lowest activity in 
January in both calendar years. The temporal pattern of tick activity in dogs was similar to 
the overall population, with peak activity in June (maximum of 65.5 tick based EHRs per 
10,000 EHRs over a single week) and lowest levels between December and February (Fig. 
8.3). In contrast, cats seemed to have an earlier peak in weekly tick activity in May (with a 
maximum of 87.2 tick based EHRs per 10,000 EHRs), with a secondary smaller peak in the 
autumn, and their lowest levels in February (Fig. 8.3). In the winter of 2015-2016, ticks were 
still recorded in every week on cats, whilst for two separate weeks none were recorded on 
dogs. The mean weekly rate of tick activity was lower for dogs (14.8 tick based EHRs per 
10,000 EHRs) than for cats (18.3 tick based EHRs per 10,000 EHRs). 
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Figure 8.3 Time series plot showing the weekly number of tick based electronic health records (EHRs) per 
10,000 EHRs in dogs and cats between April 2014 and May 2016 
There was considerable variation in the spatial distribution of tick activity across each 
postcode area in Great Britain (Fig. 8.4). The ten postcode areas with highest tick activity 
across all seasons were (in descending numerical order); Bournemouth, Hemel Hempstead, 
Southampton, Falkirk, Salisbury, Guildford, Croydon, Llandudno, Reading and Lancaster. Of 
these, Southampton, Bournemouth, Guildford, Reading, Llandudno and Lancaster peaked in 
spring; the remainder peaking in summer. No postcode areas had their peak activity in 
autumn or winter. The areas with no tick activity across all seasons were Hereford, Oldham 
and Wolverhampton.  
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Figure 8.4 Geographical distribution of tick based electronic health records (EHRs) per 10,000 EHRs by owners’ 
postcode area for each season between April 2014 and May 2016. The dotted postcode areas represent 
areas with less than 200 EHRs in total during the relevant time period. 
8.4 Discussion 
Ticks are an important vector of disease but continuous near real-time surveillance has 
proved challenging. Here it is shown how text mining of real-time companion animal EHRs 
from a large sentinel population of veterinary clinics may provide a novel form of passive 
surveillance to describe temporal and spatial trends in tick activity across Great Britain. This 
could provide an early warning system to the risk of veterinary disease and human health 
risks associated with ticks.  
The SAVSNET data showed a seasonality to tick activity consistent with previous reports with 
peaks of activity at the start of the summer and minimal activity during winter [28,296–298]. 
Although identification of the life cycle stage of the ticks referred to within the EHRs was not 
possible, it was assumed this seasonality largely reflects that of adult ticks, and to a lesser 
extent nymphs, of Ixodes ricinus, as these are the most common ticks found on companion 
animals in Great Britain [28,137,287,297,299]. This tick is susceptible to desiccation and its 
host seeking behaviour (questing) is greatly influenced by changes in temperature and 
humidity [300]. It therefore has an annual variation of peak activity, with levels rising in early 
spring and peaking between April and July, with low levels in winter [297], although this may 
show regional variation [301]. The fact that the seasonal profile observed in dogs was similar 
to that in the total population, is a reflection of the demographic predominance of dogs in 
the data and in other such veterinary visiting populations [302,303]. 
Interestingly, tick activity on cats showed marked differences to that seen in dogs, raising 
several important questions relating both to ectoparasite biology, as well as owner and 
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veterinary surgeon behaviour. This study is the first to suggest that cats are more likely to 
present to veterinary clinics with ticks than dogs. Previous studies based on tick submissions 
either excluded cats [137,287] or lacked suitable population denominator data to calculate 
a relative risk [28]. Whether this represents a genuine increased risk of ticks on cats, or that 
ticks on cats are more likely to be observed by owners and presented to the veterinary 
surgery, or whether veterinary surgeons are more likely to record ticks on cats in their EHRs, 
remains to be determined. As well as this overall increased risk, cats continued to present 
with ticks during the winter of 2015-2016, in contrast to dogs where there were short periods 
where ticks were not identified in this population. During these months, dog owners may be 
less inclined to take their dogs for exercise where they may be exposed to ticks due to 
shortened day length, cooler temperatures and higher rainfall. However, domestic cats in 
the UK may remain susceptible to ticks, albeit at lower levels, due to their ability to explore 
outside habitats at their own free will due to the common use of cat flaps.  
Ticks on cats also showed a different temporal pattern of tick activity with an earlier main 
peak in the spring and some evidence for a second smaller peak in the autumn. The precise 
reason for this apparent difference remains unknown but may relate to differences in host 
susceptibility to different tick species. Cats are significantly more likely to carry Ixodes 
hexagonus than I. ricinus [299] and I. hexagonus is more frequently found on cats than dogs 
[28,286,299]. The activity of I. hexagonus is closely linked to the density and behaviour of its 
primary host, the European hedgehog (Erinaceus europaeus) [304]. I. hexagonus is more 
prevalent earlier in the year than I. ricinus [304,305], coinciding with the emergence of 
hedgehogs from hibernation [306], and possibly explaining the earlier peak of tick activity 
identified in cats. The second autumnal peak could represent interaction between cats and 
hedgehogs at a time when hedgehogs are preparing for hibernation and juveniles are gaining 
independence, leading to greater hedgehog numbers being seen [306], all at a time when I. 
hexagonus is also at great abundance on the hedgehogs themselves [304,305].   
The spatial distribution described generally mirrors previous work on tick distributions in 
Great Britain [28,137,286,287,296]. Comparing it to the most recent study published using 
data from a shorter, but overlapping time period (16 weeks between April – July 2015), both 
studies identified the highest levels of tick activity in southern postcode areas of England, 
with high levels also in the south of Scotland [137]. However, in contrast, higher levels of 
activity were seen in north and mid-Wales, and north-west England, and less clear areas of 
high activity in north Norfolk and the north-east of England. These observations are likely to 
143 
 
reflect differences in methodology used by the two projects including veterinary clinic 
recruitment, the period of sampling, and potentially tick distribution [137].  
Collection of continuous surveillance data over two years across GB has allowed us to begin 
to describe a complex mosaic of tick activity across the country in different seasons. 
However, broad trends can be identified. In winter, low levels of tick activity remain 
throughout England and Wales, challenging the belief of some vets, who recorded in their 
EHRs that ticks pose no risk in winter (unpublished observations). The results also showed 
that the timing of peak activity varied by postcode area, with the majority of areas peaking 
in the spring, the remainder peaking in the summer. The data set described here represents 
a rich research tool in which to explore the varied impact of climate, and other environmental 
and ecological factors, on tick activity.  
To maintain a high specificity, a very restrictive case definition was applied, only including 
ticks that were seen by a veterinary surgeon or nurse and recorded during the consultation. 
Therefore, it is clear that not all ticks on cats and dogs will be included in this study. Many 
ticks on companion animals will not present to the veterinary practice either because the 
owner is not concerned, or removed the tick themselves, or the ticks were not noticed. 
Equally ticks on animals in a veterinary consultation may not be noticed, or not recorded, 
especially where they are incidental findings in relation to what may be a more serious 
clinical need. Indeed, where dogs had a bespoke thorough clinical examination as part of a 
research study to identify tick carriage, reported tick prevalence was much higher (30%) 
[137]. This study was however carried out during peak tick activity (April-July) and as the 
authors stated, practitioners participating in the study may have been more likely to sample 
animals with observed ticks on them. Although it is clear that the values reported are 
therefore an underestimate of overall tick activity on companion animals, one is confident 
that they can describe relevant levels of relative risk. It must be acknowledged that health 
scares and media coverage could influence owner behaviour and veterinary recording 
behaviour. This has been previously discussed in relation to the Babesia canis outbreak seen 
in early 2016 [145]. However, in this particular case, this outbreak did not appear to influence 
the overall temporal trends of this data (data not presented).   
Arrival of exotic ticks has been of great concern to both the veterinary and medical 
professions as they have the potential to carry pathogens not currently transmitted in the 
UK [175,307–309]. This has driven a need for species level surveillance of ticks such as 
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provided by PHE [286] and the Big Tick project [137]. Within this data, only five EHRs included 
information at the genus and species level; two referring to Ixodes spp, one to I. ricinus, one 
to Dermacentor spp and one EHR referring to both Dermacentor and Rhipicephalus spp. 
Although these numbers are clearly low and in the absence of microscopic confirmation need 
to be treated with some caution, they still raise important questions. Whilst a few foci of 
Dermacentor are known to exist in the UK [286], Rhipicephalus sanguineus has only been 
reported in dogs that have travelled in the rest of Europe [137,309], such that reference to 
Rhipicephalus spp in even one EHR could be significant. The infrequent mention of tick 
species likely reflect time constraints of a short consultation, the challenge of identification, 
especially if the tick is engorged, and veterinary surgeons deeming it clinically irrelevant. In 
the future, the reference to rare and exotic tick species identified by EHR surveillance, could 
be followed up by submission of the tick to relevant health authorities with tick identification 
capabilities; such as PHE. Surveillance systems based on EHRs would be improved if 
veterinary surgeons were encouraged to record within the EHR any recent travel history and 
information about tick species where they are confident to do so.  
The limitations of this study are inherent to its methodology. Since recruitment of practices 
is not random, there may be selection bias in the results, meaning generalisability to the 
entire UK population of veterinary visiting dogs and cats is not possible. In addition, 
population statistics for companion animals in the UK are generally poor or unavailable, such 
that the results cannot be described as incidence; this may change as compulsory 
microchipping of dogs has recently come into legislation [310]. Some postcode areas have 
relatively small amounts of data and were excluded from analysis. However, the fact that 
56% (70 of 124) of postcode areas contributed more than 5,000 EHRs during the study 
period, and that 42% (52 out of 124) of areas contributed more than 10,000 EHRs suggests 
that there is already good data coverage for large parts of Great Britain. As SAVSNET 
continues to expand through clinic recruitment, it is believed that the spatial distribution of 
clinics and the number of EHRs collected will become more homogenous. SAVSNET data will 
always underestimate true tick activity on companion animals, and veterinary surgeons or 
nurses rarely record the tick species in EHR. In addition, like other studies that define a tick’s 
location by the pet owner’s postcode [137], the results should be seen as a proxy for tick 
activity at a given geographical area, rather than the location where the animal necessarily 
acquired the tick.  
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Despite these limitations, it is believed that this form of surveillance offers some real 
benefits. Using EHRs is very passive in nature, as once a veterinary clinic has been enrolled, 
no changes in clinician behaviour need occur for the data to be captured. This data is 
collected in real-time, with the only rate-limiting step currently being the time taken to verify 
the strict case definition. Compared to systems that rely on the general public identifying a 
tick, ticks recorded in EHRs are identified by a qualified health care professional [289]. There 
is also minimal labour required, except the upkeep of a system to collect the EHRs on which 
it relies. As the results are similar to previous surveillance and field work performed in the 
UK, it is believed that they do provide a novel and complementary approach for tick 
surveillance that could be adopted by other countries where mature pet animal EHRs exist. 
As more clinics are recruited the representativeness of such systems can be improved. 
Linking data through postcode to other data sources will provide new opportunities to 
understand the effect of climate change and land use changes on the distribution and activity 
levels of ticks [26,27,175,307,311].  
8.5 Conclusions 
In summary, this study shows how the passive real-time collection of companion animal EHRs 
can provide efficient, accurate and novel data on tick activity in a large national sentinel 
population of companion animals. We highlight for the first time temporal differences of tick 
exposure between domesticated cats and dogs. As the availability of EHRs increases, such 
methodology can provide a comprehensive temporal and spatial understanding of tick 
activity, and in combination with other systems already in place, we believe can further 
inform real-time tick and TBD risk models, aiding a ‘One Health’ approach for public health 
messaging and tick control. 
The extent to which this work contributes to the overall aims of this thesis regarding Lyme 
disease surveillance can be summarised as follows: 
• Incidence: Not applicable. However, seasonal trends were seen in tick activity, with 
peaks in summer months. 
• Sociodemographics: Not applicable. However, cats and dogs were identified as the 
main species that could be used in future sentinel surveillance systems  
• Geographical hotspots: These were identified in southern England and north Wales.  
• Patient presentation and management: Not applicable. 
• Additional information: SAVSNET has the potential to act as a sentinel surveillance 
system for tick risk. However, this needs to be formally assessed (Chapter 9). The 
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laboratory data contained within SAVSNET needs to be assessed, as companion 
animal TBD surveillance data is severely lacking [280]. SAVSNET’s laboratory data for 
zoonotic infections, like Lyme disease, could be a more useful sentinel surveillance 
system than tick activity data. 
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Chapter 9 A comparison of datasets 
9.1 Introduction 
Over the last six chapters, various health datasets, and the information they could add to 
Lyme disease surveillance in the United Kingdom, have been discussed. For each dataset 
the following questions, as set out in Chapter 1, were considered: 
• For each health dataset appraised (see Chapters 3-8); 
o What is the incidence of Lyme disease? 
o What are the sociodemographics of the patient population? 
o Can any geographical hotspots be identified? 
o Can any data about patient presentation and management be extracted? 
o Is there any additional information about the epidemiology and 
management of cases which is unique to this dataset? 
This leaves the two following research questions unanswered: 
• Using the current laboratory-confirmed based surveillance system (RIPL) as a 
reference point, how does each of the other datasets compare? How complete is 
each dataset, and is there a stable multiplication factor that can be applied to RIPL, 
that can provide an improved overall annual incidence estimate?  
• Based on the datasets analysed, what policy (or policies) described by EPPI should 
the public health authorities of the United Kingdom adopt? (Chapter 10)  
Within this chapter datasets are compared, in terms of demographics, spatial, and temporal 
patterns, and investigated as to whether stable multiplication factors exist between the 
datasets. 
9.2 Methods 
The Zoonoses report [153], part of which was analysed as the RIPL dataset in Chapter 3, 
represents the British Government’s official laboratory-confirmed case numbers for Lyme 
disease in the UK. This shall be the reference dataset when comparing official UK incidence 
figures to that within THIN. The data in the Zoonoses report is not stratified by any 
sociodemographic or geographic variables, and only reports new national case counts. For 
the remaining comparisons the RIPL dataset will be used as the reference dataset and will 
therefore focus on English and Welsh data. It must be noted that SGSS data has been 
excluded from analysis, as it was not a reliable dataset for Lyme disease (Chapter 3). Likewise, 
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only HES and PEDW admissions data will be used as a comparator as HES A&E and 
outpatients data were deemed too sparse and unreliable (Chapter 4). 
9.2.1 Methods – Demographic comparisons 
Only three datasets had demographic data available for comparison; namely, RIPL, HES and 
THIN. Neither SAVSNET nor Twitter contained information about patient demographics.  
To visually compare the structure of the Lyme disease case populations captured within each 
dataset, population pyramids were constructed based on case count data and compared to 
the national population pyramid [159]. The sex ratio for each dataset was calculated for 5-
year age-bands and overall. Chi2 tests were performed for each age-band, and overall, to 
compare the sex ratio of each dataset with those in RIPL reference dataset. 
Measures of ethnicity, rural-urban status and societal deprivation were compared 
descriptively. Where a dominator population was not available for analysis, these factors 
were compared to 2015 national population demographics as provided by the ONS [159]. 
9.2.2 Methods – Spatial comparisons 
Four datasets had geographical data with a fine enough geographical resolution to perform 
comparative spatial analysis; these were the RIPL, HES, Twitter and SAVSNET datasets. THIN 
contained no degree of geographical resolution, and as discussed in Chapter 3, SGSS has been 
removed from further analysis. For all datasets, annual information was sparse; data was 
therefore aggregated and analysed at an average annual incidence per geographical unit. 
Only geographical data for England and Wales could be analysed, as the RIPL dataset only 
provides information for these two countries. Local authority was chosen as the geographical 
unit for analysis, as this offered finer resolution than postcode area, without producing large 
numbers of areas with zero incidence. Comparisons between Twitter and RIPL geographical 
data have already been discussed in Chapter 7. The remaining datasets to be compared were 
RIPL, HES and SAVSNET (Fig. 9.1). 
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Figure 9.1 Geographical distribution of Lyme disease incidence (RIPL, HES), and ticks found on companion 
animals (SAVSNET). Areas with no positive cases are shaded black. 
The geographical analysis of HES and THIN data has so far, in this thesis, focused on 
descriptive mapping of their incidence data. The RIPL data was explored further through 
exploratory spatial data analysis (ESDA) [164,165] using global Moran’s I value and LISA (Local  
Indicators of Spatial Association) analysis (Chapter 3). These methodologies were used to 
identify global and local outliers, identify global trends, examine local variation and examine 
spatial autocorrelation. By performing this analysis, further insight into the geographical 
differences in the incidence of laboratory-confirmed Lyme disease were gained. ESDA 
methodology can be adapted to compare how multiple variables are distributed over the 
same space [164,165]. They can therefore be used to explore geographical associations 
between the laboratory-confirmed incidence of Lyme disease (RIPL) and hospitals 
admissions data (HES) or tick activity on companion animals (SAVSNET). The two 
methodologies used were the calculation of a bivariate global Moran’s I value and the 
calculation of local indicator of spatial association (LISA) values for each local authority.  
The bivariate global Moran’s I value describes the direction and strength of a relationship 
between two variables (e.g. RIPL Lyme disease incidence and HES Lyme disease incidence) in 
each geographical unit and measures the overall level of clustering. As the degree of spatial 
autocorrelation in a dataset is not always globally uniform, local statistics were critical. LISA 
provides this, by identifying locations of spatial clusters and outlier data.  
The significance of these statistics was tested by comparing them to a reference distribution 
created by 2000 random permutations of the underlying spatial reference distribution 
[164,165]. A Queen’s contiguity was used to define spatial neighbours; this defines a 
neighbouring area as one with shared borders and vertexes. The global Moran’s I value can 
be visualised in a bivariate LISA plot, which shows the correlation between one variable (for 
example, RIPL incidence) and a different variable (HES incidence) in a local authority and 
RIPL HES SAVSNET 
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neighbouring areas. If the slope of the plot significantly differs from zero, there is a 
relationship between the two variables. Information from the scatter plot was used to create 
a cluster map to show spatial areas with significant concordant or discordant relationships. 
The local authorities with significant spatial correlation were identified by type of spatial 
autocorrelation and mirror the quadrants shown in the Moran scatter plot. Essentially the 
high-high and low-low areas represent positive spatial autocorrelation, and so spatial 
clusters, while the high-low and low-high areas represent negative spatial autocorrelation 
and are spatial outliers. A cluster is defined as an area with a value more similar to its 
neighbours than would be the case under spatial randomness. As the cluster map displays 
only the core of the cluster, the cluster is likely to extend to neighbouring locations. 
This methodology was used to explore the associations between the laboratory-confirmed 
incidence of Lyme disease and the incidence of hospital admission, and the incidence of ticks 
found in companion animal electronic health records. 
9.2.3 Methods – Temporal comparisons 
To compare case counts and disease incidence, datasets need to include figures for the same 
time period. For UK data, the Zoonoses Report will act as the reference dataset and it covers 
the years 2007 to 2016 inclusive. Therefore, comparator datasets must provide case counts 
and incidence figures for the same period. The only dataset matching these criteria was THIN 
(Chapter 5). Since THIN only provides age-standardised incidence rates, case counts have 
been extrapolated using the ONS population figures [159]. The UK’s case counts, and 
incidence figures, were first compared between the Zoonoses Report and THIN dataset. 
To formally assess the similarities between the datasets a linear regression model for each 
dataset, and a combined model, was constructed. Slopes were compared by examining the 
interaction of year by dataset using an ANOVA. The residual variance of the two datasets was 
compared utilising a Fisher’s R-to-z transformation of the Pearson correlations of the two 
datasets.  
English and Welsh annual count and incidence figures were compared using the same 
methodology for the years 2007 to 2016. The datasets analysed were: the Zoonoses Report, 
HES and PEDW admissions, and THIN. 
Monthly incidence data were only available for comparison for the period 2013-2015, for the 
RIPL, HES and THIN datasets. Comparisons were only possible for English data, as there was 
no Northern Irish or Scottish data, bar THIN, and Welsh data was too sparse to perform 
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analytics. The increased number of data time points meant that time series analysis was 
possible. Time series analysis provides an understanding of the underlying forces and 
structure that produce the observed incidence data. By decomposing a time series, an 
enhanced understanding of these structures can be gained. The trend component reflects 
the long-term progression of the time series, this can be increasing or decreasing and can be 
non-linear. The seasonal component reflects any seasonal variation, in this case over the 
twelve months of a year. The random component represents the residuals of the time series 
once trend and seasonal components have been removed. This should be stationary and 
random, to show that factors influencing the time series have been accounted for by the 
other components. By performing time series analysis of each Lyme disease dataset, and 
analysing each component separately, the similarity of the underlying processes defining the 
time series can be compared. If they are similar, then it could be concluded that each 
dataset’s incidence data is driven by the same underlying processes and therefore reflective 
of similar disease and reporting dynamics.  
Time series analysis was performed by decomposing the time series of the RIPL, HES and 
THIN data, using a Loess smoothing approach [312], to their trend, seasonal and random 
components. These components were compared visually and distance measures calculated 
to provide a formal assessment of the similarities between the time series [313,314]. The 
combined seasonal and random components were described, to visually identify the relative 
importance of the trend component on the data. To assess whether the random component 
of each dataset contained any further trends an augmented Dickey-Fuller (ADF) test was 
performed [315]. This tested the null hypothesis that the random component of each time 
series was not stationary.  
The distance similarity measures chosen were Euclidean distance and dynamic time-warping 
(DTW) distance. The Euclidean distance is one of the most commonly used measures and 
provides a figure based upon the straight-line distance between points in two time series at 
the same fixed point in time. This works well when there is limited lag between the datasets. 
However, if a temporal lag is present, the distance can become unrepresentative despite the 
shape of the time series being similar. To correct for this a DTW distance was also calculated. 
This is calculated in a similar manner to the Euclidean distance, but it takes any lag into 
account by optimally aligning the points in the time series (Fig. 9.2) [314,316]. 
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Figure 9.2 The different basic assumptions to calculate Euclidean distance and dynamic time warping distance. 
Permission to use the image was kindly provided by its creator, Professor Eamonn Keogh [303]. 
To reduce computational time calculating the DTW distance, the data was constrained using 
a Sakoe-Chiba band [313,314,316]. The accepted bandwidth of 10% of n (i.e. 10% of the 36 
months analysed) was chosen. 
However, as the aim of this comparison was to compare the shape of each components’ 
distributions, a problem of data magnitude would arise. This was due to the incidence being 
markedly different in each dataset, for example the incidence of Lyme disease in the datasets 
in 2015 was, 1.91 cases per 100,000 in RIPL, 0.45 cases per 100,000 in HES, and 5.23 cases 
per 100,000 in THIN. Therefore, data transformation was needed to allow comparison of the 
time series’ shapes. 
The three traditional methods of data transformation (log, square-root, and arcsine 
transformations) were not appropriate as none of these methodologies deal with issues of 
differences in magnitude between datasets. A new magnitude transformation was created, 
which aimed to maintain relative proportions of the confidence intervals and mean of each 
curve. Effectively the ratio between a comparison dataset’s upper confidence interval of the 
curve and the RIPL dataset’s confidence interval of the curve, was used as a multiplier to the 
comparison curve. 
𝑛𝑒𝑤 𝑐𝑢𝑟𝑣𝑒
= 〈
{𝑚𝑒𝑎𝑛(𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝐻𝐸𝑆 𝑜𝑟 𝑇𝐻𝐼𝑁 𝑐𝑢𝑟𝑣𝑒) + 1.96 × 𝑆𝐷(𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝐻𝐸𝑆 𝑜𝑟 𝑇𝐻𝐼𝑁 𝑐𝑢𝑟𝑣𝑒)}
{𝑚𝑒𝑎𝑛(𝑅𝐼𝑃𝐿 𝑐𝑢𝑟𝑣𝑒) + 1.96 × 𝑆𝐷(𝑅𝐼𝑃𝐿 𝑐𝑢𝑟𝑣𝑒)}
〉
× (𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝐻𝐸𝑆 𝑜𝑟 𝑇𝐻𝐼𝑁 𝑐𝑢𝑟𝑣𝑒) 
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This allowed all curves to be framed within the same upper and lower limits whilst 
maintaining the relative shape of the curves and keeping the temporal points fixed. In 
summary the time series were first transformed, then decomposed, and finally Euclidean 
and dynamic time-warping (DTW) distances were calculated. 
To assess all the datasets, some of which could not be included in the above analysis, each 
dataset’s monthly data was aggregated. With this data, a plot was created displaying the 
percentage of cases, out of the entire year, occurring in each month for each dataset. 
9.2.4 Methods – Dataset completeness 
Despite the proliferation of research based upon electronic health records, no standardised 
definition or process has been described to assess dataset completeness [317]. As Weiskopf 
et al importantly note; 
 ‘Completeness is contextual and is determined through an understanding of 
specific data needs. The number of complete records available for analysis is 
dependent upon the definition of completeness being used.[317]’ 
The simplest and easiest measure, to calculate and understand, was adopted [318,319]. For 
each dataset variable, the percentage of total records present that could be used for analysis 
was calculated. An overall score was given, equaling the mean of each respective dataset’s 
percentages. 
9.3 Results 
9.3.1 Results – Demographic comparisons 
Population pyramids of each dataset and the ONS national population for England and Wales 
were constructed (Fig. 9.3) 
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Figure 9.3 Population Pyramids for England and Wales. A = ONS population official figures 2015. B = Laboratory-
confirmed cases of Lyme disease (RIPL, 2013-2016). C = hospital admissions of Lyme disease (HES & PEDW, 
1998-2015). D = Lyme disease cases presenting in primary care (THIN, 1998-2016). Blue = Male, Red = Female.  
The ONS pyramid is evenly balanced between sexes and its most populous age-band is 0-5 
years. The pyramid is relatively stable from 6 to 70 years old, at which point the population 
starts to decrease. In contrast the RIPL pyramid is noticeably skewed towards males, 
although its general shape is symmetrical and bimodal with peaks at 6-10 and 46-65 years 
old. The HES data matches this distribution, except that it is skewed towards females rather 
than males and has a more pronounced bimodal distribution. The THIN pyramid is less 
obviously bimodal, with potential peaks at 6-10 and 56-60 years old, and as described in 
Chapter 5, no overall predominance in sex. However, its shape is more similar to RIPL and 
HES than to the ONS data.  
The sex ratio for each dataset was plotted (Fig. 9.4) and compared using a Chi² test (Table 
9.1). 
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Figure 9.4 The sex ratio for each dataset over varying age bands. (Red = RIPL, Green = HES, Blue = THIN, Black 
= ONS data) 
Table 9.1 The sex ratio for each dataset by age band. When a Chi² showed a significant difference to the 
corresponding RIPL sex ratio an asterisk is present *<0.1, **<0.05, ***<0.01. 
Age Group RIPL 
(Reference Value) 
HES & PEDW THIN 
 
England and  
Wales (ONS) 
0-5 1.09 1.13 1.31 1.05 
6-10 1.44 0.85** 1.16 1.05** 
11-15 1.56 1.63 1.12 1.05** 
16-20 0.78 0.35* 0.72 1.06 
21-25 0.95 0.37*** 0.55** 1.04 
26-30 1.02 0.56** 0.86 1.00 
31-35 0.99 0.75 0.74 0.99 
36-40 1.31 0.66*** 0.67*** 0.99** 
41-45 1.35 0.62*** 1.02 0.98*** 
46-50 1.29 0.82** 0.79** 0.97** 
51-55 1.12 0.62*** 0.88 0.98 
56-60 1.21 0.61*** 0.79** 0.98* 
61-65 1.08 0.55*** 0.87 0.95 
66-70 1.13 0.68** 0.83 0.94 
71-75 1.00 0.73 0.89 0.90 
76-80 1.21 0.64** 0.72 0.84* 
81-85 0.87 0.41 1.00 0.73 
85+ 0.77 0.32 0.50 0.51 
Overall 1.14 0.66*** 0.84*** 0.97*** 
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The overall sex ratio in the HES, THIN and ONS datasets all differed to that of RIPL. RIPL had 
a male bias, whilst the others displayed a female bias.  
The two age groups that show agreement between datasets were the 11-15 year olds and 
those between 16 and 35, even though the proportions differ somewhat between the 
datasets. The 11-15 year olds were mainly male at a ratio that does not differ between 
datasets but were significantly different to the national population. Between 16 and 35 there 
is a predominance of females in the Lyme datasets, whilst the ONS has an even sex ratio.  
In all datasets, age groups past the age of 36 show stability in their sex ratios, however 
differences between datasets were present. The HES and THIN datasets, in the main, have a 
female bias with a relatively stable ratio, until after 75 years old, when they become 
increasingly more female. During the 36-75 age range the ONS sex ratio also remains stable, 
with a slight female predominance, and then sharply becomes more skewed towards female 
at around 75 years old. In contrast the RIPL population has a male bias until 81 when this 
switches to female.  
Due to the structure of the datasets assessed, only two datasets had ethnicity data, HES and 
THIN. The lack of denominator ethnicity data meant that both these datasets were compared 
to the ONS 2015 census population, in which 86% of the English and Welsh population 
identified with being white. In the HES and PEDW datasets, there was a significant difference 
to the ONS with 96% identifying with a white ethnicity (Chapter 4). Likewise, the English and 
Welsh population in the THIN dataset had significantly greater proportions of white ethnicity; 
94% compared to 86% (Chapter 5). 
In all three datasets there was a significant relationship between Lyme disease status and 
measures of deprivation. The RIPL and HES datasets were compared to the census figures of 
the Index of Multiple Deprivation, a measure of societal deprivation. In both these datasets, 
as deprivation increased, so the number of Lyme disease cases decreased (Chapters 3, 4). 
THIN provided a material measure of deprivation, the Townsend score. In this database a 
significantly higher incidence of Lyme disease coded cases was found in the least deprived 
areas. 
In the RIPL and HES datasets a significantly higher proportion of cases lived in rural areas 
compared to the national population (Chapters 3,4). In THIN dataset there was roughly a 
twofold significant increase in incidence between Lyme disease coded cases found in rural 
areas than in urban areas (Chapter 5). 
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9.3.2 Results – Spatial comparison 
The global Moran’s I value for RIPL and HES incidence was 0.47 (p<0.001), indicating an 
overall significant positive spatial correlation between the two datasets (Fig. 9.5).  
 
Figure 9.5 Bivariate Moran I’s scatterplot between RIPL and HES Lyme disease incidence at local authority level. 
The bivariate scatterplot shows a significant positive linear relationship in which local 
authorities (and their neighbours) with a higher laboratory-confirmed incidence tend to 
contain hospitals with a higher incidence of Lyme disease admissions, and vice-versa.  
This overall positive correlation was seen on the LISA cluster map (Fig. 9.6) 
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Figure 9.6 Bivariate LISA cluster map between RIPL and HES Lyme disease datasets. 
The majority of the map is covered in non-significant local authorities, this shows that in 
these localities the case incidence for both datasets does not differ from a randomly 
generated distribution of incidence. The high-high areas represent concordant significant 
clusters of high incidence. The low-low areas represent the reverse and are areas where a 
significantly low incidence of disease is recorded in both datasets. 
Only thirteen (4%) local authority areas show significant discordance. The areas that have a 
high level in RIPL and a low level in HES were scattered throughout the country. The areas 
with a low level in RIPL and high level in HES were all located in neighbouring local authorities 
in the south-west of England.  
The global Moran’s I value for RIPL and SAVNSET incidence was 0.05 (p=0.08), indicating a 
lack of spatial correlation (Fig. 9.7). 
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Figure 9.7 Bivariate Moran I’s scatterplot between RIPL Lyme disease incidence and SAVSNET tick activity at 
local authority level. 
The bivariate scatterplot shows a small positive non-significant relationship, which indicates 
that there is no spatial relationship between the laboratory-confirmed incidence of Lyme 
disease and tick activity based on companion animal electronic health records. As no 
significant spatial relationship was identified a bivariate LISA cluster map was not 
constructed. 
9.3.3 Results – Temporal comparison 
Case counts and the incidence of Lyme disease cases in the UK based on the Zoonoses report 
and THIN dataset were calculated (Fig. 9.8). 
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Figure 9.8 Case count (bars) and incidence (lines) of Lyme disease in the United Kingdom based on laboratory-
confirmed cases (Zoonoses Report) and cases identified in a primary care database (THIN). 
On visual inspection both datasets show an increasing trend of cases and disease incidence, 
with the fluctuations in numbers apparently mirroring each other. The relative ratio of 
incidence between the datasets also appears to be stable (Table 9.2). 
Table 9.2 The ratio of annual incidence between primary care Lyme diseases cases (THIN) and laboratory-
confirmed Lyme disease cases (Zoonoses Report), in the UK. 
Year 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Mean 
Ratio 
THIN 
Incidence 
4.67 5.15 5.46 5.22 5.14 4.71 5.63 4.23 7.09 6.05 N/A 
Zoonoses 
Report 
Incidence 
1.67 1.78 1.76 1.93 1.88 1.96 1.74 1.67 1.94 2.00 N/A 
THIN:Zoo 
Ratio 
2.80 2.89 3.10 2.70 2.74 2.40 3.23 2.56 3.66 3.03 
2.91 
(2.20-3.62) 
 
There was no significant interaction in the relationships of incidence to year for the Zoonoses 
Report (β=0.02), nor THIN dataset (β=0.13); F(1,16)=1.68, p=0.21. The Fisher’s R-to-z 
comparison indicated that there was no significant difference (p=0.97) of the Pearson 
correlation between the Zoonoses Report (r=0.47) and the THIN data (r=0.48), (Fig. 9.9). 
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Figure 9.9 The incidence of laboratory-confirmed and primary care diagnosed cases of Lyme disease in the 
United Kingdom, with associated linear regression lines and 95% confidence intervals; 2007-2016. 
Case counts and the incidence of Lyme disease cases in England and Wales based on the 
Zoonoses report, HES admissions and THIN were calculated (Fig. 9.10). 
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Figure 9.10 Case count (bars) and incidence (lines) of Lyme disease in England and Wales based on laboratory 
confirmed cases (Zoonoses Report), hospital admissions (HES and PEDW), and cases identified in a primary care 
database (THIN). NB. No hospital data for 2016 were available. 
On visual inspection all three datasets showed an increasing trend of cases and disease 
incidence, with the fluctuations in numbers apparently mirroring each other. The relative 
ratio of incidence between the datasets also appears to be stable (Table 9.3).  
Table 9.3 The ratio of annual incidence between primary care Lyme diseases cases (THIN), hospital admissions 
(HES), and laboratory-confirmed Lyme disease cases (Zoonoses Report), in England and Wales. 
Year 2007 2008 2009 2010 2011 2012 2013 2014 2015 Mean Ratio 
THIN 
Incidence 
3.62 3.91 4.07 3.96 3.52 3.62 4.02 2.93 4.64 N/A 
HES 
Incidence 
0.20 0.23 0.27 0.26 0.27 0.33 0.35 0.43 0.44 N/A 
Zoonoses 
Report 
Incidence 
1.47 1.48 1.56 1.62 1.71 1.84 1.64 1.49 1.83 N/A 
HES:Zoo 
Ratio 
0.14 0.16 0.17 0.16 0.16 0.18 0.21 0.29 0.24 0.19 
(0.09-0.29) 
THIN:Zoo 
Ratio 
2.46 2.64 2.61 2.44 2.06 1.97 2.45 1.97 2.54 2.35 
(1.81-2.88) 
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There was no significant interaction in the relationships of incidence to year for the Zoonoses 
Report (β=0.03), nor HES (β=0.03), nor THIN dataset (β=0.01); F(2,21)=0.08, p=0.93. The 
Fisher’s R-to-z comparison indicated that there was no significant difference (p=0.1) of the 
Pearson correlation for the Zoonoses Report (r=0.59), and the THIN data (r=0.07). However, 
there was a significant difference (p<0.01) for the Zoonoses Report (r=0.59), and the HES 
data (r=0.96) (Fig.9.11). 
 
Figure 9.11 The incidence of laboratory-confirmed, hospital admissions and primary care diagnosed cases of 
Lyme disease in the England and Wales, with associated linear regression lines and 95% confidence intervals; 
2007-2015. 
Time series decomposition of the 2013-2015 English monthly incidence data for RIPL, HES, 
and THIN, provided in three decomposed components; seasonal, trend and random 
components. The data transformation, described above in section 9.23, minimised 
differences in magnitude and enabled visual and formal comparisons, using Euclidean 
distance and DTW distance. The raw monthly incidence and transformed incidence data 
were visually compared (Fig. 9.12). 
Zoonoses Report 
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Figure 9.12 The monthly incidence of Lyme disease cases in three health datasets, and below the post-
magnitude transformation of the datasets 
This shows that the method of transformation was able to reduce the differences in 
magnitude, without compromising the relative shapes of each dataset’s time series. 
Seasonality was already apparent prior to decomposition, with peaks in all three datasets 
during the summer months.  
The trend component of each dataset time series comparison (Fig. 9.13), had an Euclidean 
distance between RIPL and HES of 0.10, and a DTW distance of 0.55, and an Euclidean 
distance between RIPL and THIN of 0.09, and a DTW distance of 0.46. 
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Figure 9.13 Trend component of the decomposed time series analysis of Lyme disease health datasets relating 
to laboratory-confirmed cases, hospital admissions and primary care; 2013-2015 
Overall all three datasets show an increasing trend over the study period. The Euclidean 
distances between datasets was similar, however, the DTW distance is quite different. 
Visually RIPL, THIN and HES share a similar wave shape but with differences in lag and 
amplitude of the wave. From July 2015 onwards, all datasets showed an almost identical 
trend.  
To explore the impact of trend on the time series, trend was removed from the overall time 
series leaving a component made up of the seasonal and random time series components 
(Fig. 9.14). 
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Figure 9.14 The combined seasonal and random time series components of three healthcare datasets for Lyme 
disease. 
By eliminating the trend component from the time series, the seasonality of the datasets 
appear to match each other more closely than before and follow a similar pattern each year. 
This indicates that the overall trend has only a small impact on the monthly incidence of 
Lyme disease. 
The seasonal component displayed similar distributions and similar distances (Fig. 9.15). The 
Euclidean distance between RIPL and HES was 0.24, and the DTW distance was 1.32, and the 
Euclidean distance between RIPL and THIN was 0.26, and the DTW distance of 1.08. 
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Figure 9.15 The repeated seasonal component of the decomposed time series analysis of Lyme disease health 
datasets relating to laboratory-confirmed cases, hospital admissions and primary care; 2013-2015 
The seasonality seen indicates that cases tend to peak in the THIN dataset in July, followed 
by hospital admissions and laboratory-confirmed cases in August.  
The random component of each dataset’s time series comparison (Fig. 9.16) had an 
Euclidean distance between RIPL and HES of 0.16, and a DTW distance of 0.73, and an 
Euclidean distance between RIPL and THIN of 0.14, and a DTW distance of 0.73. 
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Figure 9.16 Random component of the decomposed time series analysis of Lyme disease health datasets 
relating to laboratory-confirmed cases, hospital admissions and primary care; 2013-2015 
The similarity in distances, both for Euclidean distance and DTW, between the datasets show 
that they have comparable random components of their time series. The ADF test for the 
RIPL dataset, showed that the random component was not stationary (Dickey-Fuller test 
statistic=-2.22, p=0.49). The ADF test for the HES dataset, showed that the random 
component was not stationary (Dickey-Fuller test statistic=-2.80, p=0.26). The ADF test for 
the THIN dataset, showed that the random component was not stationary (Dickey-Fuller test 
statistic=-3.27, p=0.09).     
The percentage of cases, out of the all aggregated years, occurring in each month for each 
dataset was described (Fig. 9.17) 
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Figure 9.17 The percent of Lyme disease cases within each dataset by month 
For all the datasets described, the months with the highest percentage of cases were in the 
summer. SAVSNET in June, THIN in July, and RIPL, HES, and Twitter in August. The lowest 
percentages were in winter and spring, Twitter in December, SAVSNET in January, HES in 
February, THIN in March, and RIPL in April. 
9.3.4 Results – Data completeness 
The completeness of the main variables under analysis for each dataset was calculated, with 
an overall completeness score calculated (Table 9.4). 
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Table 9.4 Summary table and heatmap of the degree of completeness of variables analysed in various Lyme 
disease health datasets. 
Completeness  
Variable 
RIPL HES THIN 
(England and 
Wales) 
Twitter: 
Original 
Tweets Only 
SAVSNET 
Number of records 3,986 2,361 2,220 13,757 2,180 
Date 98.7% 
(3,935) 
100% 
(2,361) 
100% (2,220) 100% 
(13,757) 
100% 
(2,180) 
Sex 98.7% 
(3,935) 
70.9% 
(1,673) 
100% (2,220) N/A N/A 
Age 98.7% 
(3,935) 
70.9% 
(1,673) 
100% (2,220) N/A N/A 
Postcode area/ Local 
Authority 
58.3% 
(2,321) 
88.0% 
(2,078) 
N/A 52.0% (2,709) 100% 
(2,180) 
Deprivation 56.6% 
(2,257) 
96.5% 
(2,278) 
94.5% 
(2,106) 
N/A N/A 
Ethnicity N/A 79.5% 
(1,877) 
24.3% (540) N/A N/A 
Rural Urban Status 56.6% 
(2,257) 
97.1% 
(2,292) 
93.4% 
(2,073) 
N/A N/A 
Overall (An average 
of the above scores) 
66.8% 86.1% 73.2% 76.0% 100% 
 
There is a range in completeness between the datasets. RIPL is the least complete (66.8%), 
whilst SAVSNET is the most complete (100%). HES is the only dataset that contains 
information on all variables of interest and has a completeness of 86.1%. The variable with 
the poorest completeness is ethnicity in the THIN dataset (24.3%). 
9.4 Discussion 
This chapter has compared all the datasets analysed in this thesis using the variables of 
demographics, geography, time and dataset completeness. The closest similarities were 
between RIPL and HES, and RIPL and THIN. It is likely that these three datasets represent the 
same diseased population, which are interacting with different levels of the National Health 
Service. This offers scope for these datasets to be utilised within any future surveillance 
systems. Each of the variables compared will now be discussed in more depth, and their 
potential utilisation within surveillance systems will be explored in Chapter 10. 
9.4.4 Discussion – Demographics 
The general age distribution for Lyme disease cases, regardless of surveillance system, differs 
from that of the general population. It is likely to be a bimodal distribution with peaks in 
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cases seen in preteens and retirement age. The reasons for the overall differences in sex 
ratio are unknown, and have been discussed in Chapters 3-5, but may be due to differences 
in health seeking behaviour dependent on disease presentation. 
There were only two age groups where all the datasets concur in terms of the direction of 
the sex ratio. Firstly, there were more cases seen in preteen boys than girls. This may suggest 
a different exposure risk for boys. The underpinning reasons for this need further exploration 
but could be due to differences in play activities or attitudes and awareness of a tick bite. 
Secondly, in early adulthood there were more cases in women than men. The reasons for 
this are unknown, and could include differences in health care seeking behaviour, health care 
prejudices, and unknown sex specific risk factors. All datasets also share a sudden change in 
ratio in geriatrics to being predominately female. This is likely, at least in part, a reflection of 
the national population becoming predominately female in this age group. Causal 
associations cannot be drawn from the current data and should be explored in future 
research. 
The datasets providing information about ethnicity, deprivation, and rural status, all agree in 
their findings that Lyme disease patients were more likely to identify with being white and 
from areas with the least amount of deprivation, which were rural. 
Limitations and Conclusions: 
One of the limitations of the demographic data is that none of the datasets have been linked, 
the degree of overlap between them is unknown. However, the datasets will invariably 
overlap and the proportion of cases found in multiple datasets may cause bias in the 
conclusions drawn from each individual dataset. This could be resolved through the analysis 
of linked datasets, resulting in a more accurate understanding of the affected population. 
Secondly, most of the demographic variables were studied univariably, due to the structure 
of the databases under analysis. It is likely that these variables confound and interact with 
each other, and a study enabling multivariable analysis is needed.  
In this chapter, it has been assumed that each dataset has referred specifically to sex rather 
than gender. In fact, RIPL collects information on gender, whilst HES and THIN collect 
information on sex. As gender is decided through self-identification, there could be bias in 
the results and conclusions, as the gender of a patient may differ from the biological sex of 
a patient. There is the potential that the differences that were seen between RIPL and the 
172 
 
other datasets were a result of this bias rather than differences in any of the reasons 
discussed above.  
Ethnicity data in the THIN dataset proves a challenge, due to the high level of missing data. 
Here, it has been assumed that the findings described in Chapter 5 are true, using ethnicity 
data from HES to help justify this. However, this may be a false assumption. There are 
significant challenges with obtaining ethnicity data in primary care [208,320], and until these 
are resolved the interpretation of any findings related to ethnicity in primary care must be 
treated with a degree of caution. This in turn could lead to issues with targeting public health 
messaging, with the wrong demographics being targeted. 
In conclusion, all the three main datasets were different to the national population in terms 
of age and sex structure, ethnicity, rural-urban status, and measures of deprivation. Overall, 
these datasets are likely to be representative of the same diseased population accessing 
differing parts of the health care system. 
9.4.3 Discussion – Spatial comparison 
The spatial distribution of hospital admission cases was significantly similar to laboratory-
confirmed cases of Lyme disease, both sharing positive spatial autocorrelation. The bivariate 
LISA plot identified areas with significant concordant and discordant clusters of incidence. 
The high-high clusters were all in southern to south-western England, highly suggestive of 
these being true hotspots of high disease incidence in England and Wales. The reverse of this 
is also true, that areas with low-low clusters are likely to represent areas with significantly 
low levels of Lyme disease. 
The local authorities with discordant clusters with a high incidence in RIPL and low incidence 
in HES, could represent regions where diagnostic samples were received from cases 
managed within primary care without being admitted to hospital. This could be especially 
true in Wales, where there is a dispersed rural population and very few hospitals. It is 
possible that in these regions’ cases were predominantly managed in primary care. The low 
incidence in RIPL, and high in HES, could be a result of doctors in primary care being aware 
of Lyme disease and confidently treating erythema migrans presentations, without taking 
diagnostic samples and sending them onwards to RIPL. This could result in a higher incidence 
of more serious cases being admitted into hospitals.  
The ideas explaining these discordant areas are only hypotheses, and the underlying reasons 
for discordance remain unknown. Geographical data, at the same resolution, from primary 
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care would help identify areas with true discordance. Qualitative research to explore how 
patients with Lyme disease access health care, and how they are managed within the NHS, 
may provide reasons for these disparities. This type of research would need to take place 
over multiple geographies to ensure it was representative of the clusters, outliers, and areas 
with a non-significant background distribution. 
The SAVSNET data did not show significant spatial concordance with RIPL data. There are at 
least a few potential reasons why this may have occurred. Firstly, the location of where there 
is a high presence of ticks on companion animals may not be associated with high Lyme 
disease incidence. This could be related to the prevalence of Borrelia burgdorferi within 
these tick populations. SAVSNET may have captured tick populations with a low prevalence, 
and so reflect tick populations that pose a limited Lyme disease risk to humans. It would be 
interesting to see whether SAVSNET’s spatial distribution is concordant with PHE’s Tick 
Surveillance Scheme, or whether a spatial distribution of within-tick Lyme prevalence is 
concordant with the RIPL dataset. Missing data is however likely to explain the differences 
better. There were many local authorities with no data about ticks on companion animals. 
This is most likely to be due to under-reporting, as discussed in Chapter 8, rather than a 
genuine lack of ticks. The time period under analysis only represents two years’ worth of 
data, and the volume of data on ticks may not be large enough for SAVSNET to reflect the 
distribution of ticks. Currently, SAVSNET cannot be recommended as a surrogate surveillance 
system to produce risk maps in relation to ticks and Lyme disease. However, SAVSNET should 
be reassessed once there is a larger volume of data, as its potential to be part of a national 
tick and tick-borne disease surveillance system is large.  
For a discussion about the significant concordance between RIPL and Twitter data please 
refer to Chapter 7. As an aside, due to one paper based on data from the 1990s [154], 
Thetford Forest and the Lake District have persisted as ‘known’ hotspots of Lyme disease 
[12], and are regularly mentioned in press releases about Lyme disease. None of the data 
presented in this thesis support these areas as hot spots. In no dataset do these areas appear 
as areas with a high incidence of Lyme disease. There is the possibility that the main cases 
originating in these areas are visitors to them, however one would still expect a higher base-
line incidence in the local population compared to surrounding areas. Unless cases are only 
captured within primary care records, then the current narrative needs to change to highlight 
that the areas with the highest incidence are all in southern England.  
Limitations 
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There are three main limitations of the geographical data assessed. Firstly, data for Northern 
Ireland and Scotland were either unavailable or have not been published. This will prove a 
challenge for any future public health interventions or strategic planning regarding Lyme 
disease in these nations. Scotland, in particular, has a more pressing need for this data as the 
incidence of Lyme disease in primary care (Chapter 5) is much higher than the other UK 
nations. Previous research suggests that the incidence of disease is not uniformly distributed 
across Scotland, with the Highlands and Western Isles having the highest laboratory 
incidence[76] and highest prevalence in blood donors [47]. Published Scottish geographic 
incidence data is needed with high granularity to ensure that public health resources are 
targeted in the most appropriate way. 
Secondly, with the datasets that show significant spatial correlation (RIPL, HES and Twitter), 
the geographical location is based upon the patients’ or users’ home address. These data 
were therefore acting as proxies. This has been a consistent theme with the geographical 
data throughout this thesis, and it does lead to a conservative bias in exposure-response 
relationships relating to ecological fallacy. However, this is only true if one is trying to 
understand the riskiest area in terms of tick bite exposure. When looking at burden to the 
National Health Service, patient postcode is highly valuable information, as the maps 
produced throughout this thesis will show which localities potentially have the highest 
number of patients accessing their health services in relation to Lyme disease. This is 
important in terms of public health resource allocation, and highlights locations where future 
research could be conducted.  
Finally, there is a lack of geolocation data for primary care Lyme disease cases. In absolute 
numbers, primary care has the largest diseased patient population, and understanding 
where they reside is important for any successful public health management and 
interventions. Currently no primary care database available to PHE provides access to 
geographical data other than at country level. If these resources are to be used for disease 
surveillance in the future, then the unavailability of geographical data needs to be overcome. 
Information should be provided at least at local authority level, and ethical measures can be 
put in place to ensure that no issues occur relating to patient identification due to small 
numbers. 
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Conclusions 
Hospital admissions data and Twitter data have a strong spatial agreement with laboratory-
confirmed cases of Lyme disease in England and Wales. As such, they offer potential as an 
additional geographical surveillance resource. However, hospital admissions data 
consistently have an incidence over five times lower than the incidence of laboratory-
confirmed cases. Despite showing strong spatial agreement, it does not make sense to base 
a geographical surveillance tool on a dataset that captures less data than another. This makes 
HES potentially redundant for geographical surveillance. Twitter on the other hand, despite 
its limitations, offers some interesting potential as an adjunct surveillance tool (Chapter 7). 
In particular, its ability to identify people tweeting about Lyme disease in near-real time could 
be used to locate hot spots of activity. Its surveillance potential needs to be explored further 
to test its capability. These include its ability to measure levels of public concern about 
disease, or their appreciation and knowledge about the risk of ticks and their bites. 
In conclusion, until primary care data are released that provide higher resolution 
geographical data, RIPL should remain the primary resource for geographic surveillance of 
Lyme disease in England and Wales.  
9.4.3 Discussion – Temporal comparison 
The comparison of UK national Lyme disease incidence trends between the Zoonoses Report 
and THIN datasets from 2007 and 2016 in the UK show a significantly similar trend in terms 
of the degree and variability of the increase. This suggests that primary care data reflects the 
temporal trends seen in laboratory-confirmed cases at a national scale. By calculating an 
average ratio of incidence between the two datasets, further information on the stability of 
the multiplication factor between the two can be gained (Table 9.2). The overall ratio of 
incidence between the THIN dataset and that in the Zoonoses Report was 2.91 (95% CI: 2.20-
3.62). 
The English and Welsh national trend for increasing Lyme disease incidence was seen in the 
Zoonoses Report, HES, and THIN datasets from 2007 to 2015. They were significantly similar 
in terms of the degree of increase. The variability in the increase was similar between the 
Zoonoses Report and THIN, however there is a significant difference between the Zoonoses 
Report and HES. The increased variability in HES may be due to the impact of the small case 
numbers on relative incidence figures; HES has the lowest incidence of all the datasets. This 
suggests that primary care data is more representative of Lyme disease in the community 
than hospital data in terms of temporal trends seen in laboratory-confirmed cases at a 
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national scale. By calculating an average ratio of incidence between each dataset, further 
information on the stability of the multiplication factor between them can be gained (Table 
9.3). This resulted in an incidence ratio of 0.19 (95% CI: 0.09-0.29) between the incidence in 
the HES dataset and that in the Zoonoses Report. The incidence ratio between the THIN 
dataset and the Zoonoses Report was 2.35 (95% CI: 1.81-2.88). 
Exploratory time series analysis of the RIPL, HES and THIN datasets provided some interesting 
insight. The similarity in distances, both for Euclidean distance and DTW, between the 
seasonal decomposition of each datasets time series show that they have comparable 
seasonality (Figs. 9.14 and 9.15). The most interesting element displayed is the consistent lag 
in peak month between datasets across the three years. Incidence peaks first in primary care 
(THIN) during July, followed by HES and RIPL in August. This makes sense both in terms of 
the clinical progression of Lyme disease and patient management pathways within the NHS. 
Clinical signs of early localised infection, classically erythema migrans with associated flu-like 
symptoms or borrelial lymphocytoma [21,23], occur within days to weeks after a tick bite. 
These presentations would probably not be severe enough to warrant a visit to a hospital 
and cases are likely to be dealt with in primary care. Weeks to months after a tick bite 
infection has disseminated and presents as Lyme neuroborreliosis or carditis. These 
presentations are more severe and are likely to be admitted at hospitals. The late 
dissemination of arthritis or ACA, are likely to present months to years after a tick bite and 
will present at any time of year. Although it cannot be confirmed in this study, it is likely that 
the THIN peak in July mainly represents acute EM rashes, whilst the HES admissions 
represents more complex/serious presentations. Serological testing is only recommended 
for non-EM presentations, and samples should be taken four to six weeks after onset of 
symptoms [23]. Thus, if cases are predominately presenting in July, since a diagnostic sample 
is recommended to be taken at least four weeks after symptom onset [23], samples would 
arrive at RIPL four weeks later in August. It is remarkable how closely the data matches this 
hypothesis. To explore this further, clinical presentation needs to be explored in different 
health datasets and their seasonal incidence described.  
The trend components of the time series analysis were not as obviously similar as the 
seasonal components. In 2014, RIPL and THIN, but not HES, showed a dramatic decrease in 
annual incidence. This is likely to be driving the wave-like shape in the trend component of 
the time series. The fact that THIN data closely mirrors RIPL data, and has a smaller DTW 
distance, is indicative that it is likely to be representative of the trends shown in RIPL. The 
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data compared consists of only three years’ worth of data, and it is likely that if more 
temporal data were provided then one could understand the degree of annual fluctuations 
in trend. It would show whether this is a standard feature of the trend component of Lyme 
disease time series in England and Wales.  
The random component of the time series analysis showed similar Euclidean and DTW 
distances between the datasets, yet, all were non-stationary. This suggests that the datasets 
were alike but each having other underlying trends explaining the patterns of the random 
components of the time series. It was beyond the scope of this thesis to delve further into 
this analysis. However, if these data were to be used for forecasting purposes any further 
underlying trends need to be understood and described. Overall, it visually appears that the 
seasonal data is the main component of each of the time series, and the relative importance 
of the non-stationary random component of the time series currently remains unknown.  
The summary of the proportion of monthly cases is a crude method as it ignores the 
differences between years and any overall trends. The twitter data represents only 12 
months split between six months of two separate years. However, strong seasonality is seen 
again, with each dataset peaking between June and August. SAVSNET, representing tick 
activity peaks first in June, followed by THIN in July, and HES and RIPL peak in August. This 
appears to sequentially show the progression of disease presentation and NHS patient 
management, with the added peak of tick exposure a month before cases present in primary 
care. The Twitter dataset is probably too limited, in terms of number of years of data, to 
draw conclusions other than that mentions of Lyme disease on social media in the UK and 
Ireland peak in summer months. These trends reflect those already described within the 
timeseries analysis. SAVSNET data has the potential to accurately describe peak tick activity, 
which could be utilised to predict the peaks of Lyme disease cases annually. Further work is 
needed to explore this potential. 
Conclusions: 
The seasonality of all the datasets is striking, particularly as they peak sequentially in the 
summer months. First, the presence of ticks on companion animals (a proxy for tick numbers 
in the wild, and potentially for tick bites) peak in June, then cases in primary care peak in 
July, followed by hospital admissions and laboratory-confirmed cases peak in August. This 
displays the progression of disease and care pathways of an individual bitten by an infected 
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tick. The sequential series of peaks could be utilised to predict when differing sections of the 
health system will see the highest burden of Lyme disease cases each year. 
The incidence of Lyme disease coded cases in primary care electronic health records are 
reflective of laboratory-confirmed cases, used for current surveillance figures. At a UK level 
there is a stable multiplication factor of 2.91 (95% CI: 2.20-3.62) converting laboratory-
confirmed incidence to the UK incidence of Lyme disease in primary care, in England and 
Wales this is 2.35 (95% CI: 1.81-2.88). English and Welsh hospital admission records were 
less representative as they have larger relative differences in variability compared to 
laboratory records. The multiplication factor, converting laboratory incidence to hospital 
admissions incidence, is 0.18 (95% CI: 0.09-0.29) (Fig. 9.18).  
 
Primary care Lyme disease coded cases are the most similar to laboratory-confirmed cases 
in terms of annual and seasonal incidence. This is reflected in the narrow confidence intervals 
of the multiplication factor calculated between the two. Using this multiplication factor, one 
could estimate the incidence of Lyme disease activity (as currently THIN captures non-
validated cases of Lyme disease) by applying the multiplication factor to RIPL. This process 
 
Laboratory-confirmed Lyme disease 
incidence: 
1.63 (1.35-1.95) 
Lyme disease coded 
incidence in Primary Care: 
3.81 (2.89-4.73) 
Hospital admissions 
Lyme disease incidence: 
0.31 (0.14-0.48) 
MF: 2.35 
(1.81-2.88) 
MF: 0.19 
(0.09-0.29) 
MF not relevant here 
Figure 9.18 The average annual incidence (cases per 100,000) of each health dataset for England and Wales (the 
size of circle is proportional to incidence), and the multiplication factor (MF) between each. Blue = THIN (primary 
care), Red = RIPL (laboratory), and Green = HES (hospital admissions). 
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could also be used to estimate the number of hospital admissions; however, this would be 
less reliable than the THIN multiplication factor due to the relatively larger confidence 
intervals. If these multiplication factors are routinely assessed for their stability, they could 
provide a low-cost addition to the existing surveillance system and provide PHE with robust 
evidence-based annual estimates of Lyme disease for England and Wales. 
9.4.4 Discussion – Completeness 
For each dataset over half of the records were complete for all the variables captured, except 
ethnicity in THIN where less than 25% of records were complete. Twitter and SAVSNET 
provide complete temporal data. SAVSNET has excellent spatial data, whilst Twitter is less 
complete. Since both are proxy datasets and provide no information about the Lyme disease 
patient population, they will not be discussed further in terms of completeness. Out of the 
human health datasets, HES performs the best for completeness, with all variables having 
more than 70% of completeness. It is also the only dataset that contains data on all measured 
variables. THIN performs the next best, and 100% of records are complete in terms of 
baseline demographic information. However, it has two significant issues. The ethnicity data 
were highly incomplete, and no high resolution geographical data were present. These issues 
have been discussed previously in Chapter 5. The poorest performing health dataset is the 
RIPL dataset. As discussed in Chapter 3, RIPL are entirely reliant on the referring hospital 
laboratory to provide all relevant data. As these results indicate, this is currently far from 
optimal. The poor completeness scores are predominately a reflection of deprivation and 
rural status data being linked to provided patient postcode data. The majority of cases do 
have a postcode provided, but greater completeness would lead to greater confidence in any 
geographical conclusions drawn. The RIPL dataset does not collect any ethnicity data, how 
important this is currently unknown. This could be easily rectified by the addition of an 
ethnicity question to PHE’s Lyme disease test request form [158].  
Basing the selection of a dataset for surveillance purposes solely on data completeness 
wrongly assumes that completeness is related to data quality, data accuracy and the degree 
of representativeness of the Lyme disease population. Instead this information should be 
used to assist in identifying which datasets provide data on certain variables, and the degree 
to which they could be explored with confidence. 
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9.5 Summary and conclusions 
In this chapter, comparisons have been performed between the datasets described in this 
thesis in terms of agreement and completeness about several demographic, temporal and 
spatial variables (Table 9.5).  
Table 9.5 Summary table of datasets evaluated in this thesis (* represents a significant difference (p<0.05) 
between either the specified reference population or the national population, except in the Global Moran’s I 
category where it represents a significant spatial agreement; NS not significant) 
Variables Datasets 
RIPL  HES THIN Twitter SAVSNET 
Temporal 
Comparison 
Slope 0.03 
Ref 
0.03NS 0.01NS N/A N/A 
 Pearson 
Correlation 
0.59 
Ref 
0.96* 0.07NS N/A N/A 
Peak month of cases Aug Aug Jul Aug Jun 
Multiplication factor Ref 0.18  
(95% CI: 
0.09-0.29) 
2.35 
(95% CI: 
1.81-2.88) 
N/A N/A 
Spatial  Global 
Moran’s I 
Ref 0.47* N/A 0.17* 0.05 NS 
Demographic 
factors  
Sex Ratio 1.14 
Ref 
0.66* 0.84* N/A N/A 
 Index of 
Multiple 
Deprivation 
Number of cases increase as the 
level of societal deprivation 
improves* 
N/A N/A 
 Ethnicity N/A 96% 
white* 
94% 
white* 
N/A N/A 
 Rural-urban 
status 
More rural than the national 
population* 
  
Completeness  66.8% 86.1% 73.2% 76.0% 100% 
 
In Chapter 2, a surveillance pyramid was constructed to aid in the identification of potential 
datasets capturing Lyme disease (Fig. 2.1). The comparisons of incidence have highlighted, 
that if following the traditional structure, the tiers of the datasets are in the wrong order. 
The datasets with the lowest incidence were the hospital datasets and should in theory be 
placed on top of the pyramid, followed by laboratory data then primary care data. This, 
however, ignores the underlying fact that cases could occur in multiple datasets and are not 
unique to a single tier of the surveillance pyramid. One could conclude that a surveillance 
pyramid is potentially a poor model for Lyme disease surveillance. In reality it is better 
represented by a Venn diagram-like structure, similar to that proposed in the IID2 study 
[121]. However, such a diagram cannot be constructed in this study, as the degree of overlap 
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between the Lyme disease datasets remains unknown. At best the data can be summarised 
as in Fig. 9.18 and it can be acknowledged that the proportion of patients found in each 
dataset is currently unknown. Future research on Lyme disease needs to be able to quantify 
this overlap so more accurate estimates of disease incidence can be calculated. 
Regarding specific datasets, Twitter and SAVSNET have both offered potential for Lyme 
disease proxy or sentinel surveillance. However, temporal data was not long enough to allow 
comparison to current incidence surveillance data, and only Twitter showed significant 
spatial agreement with current incidence surveillance data. No meaningful data were 
available regarding case demographics. Both approaches offer exciting avenues for future 
research, but they do not offer data that is comparable to the existing surveillance system 
across many variables. As such, they have been excluded from further discussion.   
The remaining datasets (RIPL, HES and THIN) are comparable across multiple variables, 
including time, geography and demographics. They appear to be representative of the same 
diseased population, although the degree of overlap between the datasets is unknown as 
data linkage was not possible. In comparison to the current surveillance system (RIPL) HES 
additionally captures ethnicity data and is comparable except for sex ratio and variability in 
incidence trends. Despite these facts, and its high degree of completeness, there are some 
concerns about using it as a surveillance system. The dataset represents the smallest 
proportion of Lyme disease cases, and without further assessment of the clinical records of 
the patients it is difficult to know the validity of the ICD-10 codes used to define cases. There 
is potentially a large overlap of cases with the RIPL dataset, as late disseminated or 
complicated cases of Lyme disease admitted to hospitals are nearly all likely to receive 
diagnostic investigation, which would result in samples being sent to RIPL. 
The THIN dataset also captures ethnicity, though poorly, and is comparable to RIPL data 
except for the sex ratio. It has the largest representation of Lyme disease cases. One of its 
flaws as a potential surveillance system is the unavailability of geographical resolution. 
Validation of Lyme disease Read codes and coding behaviour of GPs in primary care need to 
be further explored (as discussed in Chapter 6) to provide higher levels of confidence in the 
data. This dataset is also likely to capture cases that do not appear in the other databases, 
specifically cases presenting with erythema migrans and receiving a clinical diagnosis, and 
thus may describe a wider diseased population.  
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It must be remembered that only RIPL data is currently performing as a surveillance system. 
The work presented in this thesis are observational studies, and do not formally test or 
evaluate the datasets as potential surveillance systems. Before any policy changes take place, 
formal trial and evaluation work is needed to check that the assumptions made, and 
conclusions drawn in this thesis are correct. Taking these factors all in to account, primary 
care activity data offers the greatest potential as a new or adjunct surveillance system for 
Lyme disease in England and Wales.  
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Chapter 10 Discussion 
10.1 What this thesis adds to the knowledge base 
In this thesis I have used a mixture of routine health data, and novel datasets, to provide new 
insights in to the current epidemiological situation of Lyme disease in the UK. The 
populations of Lyme disease cases that can be found in English government laboratory data, 
English and Welsh hospitals, and UK primary care, were described. A new mixed methods 
technique was described to validate the diagnostic codes (Read codes) used to identify Lyme 
disease in primary care. Twitter and a companion animal electronic health record system 
(SAVSNET) were evaluated as adjunctive surveillance tools for Lyme disease. By drawing 
comparisons between all these datasets, new options for Lyme disease surveillance were 
identified.  
In the routine health data studies (laboratory, HES and primary care) that make up this thesis 
several novel findings were identified. They all show a significant increase in Lyme disease 
incidence across their respective study periods. Notably, as discussed in Chapter 9, the 
described incidence was increasing at the same rate across various health care settings. This 
shows that each tier of the NHS is seeing a similar increasing rate of new Lyme disease cases. 
Whether this increase is due to a real increase in cases, increased public and/or physician 
awareness, or a mixture of the two was outside the scope of this thesis and should be the 
focus of further research. 
The populations affected by Lyme disease showed similar bimodal age distributions, peaking 
in preteens and around retirement age. This distribution was significantly different to the 
national population structure in England and Wales. This reflects other Lyme disease 
populations described in Europe [67,176,177,180], and suggests that exposure behaviour to 
Borrelia spp carrying ticks is similar across Europe. However, there were differences between 
the sex ratio of these populations across datasets. Reasons for this are unknown but could 
be due to differences in accessing the differing tiers of healthcare, healthcare prejudices, or 
different risk exposure behaviours. Ethnicity data was limited but suggest that the population 
affected by Lyme disease is not diverse, and predominately of a white ethnicity.  
This is the first UK based research to have explored trends in socioeconomic deprivation in 
relation to Lyme disease. All datasets showed similar trends, with the primary care data 
displaying the most compelling evidence that the incidence of Lyme disease-related 
diagnosis is highest in areas with the least deprivation. The reasons for this are likely to be 
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multifactorial and need to be explored through future research. This is critical as any public 
health interventions need to be targeted towards the appropriate population. 
This is the first time that spatial Lyme disease data has been produced for England and Wales 
at a high geographical resolution. Several datasets identified the south and south-west of 
England as the main areas with a high incidence of Lyme disease. Interestingly, previously 
recorded hotspots of disease, Thetford Forest and the Lake District [154], were not identified 
in any of the datasets evaluated. These data will be useful to local authority public health 
teams for targeting disease awareness and intervention strategies. They also provide 
locations where researchers interested in Lyme disease epidemiology, at a local level, can 
focus their efforts. 
A novel approach to validate diagnostic codes, Read codes, was developed for use in primary 
care electronic health records. Traditionally Read codes are validated through expensive and 
time-consuming methods, which may not provide additional insight in to coding behaviour. 
By conducting mixed-methods interviews with GPs, the validity of specific Lyme disease Read 
codes was described, and the thought processes used in the selection of a code explored. 
Themes (Chapter 6) were identified that describe the decision making behaviour for code 
selection in primary care. This highlighted that the conscious and unconscious behaviour 
driving coding is not solely limited to clinical acumen and awareness but is intertwined with 
personal experience and the national political landscape. The results suggested that the 
incidence described is likely to be an underestimate of the true incidence of Lyme disease in 
primary care. These findings are crucial for understanding the patient-doctor dynamic in 
primary care, which is incredibly important for such a highly politicised disease as Lyme 
disease. The research will hopefully provide a platform for further qualitative research on 
Lyme disease and coding behaviour in general. 
The remaining datasets analysed did not contain routinely collected human health data. One 
set of data was collected from a social media platform, Twitter, and the other was routinely 
collected companion animal health data, SAVSNET. As far as the author is aware, this is the 
first time that Twitter data for an infectious disease has been explored to this degree of 
geographical resolution. The data showed significant spatial concordance with that of 
national surveillance data for England and Wales. This highlights that Twitter has the 
potential to be utilised in a surveillance system and to identify locales with the greatest 
related social media activity. The data needs to be further assessed to see whether this 
activity is related to disease concerns, health promotion, or individuals discussing their own 
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cases. SAVSNET has the potential to produce temporal and spatial figures for tick activity in 
the UK. Currently the data is spatially sparse and is not concordant with known areas of high 
Lyme disease incidence. Once further data is collected using this surveillance system it could 
play an important role in the surveillance of both ticks and tick-borne diseases. 
One of the most important findings from this thesis has been the derivation of a 
multiplication factor that can be applied to laboratory surveillance figures to give a national 
estimate of Lyme disease incidence within primary care. This gives public health 
organisations better evidence of the potential burden that Lyme disease has at a national 
level, and on an annual basis. This multiplication factor has the potential to be a low-cost, 
easily implementable tool that can be used within the current Lyme disease surveillance 
framework. There is scope for further validation of this factor to identify whether it can be 
used at a local level and calculating its degree of stability over time.  
This thesis has produced new epidemiological data that was specifically requested by both 
the NICE guidelines [23] and EPPI recommendations [9,22,72–74]. It enables future 
researchers and policy makers to inform their planning and decision-making within a more 
evidence-based context. 
10.2 Lyme disease surveillance policy options 
To place the findings of this thesis into a surveillance framework, one must identify how 
these datasets could be implemented practically through national surveillance programmes. 
In Chapter 1, several Lyme disease surveillance policy options were presented; created by 
the EPPI on behalf of the Department of Health and Social Care (DHSC) [9]. These options 
will now be addressed, based upon the thesis findings, and a proposed surveillance strategy 
will be proposed. 
10.2.1 Maintain the existing system with no change 
The current surveillance system for England and Wales is based on laboratory-confirmed 
cases identified by RIPL and published in the Zoonoses Report. This is the easiest strategy to 
follow, both in terms of cost and management. As discussed in multiple chapters, this system 
is likely to underestimate the incidence of Lyme disease. This thesis has described 
multiplication factors that can be applied to the RIPL dataset to estimate the incidence of 
Lyme disease coded patients in primary care, and the incidence of Lyme disease related 
hospital admission (Fig 9.18). 
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These could provide a simple methodology for estimating the national incidence of Lyme 
disease, and would enable PHE to issue, with relative confidence, statements such as ‘for 
each laboratory-confirmed Lyme disease case, two may be seen in primary care’. Further 
assessment of these multiplication factors is needed to test their robustness over time.  
As a tertiary reference laboratory, RIPL currently lacks case ethnicity reporting, and 
geographical reporting of cases is incomplete. If this policy option is chosen, then these two 
issues need to be addressed. Further confusing the situation is the potentially missed 
laboratory-diagnosed cases that could either appear in SGSS or private laboratory databases 
(chapter 3). This needs to be rectified.  
There are two potential solutions. Firstly, to legislate Borrelia burgdorferi as a notifiable 
causative organism (instead of Borrelia spp) through the 2010 Health Protection 
(Notification) Regulations [77]. In theory, all laboratory-confirmed cases of Lyme disease 
would then be captured through SGSS. This would have the additional benefit of the 
collection of ethnicity and case home address data, as they are mandatory information to be 
provided in SGSS. Therefore, more complete demographic information would be collected. 
However, as discussed in chapter 3, 91.6% of all Borrelia spp reports in SGSS were already 
classified as Borrelia burgdorferi, so it could be questioned whether such a change in 
legislation would have any significant impact. It is likely that the inconsistencies between 
SGSS and RIPL would remain. An audit of the Lyme disease tests performed by referring 
laboratories, and which results they report to SGSS, would help to highlight some of the 
reasons for the differences. Until there are no discrepancies between the RIPL and SGSS data, 
national surveillance figures should continue to be based on RIPL data. 
Secondly, PHE could recommend that all confirmatory Lyme disease testing is performed 
solely at RIPL. This would ensure that RIPL captures as many laboratory-confirmed cases as 
possible. A stricter version of this policy has been recently adopted by Health Protection 
Scotland (HPS), who have stated,  
‘Following this [sic 1st October 2018], all diagnostic laboratories [in NHS 
Scotland] will submit samples to the Reference Laboratory [Scottish Reference 
Laboratory for Lyme Disease and Tick-borne Infections, Inverness] for screening 
and confirmation, and will result in more complete data on laboratory confirmed 
cases. [321]’ 
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Therefore, all suspect Lyme disease diagnostic samples in NHS Scotland will be sent directly 
to the reference laboratory, and HPS surveillance figures will contain limited missing 
laboratory data. Routes for diagnostic testing are not as explicitly described for England 
[322], and refer to protocols within the NICE guidelines [23]. Requesting that all diagnostic 
laboratories in NHS England and Wales send positive screening samples to RIPL for 
confirmatory testing should be feasible. A statement similar to that which appears on HPS’s 
website could be added to PHE’s website [322] and/or be included in future amendments to 
the NICE guidelines [23].  
10.2.2 Introduce mandatory clinician reporting for all Lyme disease cases 
This approach has been taken in other countries in Europe (e.g. Netherlands, Belgium, 
Slovakia) [9]. These countries all have a much higher incidence than the estimates generated 
in this thesis and are likely to have a greater awareness of Lyme disease amongst the general 
population and medical professionals. There are some issues with this option. Firstly, it 
requires a significant change in legislation to the Health Protection (Notification) Regulations 
2010 [77]. Since this legislation has been passed no new diseases have been added to the 
notifiable disease list. Since its preceding legislation, The Public Health (Infectious Diseases) 
Regulations 1988 [323], only five diseases have been added (botulism, brucellosis, invasive 
group A streptococcal disease, Legionnaires’ disease, and severe acute respiratory syndrome 
(SARS)), and three have been removed (AIDS, leptospirosis, and ophthalmia neonatorum). 
To introduce mandatory reporting, Lyme disease would have to become Schedule 1 
notifiable disease in addition to Borrelia spp being a Schedule 2 causative agent.  
The differences between the interpretation of a Schedule 1 notifiable disease and Schedule 
2 causative agent lie in the respective public health actions to a positive case. The differences 
are essentially that of the degree of urgency and the scale of a response [77]. A suspected 
Schedule 1 disease must be notified to a ‘proper officer’ of a local authority within three 
days, or ‘orally as reasonably practical.’ A ‘proper officer’ is someone given statutory power 
to initiate actions regarding notifiable diseases [323]. These public health and disease control 
actions could include, among others, the quarantine of individuals, the initiation of contact 
tracing, mass vaccination, or the withdrawal of food items from sale. A laboratory identifying 
a Schedule 2 causative agent must notify PHE within 7 days, this is usually through SGSS. If 
the  
‘diagnostic laboratory reasonably believes that the Health Protection Agency 
[sic PHE] has already been notified in accordance with this regulation by the 
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operator of another diagnostic laboratory in relation to the same causative 
agent being found in a sample from the same person.[77]’ 
This means that if a confirmatory test has been performed by a PHE laboratory (for example 
RIPL), there is no need to notify PHE. Schedule 2s are not notified to a ‘proper officer’ but 
are notified directly to PHE. PHE holds no statutory power to implement any public health 
actions, without the assistance of a ‘proper officer’. As such, Schedule 2 pathogens require 
surveillance but do not need immediate public health interventions on detection. In 
summary, Schedule 1 require urgent public health action, whilst schedule 2 require 
surveillance. 
In comparison to the notifiable disease list, Lyme disease’s characteristics are very different. 
It has no human to human spread, it is not vaccine preventable, it is not highly contagious 
with the potential for epidemic spread, it is not fatal in the vast majority of cases, and it is 
not a disease virtually eliminated from, or exotic to, the country. The National Institute for 
Public Health and the Environment (RIVM), the Netherlands, have made a decision aid for 
policy makers to decide whether an infectious disease should be notifiable [324]. By 
following the criteria in this decision aid Lyme disease would not qualify for being notifiable. 
The criteria for a disease becoming notifiable in England are not explicit, but in my opinion, 
it is difficult to justify it becoming notifiable based on the above, and would set a new, 
potentially unwanted precedent.  
Secondly, it is hard to think of an immediate public health intervention that could be actioned 
if a positive case of Lyme disease were identified. Control measures for Lyme disease typically 
revolve around tick bite prevention measures and education of the general public and 
medical practitioners [21,325,326]. These are all measures that take time and would need to 
be coordinated at a localised level. They lack the sense of urgency and elevation of scale, (i.e. 
the necessity for a ‘proper officer’ wielding statutory power) that a Schedule 1 disease 
traditionally demands. The author is unsure what public health action could occur 
immediately after notification which would have a direct impact on Lyme disease control and 
prevention. It could be argued that by changing the status of Lyme disease to a Schedule 1, 
local authorities in high incidence areas would be spending an inappropriate amount of 
resources, compared to other Schedule 1 diseases, dealing with the notification of Lyme 
disease cases. 
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Finally, reporting of Lyme disease is likely to be poor, due to the lack of awareness of the 
clinical presentations of Lyme disease within the British medical profession (chapter 6). There 
is the risk that this could result in any rash with an uncertain diagnosis being reported as 
Lyme disease. There are also many examples in the literature where GPs would first await a 
laboratory confirmation before notifying the appropriate authorities about a disease [327–
331]. A systematic review of the completeness of infectious disease notification in the UK 
found that the range of reporting completeness was from 3 to 95% [331]. For example, food 
poisoning was reported as having 47% completeness of notification. This is likely due to GPs 
sending food poisoning samples for diagnosis first before notifying, or assuming that the 
diagnostic laboratory would notify the ‘proper officer’ on identification of the causal agent. 
The case is then likely to be notified as the pathogen, rather than as the notifiable condition 
‘food poisoning.’ One can see that this could happen with Lyme disease; the GP would send 
a diagnostic sample for confirmation and may not notify a case as they would correctly 
assume that RIPL would do so if the diagnostic result were positive. Essentially, GPs are likely 
to only report laboratory-confirmed cases rather than “on suspicion”. Therefore, 
underreporting of cases would still be likely to remain.  
Therefore, to ensure appropriate reporting, mass education of health professionals about 
Lyme disease and the appropriate notification process would be needed, with the potential 
addition of making it a QOF-able condition. This is known to be successful [332], but these 
measures would be costly and time-consuming approaches for the DHSC. 
The systematic review of Lyme disease surveillance systems, discussed in chapter 1, 
concluded that the introduction of mandatory clinician notification would increase the 
number of cases captured by surveillance, but it would not necessarily be a more reliable 
methodology than laboratory-confirmed cases alone. In my opinion there needs to be a cost-
benefit analysis of this policy option before adoption, as it currently seems difficult to justify. 
10.2.3 Introduce mandatory clinician reporting for late or disseminated Lyme 
disease cases 
This option has the same issues as above. Given that the awareness of the differing clinical 
presentations of Lyme disease varies by location, and is potentially already poor in some 
areas, it may be challenging for clinicians to identify late or disseminated Lyme disease cases. 
Many of these cases would be managed in a hospital setting and be likely to have diagnostic 
samples taken. If so, they would already appear within the RIPL dataset. This option could 
therefore produce a change in legislation but not impact the number of Lyme disease cases 
reported. However, if it were adopted, it would be synergistic with the European Centre for 
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Disease Prevention and Control’s (ECDC) surveillance list [333,334], where Lyme 
neuroborreliosis is under surveillance.  
10.2.4 Include Lyme disease in clinician sentinel networks 
This would be one of the easiest options to adopt. In this thesis, Read codes have been 
identified that could be used in primary care sentinel networks (chapter 5). Currently two 
systems could be adapted for this process, the Real Time Syndromic Surveillance Team 
(ReSST) [335], as part of PHE, and the RCGP research and surveillance centre [336,337]. The 
ReSST collects anonymised GP consultation data from two clinical databases, QSurveillance 
and SystmOne [335] (See Chapter 2). The ReSST covers 55% of England’s population in 
primary care and the RCGP network only covers 2.9%. The geographical distribution of the 
ReSST is undisclosed, whilst that of the RCGP network is very unrepresentative (it only has 
two practices located in the disease hotspots identified in this thesis [337]). As discussed in 
chapter 2, there are a variety of research databases that could be used for surveillance, such 
as THIN (chapter 5). They are all more representative than the RCGP, however they are not 
primarily designed as surveillance systems, and do not provide geographical distribution. If 
this policy option were adopted then the ReSST would be the obvious network to choose, 
with the caveat that geographical information is also collected. 
10.2.5 Introduce enhanced surveillance using clinician questionnaires 
This option will not identify further cases but would provide more information about the 
confirmed cases identified by RIPL. Information about the case presentation and 
management of cases within the UK is needed, as there is a sparsity of data [9,23]. It would 
enable the collection of exposure data and would potentially be useful for identifying risk 
factors. This surveillance method is time-consuming and expensive, and the cost-benefit 
ratio of this approach needs to be assessed. This is especially true for Lyme disease in England 
and Wales as diagnostic samples are sent to RIPL via hospital microbiology units, rather than 
directly from primary care; this results in data attrition (Chapter 3). Some of the data lost 
would include primary care clinicians’ contact details. A significant amount of resource and 
goodwill would be needed from the referring hospital laboratory to facilitate RIPL contacting 
a referring GP to gain access to additional patient details. 
 A systematic review of notifiable diseases found that even diseases under enhanced 
surveillance had sub-optimal recording of cases [331]. Much of the demographic information 
captured in this thesis is likely to be replicated during enhanced surveillance. The 
questionnaire could provide additional information on exposure risk to individuals and help 
identify risk behaviours that could result in a tick bite, and subsequently Lyme disease. 
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10.3 Surveillance policy recommendations 
The traditional surveillance pyramid is an imperfect model as the population in each tier are 
often linked, with significant degrees of overlap. The extent of this overlap is unknown, and 
to survey only one tier is likely to represent a biased view of the diseased population. 
Therefore, a combination of health datasets is likely to offer more representative coverage 
of the diseased population. As stated by Lorenc et al;  
 ‘a combination of methods gives more complete coverage in terms of the 
identification of cases than any single method alone, but also that no combination 
can guarantee full coverage of all cases.’ [9] 
This thesis has concluded that the THIN and RIPL datasets are likely to be the most 
representative of the health datasets available for Lyme disease surveillance, and so any 
surveillance policies should be based on these or similar systems. I believe that a Lyme 
disease surveillance policy should: 
• Provide reliable estimates of the incidence of Lyme disease in primary care, 
calculated from RIPL figures and the multiplication factor described in this thesis. 
This should be a very achievable goal. 
• Maintain current surveillance performed by RIPL and legislate that it be the only 
laboratory, in England and Wales, allowed to perform confirmatory testing. This 
would remove the need for the flawed SGSS reports, at least regarding Lyme disease. 
• Include Lyme disease Read codes within ReSST. These will provide estimates of the 
incidence of Lyme disease in primary care, at much greater demographic coverage 
than any research primary care electronic health record database. Pursue 
geographical data of these cases. If this is not possible, then further assessment of 
primary care databases like THIN or CPRD should be performed to assess the stability 
of the proposed multiplication factor. Access to geographical data in these datasets 
should be sought.  
• Tailor the RIPL sample submission form to include more questions, that would be 
traditionally collected within an enhanced surveillance questionnaire. Incomplete 
forms of positive cases should be followed up. Information greatly needed include 
geographical data, case management and treatment choices, ethnicity, and tick bite 
history. As noted above, there are likely to be resource issues associated with the 
follow up process, and if enforced, potential resistance from referring clinicians. 
However, I feel it would provide additional data, and so it would be prudent to try. 
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10.4 Limitations and future research 
10.4.1 Limitations 
Seven datasets have been independently assessed for their ability to describe Lyme disease 
incidence and case demographics. This analysis has not allowed the datasets to be linked. 
This presents a challenge, as the extent of the overlap of cases between the datasets remains 
unknown. In chapter 4, it was found that over 25% of hospital admissions originated from 
primary care. However, without official linkage of the datasets the exact degree of overlap 
is unclear. Ethical approval was granted to link THIN to HES but it was technically impossible 
to interface the two systems. Linking the RIPL servers to any other database is not allowed 
due to the sensitive nature of some of the other conditions contained within it. Since the 
RIPL-THIN multiplication factor is based upon two unlinked databases, we do not know the 
degree of overlap between them and therefore how the multiplication factor is affected. 
Ideally any future work needs to be able to describe and define the degree of overlap 
between different health datasets. 
The structure of the datasets and the inability to stratify some of the denominator 
populations meant that only univariate analysis could be performed, without multivariable 
analysis. For example, within both RIPL and HES, a denominator population was not provided 
and so the ONS population was used. As these two datasets are independent, it would be 
remiss to perform multivariable analysis as the numerator datasets are nested, in an 
unknown manner, within the denominator population and they could not be stratified to the 
same levels. For example, one could stratify the national population by age, sex and year, 
but not additionally by postcode area, ethnicity and rural-urban status. THIN did have a 
denominator population, and so could be stratified by all variables except ethnicity. The lack 
of ethnicity stratification may be explained by the low level of record completeness for this 
variable. The study design of the analysis of THIN was solely ecological, and so multivariable 
analysis was not planned. This would be recommended for any future research on this or 
similar primary care databases. Without the ability to perform multivariable analysis these 
demographic factors cannot be disentangled to identify any interaction or confounding 
effects of the variables under investigation and the bias inherent in them remains unknown.  
From a surveillance perspective, the relative lack of geographical data is a fundamental 
limitation. As shown within this thesis, Lyme disease is a condition that has strong positive 
spatial autocorrelation. However, the two main datasets recommended for future 
surveillance policies have either no geographical data (THIN) or data is only available for 
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around half of all cases (RIPL). This needs to be urgently addressed. For any future modelling 
of Lyme disease in the UK these data need to be more robust than at present. In addition, it 
has been discussed across multiple chapters how the geographical data is reliant on case 
residence postcode rather than tick bite location. Nonetheless, in high risk areas the great 
majority of cases are probably acquired locally during rural activities, and the error rate is 
likely to be small. In cities, cases are likely to originate from many centres and may result in 
a higher proportion of “out-of-area” acquisitions. The extent that this impacts tick bite/risk 
modelling is unclear and needs to be explored. The current data is still useful as it indicates 
where Lyme disease places a burden on health care, and so can be used for appropriate 
resource allocation and to target public health messaging and interventions.  
A potential limitation of all the datasets explored is a lack of information about the 
background prevalence of Lyme disease in the UK population. Since the datasets are 
interrelated it is difficult to interpret whether the observed incidence and dataset synergies 
relate to the background risk of exposure and prevalence or are due to deficiencies in the 
clinical management and diagnostic systems in different locations. This offers scope for 
future research. A Lyme disease seroprevalence study like that performed in Scotland [47], 
would provide an understanding of the underlying spatial distribution of prevalence, and 
potentially disease risk. If maps generated from such a study had significant concordance 
with data produced through national Lyme disease surveillance, we could be more confident 
that the current surveillance system is fit for purpose and not missing previously unidentified 
hotspots of disease.  
The final limitation is around the identification of a Lyme disease case within a dataset. Only 
RIPL offers strict clarity, as cases are identified based on the results of diagnostic tests. The 
remaining datasets were based on diagnostic coding and are therefore reliant on appropriate 
coding by a health professional. As discussed in chapter 6, this is not as reliable as initially 
perceived, as there may be a lack of awareness of a certain condition, or there may be a 
reluctance to code for a variety of reasons. This means that the diseased populations 
described are still likely to be biased and not represent the entire population seen either in 
hospital or primary care. This is a known issue across all research and surveillance performed 
on datasets reliant on diagnostic codes such as ICD-10 and Read codes. To date no solution 
to this problem has been identified. As previously discussed even making a code QOF-able 
does not result in more reliable coding. Validation of Lyme disease codes needs to be further 
investigated to avoid the maxim of ‘garbage in, garbage out’.  
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10.4.2 Future research 
The most immediate potential for future research is to assess whether the ReSST or one or 
more primary care database, can be used as a continuing surveillance system for Lyme 
disease. A formal surveillance system assessment needs to be performed to decide on their 
potential. Alongside this, the stability of the multiplication factor identified needs to be 
assessed to decide whether this number can be utilised as an estimate for the number of 
Lyme disease cases seen in primary care in the UK. 
The analysis of the datasets in this thesis has focused solely on disease incidence and 
demographics, however, this misses a large amount of the data contained within them. The 
HES and THIN datasets could be examined further to identify the prevalence of the various 
clinical presentations of Lyme disease in the UK and how they are clinically managed. This 
could include analysis of treatment and referral choices. This information is currently not 
present for the UK and its analysis would fill important gaps in the evidence base regarding 
Lyme disease. Following this work, health economic analysis would be strongly 
recommended, to calculate the burden that Lyme disease currently places on the NHS. 
There is a need for a UK-wide seroprevalence survey to understand the background risk of 
Lyme disease, therefore providing exposure data for the UK population. To date, similar work 
has only been performed in Scotland [47]. Such research would allow better interpretation 
of regional variations in incidence, such as those identified in the thesis. For example, are the 
areas with low case numbers reflective of a low exposure risk or poor data recording or poor 
case recognition? It would place the findings of the thesis into better context, and provide 
the opportunity to identify risk factors associated with higher Lyme disease seroprevalence, 
such as occupational/recreational practices. The resultant data could be linked to tick 
distribution maps, produced by the Tick Surveillance Scheme [24,286], to produce high 
resolution Lyme disease risk maps for the UK. It would enable better targeting of public 
health advice and future Lyme disease interventions. It would provide more robust evidence 
of the true burden of Lyme disease in the UK and produce a definitive answer to the level of 
Lyme disease exposure to the UK population.  
This research, excluding the SAVSNET chapter, has excluded the inclusion of ticks in its 
analysis. Ticks are obviously critical to the spread and risk of Lyme disease. There are multiple 
research groups within the UK who are currently performing valuable research regarding 
ticks, though mainly from an ecological perspective. Important epidemiological and 
management questions that still need answering include, ‘can the incidence of tick bites, 
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both temporally and spatially, be used to predict the incidence of Lyme disease?’ and ’how 
are tick bites currently managed in the UK?’ Answers to these could offer scope for tick-based 
surveillance methods for Lyme disease, and may highlight the need for education and 
awareness around the management of tick bites. 
The final area that needs exploring is patient and health care professionals behaviours, 
experience and knowledge around Lyme disease. As highlighted in Chapter 6, the reasons 
behind GP coding behaviour is more complex than perhaps perceived. The interview process, 
rather than the questionnaire, drew out how GPs feel and behave. Despite the bias in the 
group, it provided some fascinating insights. Similar qualitative research is needed to further 
explore coding behaviour, and to understand health professionals’ attitudes and beliefs to 
Lyme disease. For patients, research is needed to understand how, when and why they 
access various elements of the health care system. It is also needed to understand the views 
and beliefs within the Lyme disease affected population, both those with solely an EM rash 
and those that identify with having ‘chronic Lyme disease’. By understanding personal drivers 
to attitude and behaviour, public health strategies can be designed that reflect and respond 
to these drivers better than present. 
10.5 Conclusions 
Lyme disease offers a unique set of surveillance challenges in the UK. Little is known about 
its UK epidemiology, not all cases need diagnostic confirmation, and the awareness of its 
various presentations amongst health professionals is variable. I have identified a variety of 
health datasets that could be used as part of an integrated disease surveillance system.  
The NICE guidelines stated there was a lack of epidemiological data about Lyme disease in 
the UK. This thesis has filled elements of this evidence gap, by presenting new incidence 
figures, providing new Lyme disease incidence maps for England and Wales, and for the first 
time, describing the socio-demographics of the Lyme disease affected population in the UK. 
This work will provide a new reference point for future surveillance and research projects for 
Lyme disease in this country.  
There are two key policy recommendations resulting from this research. Firstly, current 
geographical data is relatively sparse, despite the identification of significant hotspots of 
disease in southern England. Due to this geographical restriction any surveillance systems 
adopted by Public Health England need to ensure that the capture of geographical data is 
deemed a vital part of the system. This will allow the assessment of disease spread and the 
appropriate allocation of public health resources and interventions. Secondly, a combination 
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of health datasets for surveillance is likely to be the most representative of the diseased 
population. Primary care and laboratory datasets appear to be the most representative, and 
a multiplication factor of 2.35 has been calculated between the two. This multiplication 
factor can be used to provide estimates of national and local Lyme disease incidence in 
primary care and assist in the allocation of public health resources for Lyme disease control, 
presentation, and education. The use of routinely collected primary care electronic health 
records data alongside laboratory data, should be considered as the core of any future Lyme 
disease surveillance policy. 
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Appendix II GP Validation Study: Participant Consent Form 
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Appendix III GP Validation Study: Questionnaire 
Version 1.2   07/06/17 IRAS Number - 208815 
Understanding the decision making process of general practitioners (GPs) presented with 
non-specific conditions 
 
Participant Number: 
 
Researcher, please note start time: …………….. 
 
Gender 
 Male 
 Female 
 
Year of Birth 
 
What is the first half of your practice postcode? (For example; ST15) 
 
How many years have you been in general practice? 
Are you a GP with a special interest? 
 Yes 
 No 
 
 
What is your special interest? 
 
In the following cases we will use the term Practice Management System (PMS). This refers 
to the computer based system that houses your patients' electronic health records. 
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Case 1 
29 year old female  
Presentation:  A headache and fever for the last three days. On examination a single skin 
lesion is presented.      
 
(Courtesy of CDC/James Gathany) 
 
What are your three differential diagnoses for this case? 
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You discover that she has recently been bitten by a tick. What are your differentials now? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 2 
10 Year Old Female 
Presentation: Over the last few weeks has developed this painless nodule on her left ear 
lobe, no other abnormal clinical signs were seen.     
 
(Courtesy of: http://www.meduni09.edis.at/eucalb/cms_15/index.php?option=com_content&task=view&id=98&Itemid=109) 
What are your three differential diagnoses for this case? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
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Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
 
 
Case 3 
 
71 Year Old Male 
Presentation: Over the last six months the extensor surface of his hands have gradually 
developed blueish red discolouration, with thinning and wrinkling of the skin. He has also 
developed a sensory peripheral neuropathy of the extensor surface of his right hand and 
forearm. He is showing strong signs of allodynia, an exaggerated nociceptive pain reaction 
to minimal trauma. 
 
 
 
(Courtesy of http://www.dermis.net) 
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What are your three differential diagnoses for this case? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
  
238 
 
Case 4  
10 year old female   
Presentation: Acute unilateral facial palsy and headaches.     
 
(Courtesy of Wellcome Images) 
What are your three differential diagnoses for this case? 
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You discover an insect bite on her scalp. 
What are your differentials now?  
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 5 
44Year Old Male 
Presentation: Recurrent episodes of synovitis in both knees, which has been persisting for 
the last 4 months. 
What are your three differential diagnoses for this case? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 6  
25 Year Old Female   
Presentation: Presents with three identical lesions (one shown in picture) across her torso. 
No other clinical findings, and on discussion spent the previous day walking on Dartmoor.     
 
(Courtesy of http://www.dermis.net) 
What are your three differential diagnoses for this case? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 7 
32 Year Old Male   
Presentation: Last week took part in a 10km fun run, which he competes in on a regular 
basis. He has now noticed missed heart beats and a fluttering in his chest.     
What are your three differential diagnoses for this case?  
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 8 
53 year old female 
Presentation: Presents with fatigue and post-exertional malaise, anxiety, headaches and 
self-reported memory issues.     
What are your three differential diagnoses for this case? 
After examination she presents you with a report from an international lab stating that she 
is positive for Lyme disease. She requests that you treat her with long term antibiotics. 
What are your differentials now? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 9 
62 Year Old Male 
Presentation: Fatigue, aching of his knees and ankles, poor ability to concentrate, general 
muscle pain and mood swings.     
What are your three differential diagnoses for this case? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 10 
15 Year Old Male   
Presentation: Only complaint is seen in the below image     
 
(Courtesy of Public Health England; contains public sector information licensed under the Open Government Licence v3.0) 
What are your three differential diagnoses for this case? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Case 11 
38 Year Old Male   
Presentation: Presents feeling low, sleeping badly, says he has noticed change in the 
character of his writing and difficulty with fine movements of his hands e.g. turning keys in 
locks. He had been fine until 1 month before. 2 months before he helped out on a scout 
camp and he came to see the GP shortly after that with a rash on his shoulder and the GP 
gave him erythromycin.     
What are your three differential diagnoses for this case? 
How would you code your top diagnosis on your PMS? 
Would you perform further diagnostics for this case? 
 Yes 
 No 
If yes, what would they be? 
Would you prescribe a treatment for this case? 
 Yes 
 No 
If yes, what would you prescribe, and what would the course of treatment be? 
Would you refer this patient? 
 Yes 
 No 
If yes, where/to whom would you refer this patient? 
Any further comments? (For example, personal reflections about decision making or 
further information on case management.) 
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Post Interview Questions 
 
Lyme Knowledge Assessment 
1) Prior to this questionnaire had you heard of Lyme disease? (Y/N) 
2) What causes it? 
3) Do you know where/who the reference lab is? 
4) Do you think UK testing is reliable (Y/N) 
5) Do you think Chronic Lyme disease exists? (Y/N) 
6) Do you think Chronic Fatigue syndrome exists? (Y/N) 
7) Who would you seek for advice about a Lyme disease patient? 
 
Assessment of the Questionnaire  
1) How does being initially blinded to the research make you feel?  
2) Are you still happy to consent? Why? 
3) Do you understand why the blinding was performed? (If no, researcher to explain 
methodology more) 
4) Did you recognise that the study was about Lyme disease? (If yes, how and at what 
stage?) 
5) How would you improve the blinding? 
6) Are there any questions that you didn’t understand or need improving? 
7) How do you feel about the format and structure of the questionnaire? (Try to elicit 
from the participant positives and negatives) 
8) How well do you think it would work in an on-line format, especially in regards to 
the questions around coding? 
9) How would you distribute the survey to GPs on-line? Any websites that they use in 
particular? 
 
 
 
Researcher, please note end time: …………………………… 
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Appendix IV GP Validation Study – Participant exit information 
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Appendix V GP Validation Study – Case 1 Answers 
 
Appendix Table 1 A summary of GP responses to a blinded case presentation of a classic erythema migrans 
(EM) rash; Case 1. 
Differential and coding questions. 7 (87.5%) GPs answered questions on this case 
Initial 
Differentials 
Percentage 
of GPs 
with this 
differential 
(n) 
Differential 
after tick bite 
reveal 
Percentage of 
GPs with this 
differential 
(n) 
Read Codes 
chosen 
Percentage 
of GPs with 
this code (n) 
Lyme disease 71.4% (5) Lyme disease 85.7% (6) Rash 42.6% (3) 
Bite 28.6%  (2) Rash 14.3% (1) Lyme disease 28.6%  (2) 
Drug reaction 14.3% (1) Target lesion 14.3% (1) Target lesion 28.6%  (2) 
Erythema 
multiform 
14.3% (1)   Erythema 
migrans 
14.3% (1) 
Erythema 
nodosum 
14.3% (1)   Suspected 
Lyme disease 
14.3% (1) 
Herald lesion 14.3% (1)     
Localised skin 
dermatitis 
14.3% (1)     
Non-specific 
eruption 
14.3% (1)     
Rash 14.3% (1)     
Target Lesion 14.3% (1)     
  
Would you perform diagnostics? (% Yes) 71.4% (5) 
 Bloods – 100% (5) 
Would you prescribe anything? (% Yes) 71.4% (5) 
 Check guidelines first – 80% (4) 
Antibiotics – 20% (1) 
Would you refer this case? (% Yes) 57.1% (4) 
 Admit straight to hospital – 50% (2) 
Infectious disease department – 25% (1) 
Look up where to refer to – 25% (1) 
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Appendix VI GP Validation Study – Case 2 Answers 
 
Appendix Table 2 A summary of GP responses to a blinded case presentation of Borrelial lymphocytoma; Case 
2. 
Differential and coding questions. 7 (87.5%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Allergy 14.3% (1) Ear swelling 28.6%  (2) 
Bite 14.3% (1) Cellulitis 14.3% (1) 
Cellulitis 14.3% (1) Erythema of pinna 14.3% (1) 
Chondritis 14.3% (1) Inflammation of pinna 14.3% (1) 
Cyst 14.3% (1) No code 14.3% (1) 
Ear symptom 14.3% (1) Skin nodule 14.3% (1) 
Eczema 14.3% (1)   
Infection 14.3% (1)   
Inflammation of pinna 14.3% (1)   
Irritation 14.3% (1)   
Malignant lump 14.3% (1)   
No idea 14.3% (1)   
Painless abscess 14.3% (1)   
    
Would you perform diagnostics? (% Yes) 28.6% (2) 
 Bloods – 50% (1) 
Look up what diagnostics – 50% (1) 
Would you prescribe anything? (% Yes) 42.9% (3) 
 Flucoxacillin and steroid cream – 66.7% (2) 
Ibuprofen and anti-histamines – 33.3% (1) 
Would you refer this case? (% Yes) 57.1% (4) 
 Ear, nose and throat consultant – 50% (2) 
Dermatology consultant – 25% (1) 
Look up where to refer to – 25% (1) 
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Appendix VII GP Validation Study – Case 3 Answers 
 
Appendix Table 3 A summary of GP responses to a blinded case presentation of acrodermatitis chronica 
atrophicans (ACA); Case 3. 
Differential and coding questions. 8 (100%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Alcohol related issue 50% (4) Peripheral neuropathy 37.5% (3) 
Vitamin B12 deficiency 37.5% (3) Sensory loss 25% (2) 
Diabetes 25% (2) No code 12.5% (1) 
Natural ageing 25% (2) Neuropathy 12.5% (1) 
No idea 25% (2) Numbness 12.5% (1) 
Rheumatological cause 25% (2)   
Arthritis 12.5% (1)   
Cervical neck problems 12.5% (1)   
Iatrogenic cause 12.5% (1)   
Liver disease 12.5% (1)   
Multiple sclerosis 12.5% (1)   
Neurovascular issue 12.5% (1)   
New systemic condition 12.5% (1)   
Nutritional condition 12.5% (1)   
Peripheral neuropathy 12.5% (1)   
Radicular nerve root palsy 12.5% (1)   
Reynaud’s phenomenon 12.5% (1)   
Thoracic outlet tumour 12.5% (1)   
Thyroid issue 12.5% (1)   
    
Would you perform diagnostics? (% Yes) 100% (8) 
 Bloods – 87.5% (7) 
Nerve conduction study – 37.5% (3) 
Diagnostic imaging – 25% (2) 
Electomyography – 12.5% (1) 
Neurological examination – 12.5% (1) 
Would you prescribe anything? (% Yes) 25% (2) 
 Painkillers – 100% (2) 
Gabapentins – 50% (1) 
Would you refer this case? (% Yes) 50% (4) 
 Neurology consultant – 75% (3) 
Dermatology consultant – 25% (1) 
Musculoskeletal consultant – 25% (1) 
Rheumatological consultant – 25% (1) 
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Appendix VIII GP Validation Study – Case 4 Answers 
 
Appendix Table 4 A summary of GP responses to a blinded case presentation of Bell’s palsy caused by Lyme 
disease; Case 4. 
Differential and coding questions. 7 (87.5%) GPs answered questions on this case 
Initial 
Differentials 
Percentage 
of GPs 
with this 
differential 
(n) 
Differential 
after tick bite 
reveal 
Percentage 
of GPs with 
this 
differential 
(n) 
Read Codes 
chosen 
Percentage 
of GPs with 
this code (n) 
Bell’s palsy 100% (7) Bell’s palsy 100% (7) Bell’s palsy 57.1% (4) 
Brain tumour 42.9%  (3) Brain tumour 28.6% (2) Nerve palsy 28.6%  (2) 
Space occupying 
lesion 
28.6% (2) AV 
Malformations 
14.3% (1) Facial palsy 14.3% (1) 
Arteriovenous 
malformation 
14.3% (1) Ear problems 14.3% (1) Suspected 
zoster 
14.3% (1) 
Ear problems 14.3% (1) Intracellabellar 
event 
14.3% (1) Unilateral facial 
palsy 
14.3% (1) 
Intracellabellar 
event 
14.3% (1) Lyme disease 14.3% (1)   
Nerve condition 14.3% (1) Tick-borne 
virus 
14.3% (1)   
Viral infection 14.3% (1)     
Zoster virus 
infection 
14.3% (1)     
  
Would you perform diagnostics? (% Yes) 71.4% (5) 
 CT scan – 80% (4) 
Cranial Nerve exam – 40% (2) 
Bloods – 20% (1) 
Ophthalmic exam – 20% (1) 
Would you prescribe anything? (% Yes) 14.3% (1) 
 Prednisolone and anti-viral – 100% (1) 
Would you refer this case? (% Yes) 85.6% (6) 
 Paediatric consultant – 66.7% (4) 
Ear, nose and throat consultant – 16.7% (1) 
Emergency ophthalmology clinic – 16.7% (1) 
Neurology consultant – 16.7% (1) 
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Appendix IX GP Validation Study – Case 5 Answers 
 
Appendix Table 5 A summary of GP responses to a blinded case presentation of recurrent synovitis of knees; 
Case 5. 
Differential and coding questions. 7 (87.5%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Osteoarthritis 71.4% (5) Knee pain 42.9% (3) 
Rheumatoid arthritis 57.1% (4) Synovitis 28.6% (2) 
Gout 42.9% (3) Polyarthropathy 14.3% (1) 
Inflammatory arthritis 28.6% (2) Inflammatory arthritis 14.3% (1) 
Bursitis 14.3% (1)   
Knee infection 14.3% (1)   
Lupus 14.3% (1)   
Polyarthritis 14.3% (1)   
Post-infectious arthritis 14.3% (1)   
    
Would you perform diagnostics? (% Yes) 100% (7) 
 Bloods – 85.7% (6) 
Diagnostic imaging – 71.4% (5) 
Would you prescribe anything? (% Yes) 100% (7) 
 Non-steroidal  anti-inflammatories – 100% (7) 
Painkillers – 14.3% (1) 
Would you refer this case? (% Yes) 42.9% (3) 
 Musculoskeletal consultant – 66.7% (2) 
Rheumatological consultant – 66.7% (2) 
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Appendix X GP Validation Study – Case 6 Answers 
 
Appendix Table 6 A summary of GP responses to a blinded case presentation of multiple EM rashes; Case 6. 
Differential and coding questions. 7 (87.5%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Insect bite 85.7% (6) Non-specific rash 28.6% (2) 
Fungal infection 42.9% (3) Erythema migrans 14.3% (1) 
Lyme disease 42.9% (3) Insect bite 14.3% (1) 
Contact dermatitis 28.6% (2) No code 14.3% (1) 
Allergy 14.3% (1) Non-specific dermatitis 14.3% (1) 
Eczema 14.3% (1) Rash 14.3% (1) 
Rash 14.3% (1) Skin lesion 14.3% (1) 
Ringworm 14.3% (1)   
Skin eruption 14.3% (1)   
Tick bite 14.3% (1)   
Viral infection 14.3% (1)   
    
Would you perform diagnostics? (% Yes) 42.9% (3) 
 Bloods – 66.7% (2) 
Skin scrape – 33.3% (1) 
Trial of medication – 33.3% (1) 
Would you prescribe anything? (% Yes) 85.7% (6) 
 Steroid and fungal cream – 50% (3) 
Antibiotics – 16.7% (1) 
Eyrthromycin – 16.7% (1) 
Hydrocortisone cream – 16.7% (1) 
Would you refer this case? (% Yes) 0% (0) 
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Appendix XI GP Validation Study – Case 7 Answers 
 
Appendix Table 7 A summary of GP responses to a blinded case presentation of heart rhythm abnormalities; 
Case 7. 
Differential and coding questions. 7 (87.5%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Arrhythmia 57.1% (4) Palpitations 71.4% (5) 
Palpitations 42.9% (3) Arrhythmia 14.3% (1) 
Anxiety 28.6% (2) No code 14.3% (1) 
Atrial fibrillation 28.6% (2)   
Ectopic beats 28.6% (2)   
Anaemia 14.3% (1)   
Heart defect 14.3% (1)   
Performance enhancing 
drugs 
14.3% (1)   
Recreational drug use 14.3% (1)   
Stress 14.3% (1)   
Supraventricular tachycardia 14.3% (1)   
    
Would you perform diagnostics? (% Yes) 85.7% (6) 
 Electrocardiogram – 100% (6) 
Bloods – 83.3% (5) 
Test for drug use – 16.7% (1) 
Urinalysis – 16.7% (1) 
Would you prescribe anything? (% Yes) 0% (0) 
  
Would you refer this case? (% Yes) 28.6% (2) 
 Cardiology consultant – 50% (1) 
Refer to emergency department – 50% (1) 
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Appendix XII GP Validation Study – Case 8 Answers 
 
Appendix Table 8 A summary of GP responses to a blinded case presentation of multiple symptoms; Case 8. 
Differential and coding questions. 5 (62.5%) GPs answered questions on this case 
Initial 
Differentials 
Percentage 
of GPs 
with this 
differential 
(n) 
Differential 
after results 
reveal 
Percentage 
of GPs with 
this 
differential 
(n) 
Read Codes 
chosen 
Percentage 
of GPs with 
this code (n) 
Thyroid 
problems 
80% (5) Thyroid 
problems 
60% (3) Tired all the 
time 
60% (3) 
Chronic fatigue 
syndrome (CFS) 
60%  (3) CFS 40% (2) Anxiety with 
depression 
20% (1) 
Depression 60% (3) Depression 40% (2) Fatigue 20% (1) 
Anaemia 40% (2) Anaemia 20% (1) No code 20% (1) 
Anxiety 40% (2) Anxiety 20% (1)   
Menopausal 20% (1) Lyme disease 20% (1)   
Psychosomatic 
cause 
20% (1) Menopausal 20% (1)   
Tired all the time 20% (1) Tired all the 
time 
   
  
Would you perform diagnostics? (% Yes) 100% (5) 
 Bloods – 60% (3) 
Lyme disease serology – 40% (2) 
PHQ-9 – 20% (1) 
Would you prescribe anything? (% Yes) 20% (1) 
 Counselling – 100% (1) 
Would you refer this case? (% Yes) 60% (3) 
 Infectious disease consultant – 66.7% (2) 
Microbiology consultant– 33.3% (1) 
Neurology consultant – 33.3% (1) 
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Appendix XIII GP Validation Study – Case 9 Answers 
 
Appendix Table 9 A summary of GP responses to a blinded case presentation of multiple symptoms; Case 9. 
Differential and coding questions. 7 (87.5%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Depression 71.4% (5) Fatigue 42.9% (3) 
Anaemia 42.9% (3) Polyarthralgia 28.6% (2) 
Thyroid problems 42.9% (3) Low mood 14.3% (1) 
Chronic fatigue syndrome 28.6% (2) No code 14.3% (1) 
Fibromyalgia 28.6% (2) Tired all the time 14.3% (1) 
Osteoarthritis 28.6% (2)   
Anxiety 14.3% (1)   
Arthralgia 14.3% (1)   
Iatrogenic 14.3% (1)   
Multiple joint pain 14.3% (1)   
Polymyalgia 14.3% (1)   
Psychosomatic cause 14.3% (1)   
Rheumatological cause 14.3% (1)   
    
Would you perform diagnostics? (% Yes) 100% (7) 
 Bloods – 100% (7) 
PHQ-9 – 28.6% (2) 
Prostate specific antigen test – 14.3% (1) 
Stool analysis – 14.3% (1) 
Urinalysis – 14.3% (1) 
X-ray – 14.3% (1) 
Would you prescribe anything? (% Yes) 71.4% (5) 
 Painkiller – 40% (2) 
Treat symptomatically - 40% (2) 
Non-steroidal anti-inflammatories – 20% (1) 
Would you refer this case? (% Yes) 14.3% (1) 
 Radiology department – 100% (1) 
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Appendix XIV GP Validation Study – Case 10 Answers 
 
Appendix Table 10 A summary of GP responses to a blinded case presentation of a tick; Case 10. 
Differential and coding questions. 6 (75%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Cutaneous horn 33.3% (2) Skin lesion 33.3% (2) 
Foreign body 33.3% (2) Tick bite 33.3% (2) 
Skin lesion 33.3% (2) Pustule 16.7% (1) 
Tick 33.3% (2) Scalp lesion 16.7% (1) 
Cyst 16.7% (1)   
Granulomatous lesion 16.7% (1)   
Infected hair follicle 16.7% (1)   
Insect 16.7% (1)   
Lump 16.7% (1)   
Pustular lesion 16.7% (1)   
    
Would you perform diagnostics? (% Yes) 66.7% (4) 
 Remove and send to pathology – 100% (4) 
Would you prescribe anything? (% Yes) 16.7% (1) 
 Antibiotics – 100% (1) 
Would you refer this case? (% Yes) 0% (0) 
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Appendix XV GP Validation Study – Case 11 Answers 
 
Appendix Table 11 A summary of GP responses to a blinded case presentation of motor movement issues and 
rashes; Case 11. 
Differential and coding questions. 8 (100%) GPs answered questions on this case 
Initial Differentials Percentage of 
GPs with this 
differential (n) 
Read Codes chosen Percentage 
of GPs with 
this code (n) 
Depression 50% (4) Feeling low 25% (2) 
Neurological condition 50% (4) Low mood 25% (2) 
Anxiety 25% (2) Neurological symptoms 25% (2) 
Motor neurone disease 25% (2) No code 12.5% (1) 
Parkinson’s disease 25% (2) Parasitic infection 12.5% (1) 
Alcohol intake problems 12.5% (1)   
Brain tumour 12.5% (1)   
Dementia 12.5% (1)   
Drug induced 12.5% (1)   
Fungal lesion 12.5% (1)   
Herald lesion 12.5% (1)   
Infectious disease issue 12.5% (1)   
Lyme disease 12.5% (1)   
Mental health issue 12.5% (1)   
Parasitic infection 12.5% (1)   
Post-viral arthralgia 12.5% (1)   
Thyroid function 12.5% (1)   
Tick-borne virus 12.5% (1)   
    
Would you perform diagnostics? (% Yes) 87.5% (7) 
 Bloods – 71.4% (5) 
Lyme disease serology – 14.3% (1) 
Neurological exam – 14.3% (1) 
Would you prescribe anything? (% Yes) 0% (0) 
  
Would you refer this case? (% Yes) 37.5% (3) 
 Refer to emergency department – 33.3% (1) 
Infectious disease consultant – 33.3% (1) 
Neurology consultant – 33.3% (1) 
 
